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Abstract 
The older cohort is the fastest growing subsection in the population; they are the major 
users of medicines and are also more vulnerable to dysphagia which can make safe 
swallowing of solid oral dosage forms challenging. Tablets and capsules are often 
modified by crushing tablets or opening capsules and this can be hazardous for slow 
release dosage forms which reduce the pill burden for these patients but can result in 
dose dumping and toxicity due to modification. The aim of this study is to understand 
the practical issues in administering sustained release dosage forms to older adults 
with dysphagia and to develop novel sustained release dosage forms that are safe to 
swallow. 
 
A prospective study (Chapter 2) was conducted in secondary care with the focus on 
administration of sustained release dosage form. There were 49% of sustained 
release tablets and capsules modified by crushing tablets or opening capsules to 
facilitate swallowing in older adults with dysphagia. Furthermore, thickened fluids, 
yogurt and jellies were used as vehicles to deliver modified or whole dosage forms.  
 
Thickened fluids are commonly used to help safety of swallowing thin liquids by 
dysphagia patients but poorly accepted. An in vitro throat model developed for 
processing liquids was used to provide a systematic understanding and comparison 
of the flow behaviour of commonly used thickeners under simulated swallowing 
conditions. Slow in vitro oral transit time and cohesive bolus transit with increasing 
thickening was found for thickened fluids. The processing of jellies for pharmaceutical 
application in the throat model showed similar findings of oral transit time and bolus 
length to thickened fluids at high consistencies (honey and spoon thick). Rheological 
 iii 
and textural characterisation of thickened fluids (viscosity, yield stress, firmness, 
cohesiveness) showed correlation with in vitro oral transit time and cohesive transit in 
the throat model.  
 
Three instant (less than 10 minutes to form from powder when water was added) jellies 
were developed without requiring heat as a novel DIY dosage form to deliver sustained 
release microparticles containing gliclazide. Microparticles are useful dosage forms 
for patients with swallowing difficulties but can be challenging to swallow safely for 
patients unable to safely swallow thin liquids. The sodium alginate and calcium salts 
based jellies showed slow in vitro oral transit time and cohesive bolus transit in the 
throat model similar to commercial ready-to-eat jelly products. The jellies enhanced 
slow release properties of sustained release microparticles containing gliclazide 
suggesting that they can be effective vehicles to deliver the microparticles for patients 
with dysphagia.  
 
Overall, this study showed that medicines modification does occur for sustained 
release dosage forms prescribed to older adults with dysphagia. Jellies showed 
potential as alternative swallowing aids to thickened fluids which are poorly accepted 
but commonly used to improve safety of swallowing of fluids by dysphagia patients. 
Instant jellies were developed without requiring heating with swallowing processing 
features similar to thickened fluids in the in vitro throat model to facilitate delivery of 
sustained release microparticles safely for dysphagia patients. The novel drug delivery 
system developed offers a promising solution for medicines administration in patients 
with dysphagia. 
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Chapter 1 
INTRODUCTION
 2 
Eating and drinking is not only a pleasurable activity but also a necessity for the 
sustenance of life. Individuals with difficulties in swallowing can make various 
adjustments if food and drink are difficult to swallow, such as opting for softer food or 
thickened fluid (Cichero, 2015). Medicines are also significant in maintaining the 
quality of life of patients, but the most commonly prescribed dosage forms are solid 
oral dosage forms (SODF).  SODF such as tablets and capsules are preferred due to 
their convenience for patients and cost-effectiveness, but it can be challenging to 
administer these dosage forms safely and effectively to patients who have difficulties 
in swallowing. The difficulties patients may encounter in swallowing these dosage 
forms can sometimes be overlooked. Altering these formulations to facilitate 
swallowing is not as straightforward as modifying food and drinks and can result in 
hazardous consequences such as toxicity (Schier, Howland, Hoffman, & Nelson, 
2003).  
 
Difficulties in swallowing affect all age spans but are more common in older adults (65 
years and over) due to age-related diseases and the natural process of aging ( 
Stegemann et al., 2010; Wilkins, Gillies, Thomas, & Wagner, 2007). Older adults have 
a greater need for health care resources,  compared to younger counterparts due to 
increased multimorbidities; consequently requiring a greater number of medicines 
(European Medicines Agency, 2012; Jennifer Kelly, Wright, & Wood, 2012). As the 
world  population is aging and the number of adults over the age of 65 is expected to 
triple by 2050 to 1.5 billion compared to an estimated 524 million in 2010, the 
challenges encountered with administering medicines safely and effectively to patients 
with swallowing difficulties are expected to grow (National Institute on Aging, 2011).  
 
 3 
1.1 Deglutition process and dysphagia  
In order to understand dysphagia, it is essential first to understand the swallowing 
process. The oropharyngeal system serves two essential functions: the transport of 
solid or liquid bolus to the stomach and airway protection (Figure 1-1). The coordinated 
interactions between swallowing and breathing are fundamental for safe swallowing 
(Ertekin & Aydogdu, 2003). The process of swallowing is a rapid, synchronized 
process. It is generally described as three phases; the oral phase, the pharyngeal 
phase and the oesophageal phase (Table 1-1) (Matsuo & Palmer, 2008). 
 
 
Figure 1-1: Lateral view of the oral cavity and pharynx (reprinted with permission) 
from Tuleu & Wright, 2013). 
 
Dysphagia is the inability to transfer foods from the mouth to stomach safely and is 
more specifically defined as the “eating and drinking disorders which may occur in the 
oral, pharyngeal and oesophageal stages of deglutition” (Royal College of Speech and 
Language Therapists, 2013). Dysphagia can occur at a single stage of the swallowing 
process, or simultaneously in more than one stages (Stegemann et al., 2012). It can 
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be distinguished as two different types based on the location of the swallowing 
impairment; oropharyngeal and oesophageal dysphagia (Gleeson, 1999; Ratnaike, 
2003). Swallowing impairment can be a result of structural or functional impairment 
such as loss of teeth or weak contraction of the tongue (Matsuo & Palmer, 2008).  
Oropharyngeal dysphagia can affect the oral phase (forming of bolus) and oral 
propulsion stage (Ratnaike, 2003). Factors influencing oropharyngeal dysphagia 
include: xerostomia, drug-induced dysphagia, neurological conditions such as 
Parkinson’s disease and transfer of the bolus in the pharynx before the closure of the 
airway (Ertekin & Aydogdu, 2003). Oesophageal dysphagia can be caused by 
mechanical factors such as oesophageal obstruction by ulcers or tumours and 
neurological causes that affect peristaltic contractions in the oesophagus such as 
Parkinson’s disease (Nelson & Castell, 1988; Ratnaike, 2003). 
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Table 1-1: The three stages of the swallowing process 
Stages Description 
The oral phase 
(voluntary control) 
The bolus transport in the mouth is described as a two-stage process; stage I 
involves the first bite of food and its transportation to the molar teeth for particle 
size reduction (Hiiemae et al., 1996). Food is broken down and mixed with 
saliva to achieve a consistency that is easy to swallow. 
 
Stage II involves the movement of the bolus to the back of the oral cavity by the 
tongue (Hiiemae et al., 1996). The anterior part of the tongue rises to the hard 
palate while the posterior portion of the tongue lowers to propel the bolus 
through the fauces into the oropharynx (Matsuo & Palmer, 2008). 
The pharyngeal 
phase (involuntary 
control) 
Before the bolus enters the pharynx, the soft palate elevates, closing the 
nasopharynx and preventing regurgitation into the nasal cavity (Ertekin & 
Aydogdu, 2003). The hyoid bone and larynx are also elevated, and the epiglottis 
is bent backward to help tuck the larynx under the tongue, protecting the 
larynx’s entrance from the bolus entry (Ertekin & Aydogdu, 2003; Matsuo & 
Palmer, 2008). The bolus is then propelled downwards towards the 
oesophagus by peristalsis (Chadwick & Jolliffe, 2009). 
 
The oesophageal 
phase (involuntary 
phase) 
The opening of the upper oesophageal sphincter allows the bolus to enter the 
oesophagus. The bolus is transported through the oesophagus by peristalsis, 
and the opening of the lower oesophageal sphincter allows the entry of the food 
into the stomach (Matsuo & Palmer, 2008). 
 
 
  
1.2 Dysphagia as a consequence of aging, age-related diseases and medicines 
The cause of dysphagia is often considered as a result of underlying conditions. The 
causes of dysphagia during infancy, childhood, and adolescence include 
neurodevelopmental delay and acute infectious causes (Roden & Altman, 2013). In 
the middle-aged population gastro-oesophageal causes are observed (Roden & 
Altman, 2013). In older adults, dysphagia is commonly linked to oncological and 
neurological conditions such as head and neck cancer and stroke (Roden & Altman, 
2013).  
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Dysphagia affects all age spans but is more common in older adults as a result of 
physiological changes, age-related diseases and side effects of medicines (Aslam & 
Vaezi, 2013). Dysphagia is reported to occur in 10-32% of older adults in the 
community (Bloem et al., 1990; Holland et al., 2011; Kawashima, Motohashi, & 
Fujishima, 2004; Roy, Stemple, Merrill, & Thomas, 2007), 12-47.4% of hospitalised 
patients (Carrión et al., 2015; Groher & Bukatman, 1986) and as high as 68% of 
institutionalized older adults in residential care homes (Steele, Greenwood, Ens, 
Robertson, & Seidman-Carlson, 1997).  
 
Age-related diseases such as stroke, Parkinson’s disease, dementia, cancer of the 
head and neck are frequently cited for causing dysphagia. A prospective based cohort 
study found that 80% of strokes occurred in older adults over the age of 64 in the UK 
(Carroll, Murad, & Majeed, 2001). Dysphagia has been reported in 23-81% of patients 
with stroke (Crary et al., 2013; Gordon, Hewer, & Wade, 1987; Khan, Carmona, & 
Traube, 2014; Martino et al., 2005; Roden & Altman, 2013; Singh & Hamdy, 2006). 
The prevalence of Parkinson’s disease in over 65’s is reported as 1.8%, and 86% of 
the patients diagnosed with Parkinson’s disease are over 60 years of age (European 
Medicines Agency, 2006; Van Den Eeden, 2003). The prevalence of dysphagia in 
patients with Parkinson’s disease is reported to be over 80% (Altman, Yu, & Schaefer, 
2010; Kalf, de Swart, Bloem, & Munneke, 2012; Nilsson, Ekberg, Olsson, & Hindfelt, 
1996; Roden & Altman, 2013). The prevalence of dementia has been reported 
between 4-7% in over 65’s (European Medicines Agency, 2006). Dysphagia is 
reported to occur in up to 70% of patients with advanced dementia (Eggenberger & 
Nelms, 2004). Cancer of the head and neck is common with advancing age;  between 
2008 and 2010, 44% of the diagnosed cases of head and neck cancer were in patients 
 7 
aged 65 and over (Cancer Research UK, 2013). Age-related conditions affect the oral 
preparatory stage of swallowing and also result in delays in transit of the bolus in the 
latter phases (Khan et al., 2014; Roden & Altman, 2013).  
 
Medicines can also cause dysphagia as a side effect. Drugs such as anticholinergics, 
tricyclic antidepressants and sedatives can cause xerostomia (dry mouth) which 
affects bolus formation and its transportation to the stomach due to lack of lubrication 
(Balzer, 2000; Gallagher & Naidoo, 2009). Xerostomia is reported to occur in 12-39% 
of older adults, and it is more commonly a result of increased use of medicines that 
cause xerostomia rather than aging (Thomson, 2015).   
 
Dysphagia can be caused by the natural process of aging (presbyphagia). Several 
changes occur in the swallowing process for older adults as a result of aging which 
are summarised in Table 1-2. 
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Table 1-2: Effects of aging on the swallowing process 
Stages Description 
The oral phase 
(voluntary control) 
The oral preparatory phase is affected by tooth loss and general poor dentition, resulting 
in an increased number of chew strokes to break food safely (Cichero & Murdoch, 2006).  
 
An increase in connective tissue in the tongue and a reduction in masticatory strength 
results in a reduced tongue driving force, the force necessary to propel the bolus into the 
pharynx, thus increasing the oral phase duration (Cichero & Murdoch, 2006; Sonies, 
Parent, Morrish, & Baum, 1988).  
 
Rapid ingestion of large quantities of food was observed to be a common problem in 
older adults for swallowing safely and an increased amount of oral phase residue was 
noticed post-swallow for older adults (Ekberg & Feinberg, 1991; Tracy et al., 1989). 
 
The pharyngeal 
phase (involuntary 
control) 
Delays in triggering the swallowing reflex due to more time needed to form a bolus, and 
an increase in pharyngeal residue post swallowing due to weaker muscle contractions 
have also been reported in older adults thus there is often a second reflex to clear the 
residue (Cichero & Murdoch, 2006; Tracy et al., 1989). 
 
The oesophageal 
phase (involuntary 
phase) 
Alterations in the oesophageal phase due to aging involve slower bolus movement and 
clearance (Cichero & Murdoch, 2006). Gregersen, Pedersen, & Drewes (2008) found 
that the peristaltic function of the oesophagus deteriorates after the age of 40, and the 
oesophagus becomes stiffer with age. 
 
 
 
1.3 Diagnosis of dysphagia and the health implications 
Swallowing impairment can be investigated through bedside examination or by using 
instruments. Bedside examination involves observation of the patient during the 
consumption of a small amount of food or water. This examination is subjective, and 
signs of coughing, throat clearing, loss of liquid from the mouth and breathlessness 
are observed as signs of dysphagia (Singh & Hamdy, 2006). The water swallow test 
includes the patient drinking 90mL of water as they usually would and signs of 
coughing, a wet or ‘gurgly’ voice post swallowing and an increase in respiratory rate 
after swallowing is observed for dysphagia (Cichero, Heaton, & Bassett, 2009).  
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Instruments such as endoscopy and fluoroscopy can also be used to assess 
dysphagia (Sura, Madhavan, Carnaby, & Crary, 2012). Videofluroscopic Swallow 
Study (VFSS) has traditionally been used for swallowing assessments. It involves the 
administration of barium liquid followed by capturing images of its movement in the 
oropharynx and oesophagus in lateral view (Singh & Hamdy, 2006). VFSS allows 
observation of entry of the barium into the airway (penetration) or below the true vocal 
cords (aspiration) (Singh & Hamdy, 2006). Fiberoptic Endoscopic Evaluation of 
Swallowing (FEES) involves insertion of a tube through the nose to the hypopharynx 
providing a more anatomical assessment of the pharynx (Campbell-Taylor, 2008; 
Nacci et al., 2008). A bolus such as water is administered and FEES permits 
evaluation of the upper airway and upper digestive tract (Nacci et al., 2008).  
 
Swallowing difficulties can have detrimental health implications, including aspiration 
and penetration (Chadwick & Jolliffe, 2009). Penetration is defined as the passing of 
the bolus into the airway but not below the vocal cord and aspiration is the passing of 
the bolus below the vocal cord (Han et al., 2016). Aspiration can result in pneumonia 
which in severe cases can lead to death (Chen, Golub, Hapner, & Johns, 2009). 
Swallowing difficulties can also affect medicines adherence, as patients may find 
swallowing tablets or capsules difficult (Marquis et al., 2013). Dysphagia can also 
cause malnourishment (due to reduced food intake) and dehydration (due to reduced 
fluid intake) (Ekberg, Hamdy, Woisard, Wuttge-Hannig, & Ortega, 2002; Strachan & 
Greener, 2005). Difficulties in swallowing can affect eating and drinking which are 
social and pleasurable experiences for people. This can cause distress for patients 
who are unable to enjoy these pleasures and consequently cause patients to feel 
anxious and isolated (Ekberg et al., 2002). The inability to eat has been reported as a 
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social handicap that affects not only a patients’ physical wellbeing but also their mental 
wellness (Nguyen et al., 2005). 
1.4 Eating and drinking for dysphagic patients  
Dietary modification is the mainstay compensatory intervention for dysphagia 
management (Campbell-Taylor, 2008; Ney, Weiss, Kind, & Robbins, 2009). The aim 
of food and drink modification is to make the transfer of food and fluid boluses from 
the oral cavity to the oesophagus easier. A speech and language therapist would 
generally assess the patient and determine the safety of oral intake.  
 
Texture modified food is graded depending on the level of impairment in the oral 
preparatory phase, and a speech and language therapist will determine the person’s 
ability to safely swallow food textures and recommend an appropriate texture 
accordingly (Cichero, 2013). Overall, the bolus needs to be soft for those that have 
difficulties in chewing food, cohesive to help those unable to manipulate the bolus 
safely into the pharynx and moist to aid the transport of the bolus during the swallowing 
process (Cichero, 2015). Although the need for textural adaption is recognised, there 
is no recommended instrumental ranges for softness (or firmness), cohesiveness and 
adhesiveness and recommendations are subjective.  
 
There are generally three levels of texture modification depending on dysphagia 
severity that is commonly described as pureed, mashed or soft (Cichero, 2015). The 
first level of texture modification is pureed food, which does not require chewing. It is 
described as cohesive, homogeneous, non-sticky and lump-free (Cichero, 2015; 
National Dysphagia Diet Task Force & American Dietetic Association, 2002). It is 
usually recommended for patients with moderate to severe level of dysphagia and 
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patients that have severe oral phase impairment such as poor tongue control or 
significant difficulties in chewing ability (Cichero, 2015). Level 2 can be described as 
‘mashed or minced’ food. Food in this category requires minimal chewing and can 
easily form into a bolus. Meats are ground or minced, and sauces, gravy or custard 
are added to increase the moisture content of the food (Cichero, 2015). It is 
recommended for patients with mild to moderate dysphagia. Patients who fatigue with 
chewing or take a longer time to form the bolus or have dry mouth are recommended 
this modification in food texture. The third consistency is ‘soft’ food that is closest to 
the regular food and may be prescribed for patients with mild dysphagia, those with a 
mildly reduced bite or chewing strength or poor dentition (Cichero, 2015). 
 
Thin fluids (e.g. water and beverages) are modified using thickeners (gum or starch 
based) to increase viscosity allowing better control of the speed and direction of the 
bolus transiting into the pharynx, providing greater time for the airway to close and 
preventing spillage into the airway (Campbell-Taylor, 2008; Nicosia & Robbins, 2001; 
Sura et al., 2012).   
 
Viscosity (resistance to flow) is often described as the salient property for safe-
swallowing of fluids. Dysphagia thickening products often have specific quantities of 
thickeners to add to cold or hot beverages or water resulting in three levels of 
thickening. Independent of the use of thickening agents, there was no international 
standard relating to levels of viscosity and descriptors corresponding to the viscosity 
ranges (Newman, Vilardell, Clavé, & Speyer, 2016). The American National 
Dysphagia Diet Task Force (2002) developed and classified these consistencies 
(Table 1-3). The consistency stages are classified by a range of viscosities measured 
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at 50s-1 (the shear rate considered to represent the shear rate in the oral cavity during 
swallowing) for each category of thickness. The shear rate was chosen in the 1960’s, 
a study involving sensory panels was conducted to correlate actual viscosity 
measurements with perceived viscosity measurements for non-Newtonian fluids 
(Shama, Parkinson, & Sherman, 1973; Shama & Sherman, 1973). The shear rate was 
assumed to be a constant, but further investigations provided a wider range of shear 
rates (1-1000s-1) for fluids and foods using sensory evaluation by healthy volunteers 
(Shama et al., 1973; Shama & Sherman, 1973). The levels of classification of 
consistency depends on the severity of dysphagia.  
 
Table 1-3: Consistencies for thickened fluids and the viscosity range measured at 
50s-1 at 25°C (British Dietetic Assocatiaion, 2009; National Dysphagia Diet Task 
Force & American Dietetic Association, 2002). 
 
Consistency Viscosity (cP) 
Stage I, mildly thick; nectar like consistency 51-350 
Stage II, moderately thick; honey-like consistency 351-1750 
Stage III, extremely thick; spoon-thick consistency >1750 
 
The differences in levels of thickening and terminology in different countries led to the 
development of a global standardised framework and were published in November 
2015 (International Dysphagia Diet Standardisation Initiative, 2016b). The framework 
consists of 8 levels associated to consistencies of drink and food Figure 1-2. Liquidised 
food and moderately thick drink are considered to be equivalent in this framework; 
similarly  pureed food and extremely thick liquid  are shown as equivalent in Figure 1-
2 as these were determined to be the same in flow characteristics by the International 
Dysphagia Diet Standardisation Initiative (IDDSI) committee. Transitional foods 
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(Figure 1-2), such as ice cream and jellies are foods that become easier to chew or 
swallow with lubrication in the oral cavity and are used for individuals with 
developmental disabilities (International Dysphagia Diet Standardisation Initiative, 
2016b).  
 
 
 
Figure 1-2: IDDSI diet framework from The International Dysphagia Diet 
Standardisation Initiative 2016 @https://iddsi.org/framework/ (International 
Dysphagia Diet Standardisation Initiative, 2016b). 
 
1.5 Fundamental swallowing parameters 
A number of parameters are reported to influence the safe transfer of bolus from the 
mouth to the stomach (Glassburn & Deem, 1998; Nicosia & Robbins, 2001; Pelletier 
& Dhanaraj, 2006; Steele & Cichero, 2008). Parameters such as tongue pressure 
(Nicosia & Robbins, 2001; Steele, Molfenter, Péladeau-Pigeon, Polacco, & Yee, 
2014), characteristics of bolus such as viscosity, density, volume and velocity of bolus 
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transfer are included (Dantas et al., 1990; Sopade, Halley, Cichero, & Ward, 2007; 
Steele et al., 2014).  
 
1.5.1 Tongue pressure 
The tongue plays an essential role in the swallowing function; the muscles in the 
tongue provides a driving force to the bolus to propel it to the pharynx (Peladeau-
Pigeon & Steele, 2017). The amplitude of tongue pressure vary for swallowing different 
consistencies. Thin liquids (water) are reported to require lower tongue pressure ( 
approximately 15 kPa) for swallowing compared to nectar- and honey-thick fluids 
(approximately 20 kPa) (Gingrich et al., 2012; Steele et al., 2010, 2014). 
 
The maximum pressure generated by the tongue is believed to decline with age; young 
adults reportedly apply approximately 80kPa while older adults generate 
approximately 60kPa (Yoshioka, Ozawa, Yuka, Mukohyama, & Taniguchi, 2004). The 
tongue strength was reported as significantly lower for healthy older adults showing 
aspiration (36 kPa) assessed using FEES compared to older adults swallowing safely 
(42kPa) (Butler et al., 2011) The implications of reduced tongue pressure may 
increase the risk of aspiration (Peladeau-Pigeon & Steele, 2017).  
 
1.5.2 Bolus characteristics  
Individuals with dysphagia require a longer time for swallowing in the oral phase to 
prevent premature spillage of the bolus into the airway. If the bolus transit is too fast 
into the pharynx, it can spill into the airway before the complete closure of the airway 
for safe swallowing (Lundy et al., 1999). A slower transit of bolus to the pharynx can 
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be achieved by increasing the viscosity of the bolus (Clavé et al., 2006; Dantas et al., 
1990).  
 
Thickened fluids have been used in dysphagia management to achieve reduced bolus 
velocity.  Bolus velocity can be reduced by increasing the viscosity of the bolus or 
reducing the bolus volume (Clavé et al., 2006; Dantas et al., 1990; Tashiro, Ono, 
Atsuko Tanigome, Kumagai, & Kumagai, 2010).  Increasing bolus volume (2.5, 5, 10, 
20mL) was observed to increase velocity of the bolus in the pharynx (Ekberg, Olsson, 
& Sundgren-Borgström, 1988). A study assessed swallowing of thin, nectar-thick and 
spoon-thick liquids (Resource Thicken Up, a xanthan gum based thickener added to 
water) using VFSS in 46 patients with brain damage (mean age 48 years) and 46 
patients with neurodegenerative diseases (mean age 54 years) (Clavé et al., 2006). 
The findings showed that patients with brain damage presented aspiration with thin 
liquids (21.6%) which were significantly reduced to 10.5% with nectar thick liquids and 
reduced further to 5.3% with spoon-thick liquids. Aspiration was observed in up to 
29.7% of neurodegenerative patients swallowing thin liquids; this was reduced 
significantly to 22.3% with nectar, and less than 3% with spoon-thick liquids (Clavé et 
al., 2006). Another study assessing swallowing of nectar thick and honey-thick liquids 
in 711 patients aged 50-95 who have presented aspiration on thin liquids using VFSS 
found that elimination of aspiration occurred more often with honey-thickened liquids 
(63%) than nectar thick liquids (53%) (Logemann et al., 2008).  
 
Bolus volume is also reported to influence the safety of swallow. A significant risk of 
aspiration was reported for bolus volume of 20mL compared to 5, 10 and 15 mL in 
healthy older adults (61-70 years) (Butler et al., 2010). Higher bolus volumes  (2-20mL) 
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were reported to increase oral retention time and a greater magnitude of structural 
movement was required for oropharyngeal clearance (Dantas et al., 1990). However, 
too small a volume (1mL vs 5mL) was also reported more challenging to swallow by 
stroke patients (Bisch, Logemann, Rademaker, Kahrilas, & Lazarus, 1994). 
 
Although the focus of dysphagia management is modifying the viscosity of liquids, 
other properties such as cohesion and yield stress of fluids have also been mentioned 
in literature, albeit scarcely, that might contribute to safe-swallowing. Thin liquids with 
low cohesion between particles can result in spillage into the airway in dysphasic 
patients due to the patients’ inability to control laryngeal closure (Cichero & Murdoch, 
2006; Prinz & Lucas, 1997; Tashiro, Ono, Atsuko Tanigome, Kumagai, & Kumagai, 
2010). Yield stress described as the minimum stress required to enable flow is 
reported as a potentially relevant parameter in safe swallowing, as the yield stress 
must be surpassed to allow the flow of the bolus  (Cho, Yoo, & Yoo, 2012; Steele & 
Cichero, 2007). Viscosity and yield stress are both linked intrinsically to flow (Payne, 
Methven, Fairfield, Gosney, & Bell, 2011; Popa Nita, Murith, Chisholm, & Engmann, 
2013). As reported earlier, increasing thickening and hence yield stress, requires 
greater tongue strength to propel the bolus in to the pharynx (Gingrich et al., 2012; 
Steele et al., 2010, 2014). Bolus density (mass per unit volume) relating to the weight 
of the fluid has also been described particularly important for swallowing. Density and 
yield stress of fluids have been linked to increasing solid content (Germain, Dufresne, 
& Ramaswamy, 2006; Sopade et al., 2007). Dantas et al., (1990) reported barium 
paste (density of 2.8g/cm3) showed a slower oral and pharyngeal transit time in healthy 
subjects compared to liquid barium (density of 1.4g/cm3).  
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A study was conducted in eighteen young students (aged 22-25) for sensory analysis 
of  perceived ease of movement of semi-liquid samples (prepared using pregelatinized 
waxy corn starch as a thickener)  in the pharynx, comparing to videomanoflurography 
(combination of manometry and videoflurography) measurements (Takahashi, Nitou, 
Tayama, Kawana, & Ogoshi, 2002). A compression test using a texture analyser was 
used to characterise the semi-liquid samples for hardness, cohesiveness, and 
adhesiveness. Thickened samples showed an increase in hardness, viscosity and 
adhesiveness with increasing thickener concentration; however, the cohesiveness of 
all samples was similar. The study found that increased hardness, viscosity and 
adhesiveness resulted in perceived difficulty in swallowing and slower bolus transit in 
the pharynx assessed by videomanoflurography (Takahashi et al., 2002).  
1.6 In vitro swallowing models 
There have been attempts to study the in vitro swallowing behavior of fluids and food 
using less cumbersome and less invasive approaches compared to in vivo 
assessments such as endoscopy. Nicosia & Robbins (2001) used two parallel plates 
simulate the tongue movement against the palate in order to derive mathematical 
models to calculate the flow of bolus in the oral cavity. The study found that the time 
taken to clear half of the bolus in the mouth and the pressure applied by the tongue 
increased with increasing bolus density and viscosity. Mackley et al. (2013) used an 
in vitro throat model (Figure 1-3) with the geometry of an adult human throat simulating 
tongue peristalsis, to observe in vitro fluid flow behavior. The model consists of a 
“throat” with static features such as the epiglottis (Mackley et al., 2013). The roller 
represents the tongue which is activated by releasing a weight attached to the pulley 
wheel (Mackley et al., 2013). The upper section of the ‘mouth’  in the throat model 
required a tube which is pushed backward by the moving roller (Mackley et al., 2013). 
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The study found that the time taken to complete roller motion and the time taken for 
boluses to move from the epiglottis to the airway divide in the throat model increased 
with increasing viscosity of the test fluid. 
 
Figure 1-3: a) In vitro throat model (Mackley et al., 2013) and b) the modified in vitro 
throat model (reprinted with permission) from Hayoun et al., 2015). 
 
A modified version of this throat model was developed with the addition of a counter 
weight to equilibrate the weight of the pivoting arm and an initial angular position of 
the roller (θi = 45°) to better mimic the contact between the tongue and bolus (Hayoun 
et al., 2015). The study involved processing Newtonian sugar molasses in the throat 
model and found that an increase in viscosity resulted in higher residual mass in the 
oral phase and a slower bolus flow. Despite the link of density and viscosity increasing 
with solid content in thickened fluids,  a study on the flow of Resource ThickenUp Clear 
(xanthan gum thickener) and E-Z- Paque (barium) contrast agent containing 41% 
higher density than the thickener in this throat model showed that an increase in bolus 
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density to play a negligible difference in bolus propulsion in the mouth (Mowlavi et al., 
2016).  
 
There are other in vitro models focusing on the oral processing aspect of swallowing. 
Woda et al. (2010) developed and validated a mastication simulator to produce food 
bolus with similar particle sizes compared to expectorated peanuts and carrots from 
healthy subjects. Parameters such as the number of chewing cycles and duration, 
temperature control, compression force and saliva addition can be controlled. Size 
reduction in agar gels was observed using an artificial tongue (silicone rubbers of 
varying elastic moduli) in between a compression apparatus (metal) to simulate 
tongue-palate compression (Ishihara et al., 2012). The study found that fracturing of 
agar gels occured when the deformation (strain) of gels was larger than the artificial 
tongue and the gels remained intact when the strain of gels was smaller or equivalent 
to the artificial tongue (Ishihara et al., 2012). More recently, an in vitro device focusing 
on the pharyngeal swallowing process has been developed (Stading et al., 2019). A 
syringe is used to deliver a bolus into the artificial  pharynx  made of a polycarbonate-
like material (Accura ClearVue), the device can simulate closing of the larynx and a 
moving epiglottis using a stepper motor, and the upper oesophageal sphincter is 
modeled using a clamp. The device allows a velocity profile of bolus movement in the 
pharynx to be obtained (Stading et al., 2019). 
 
Although in vitro simulators cannot replace clinical testing as it is difficult to mimic the 
complicated biophysical reality of swallowing; it can be used to discriminate the flow 
behavior of different products to aid selection for in vivo testing.  
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1.7 Medicines management in patients with dysphagia 
Aspiration or choking risk is a concern for patients unable to safely swallow their 
medicines. The IDDSI recommends from a texture perspective, individuals who can 
manage regular food (Level 7, Figure 1-2), soft and bite-sized foods (Level 6, Figure 
1-2) and minced and moist foods (Level 5, Figure 1-2) may be able to swallow tablets 
and capsules safely (International Dysphagia Diet Standardisation Initiative, 2016b). 
Individuals on lower levels of texture modifications are considered at risk of choking 
or aspiration to swallow (International Dysphagia Diet Standardisation Initiative, 
2016b).  
 
There has been some endeavour to quantify the extent of difficulties in swallowing 
SODF in older adults. No definition of swallowing difficulties have been provided in 
literature relating to difficulties in swallowing SODF, however, challenges in 
swallowing the SODF are usually related to dysphagia. A study conducted in 17 
community pharmacies (independents and multiples) in England and Northern Ireland, 
distributed questionnaires to 792 patients suspected of having swallowing difficulties 
(Strachan & Greener, 2005). The study found that 60% of patients (aged 60-89) 
indicated difficulties in swallowing tablets and capsules (Strachan & Greener, 2005). 
Difficulties in swallowing SODF were observed in 29.5% of hospitalised older adults 
in France (Fodil et al., 2017). A survey of 540 nurses working mainly in nursing homes 
for older adults in the UK found that on average 15% of residents had difficulties in 
swallowing tablets and capsules (Wright, 2002). Schiele et al. (2015) found that 
patients with stroke-induced dysphagia had increased risk of penetration-aspiration 
when swallowing SODF together with spoon-thick consistency thickened fluid. Out of 
52 patients, 40.2% of patients experienced severe difficulties in swallowing SODF with 
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spoon-thick water (Schiele et al., 2015). Changing the type and shape (round, oval, 
oblong and capsule) of the SODF did not modulate the risk of penetration-aspiration 
(Schiele et al., 2015). 
 
Medicines administration difficulties are ideally addressed by prescribing alternative 
drug delivery formulations such as liquids when SODF are not suitable. In practice, in 
order to help patients swallowing their medications, SODF are sometimes 
administered unlicensed, by splitting, chewing or crushing tablets or opening capsules. 
Modifying SODF should be the last resort when no licensed alternatives are available 
(Wright et al., 2006). However, if liquid alternatives are unavailable or are expensive 
to prescribe then manipulation of SODF is common practice to facilitate ingestion of 
medicines. The practice of medicines modification is often outside the product license; 
this places the liability of harm with the prescriber or administrator (nurse or carer) 
(Barnett & Parmar, 2016). 
 
A study involving a self-administered questionnaire to nursing home nurses found the 
most common method employed by nurses for medicines administration for patients 
with swallowing difficulties was obtaining a liquid alternative (88% of nurse 
respondents), followed by crushing tablets or opening capsules (61% of nurse 
respondents) (Wright, 2002). Studies in aged-care facilities in Australia and Ireland 
found that 18-35.1% of residents had medicines modified (i.e., crushing tablets) to 
facilitate ingestion (Gillicuddy et al., 2016; Mercovich, Kyle, & Naunton, 2014; Paradiso 
et al., 2002).  This practice of modifying medicines was also observed for community-
dwelling  patients; 68% of 792 patients suspected of having swallowing difficulties, 
crushed their tablets or opened capsules to release the content to help swallow their 
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medicines (Strachan & Greener, 2005). A survey into medicines modification for five 
community pharmacies in Australia found that 10.6% of the 369 patients (ages 18- 60 
years plus) modified their medicines (Lau, Steadman, Mak, Cichero, & Nissen, 2015). 
A questionnaire survey conducted in eleven general practices in Germany, found that 
58.8% of the 393 patients (18- 80 years, mean 61.8 years) with swallowing difficulties 
modified their SODF (Schiele, Quinzler, Klimm, Pruszydlo, & Haefeli, 2013). 
Observation of medicines administration for 1257 oral doses in 36 drug rounds at a 
psychiatric hospital in the UK found that 26% of SODF were altered to facilitate 
swallowing and 44% of these alterations were not authorised by a pharmacist (Haw, 
Stubbs, & Dickens, 2007). A study in hospitals in Queensland  using self-report 
surverys found 79% (n=31) of hospitals reported medication for adults and children 
were modified at the bedside, 88% of 73 medications modified were for adults (Nissen, 
Haywood, & Steadman, 2009). 
 
It is recognised that modification of SODF is common practice to help swallow 
medicines, but this can be harmful particularly for more complex SODF where the rate 
and site of drug release must not be altered. For example, modified release 
formulations such as enteric coated and sustained release formulations are designed 
to provide either delayed release or extended release of the drug.  Enteric coated 
products are designed to pass through the stomach unaltered and release the drug 
content within the intestinal tract (Porter, Sackett, & Liu, 2017). Enteric coating is used 
for many reasons including preventing degradation of acid-labile drugs and stomach 
irritation. Alteration of these dosage forms can result in reduced drug absorption and 
efficacy and may irritate the stomach mucosa if the enteric coating is used to reduce 
irritant effects (Mercovich et al., 2014). Sustained release dosage forms are designed 
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to release drug content slowly over an extended period to reduce multiple daily dosing 
for drugs that have short half-lives (Mercovich et al., 2014; Paradiso et al., 2002). 
These dosage forms contain more drug content than conventional immediate release 
dosage forms, and altering these formulations can result in the entire drug content 
being released instantly, having the potential to cause toxicity (Schier et al., 2003).  
Even for immediate release dosage forms that are designed for immediate 
disintegration and dissolution after ingestion (mostly in the stomach), modifying these 
dosage forms may result in alternation of absorption and bioavailability (Dodds Ashley, 
Zaas, Fang, Damle, & Perfect, 2007; Henney, Fitzpatrick, Stewart, & Runyan, 2008; 
Lippert, Gbenado, Qiu, Lavin, & Kovacs, 2005; Zafar, Farkouh, Fuster, & Chesebro, 
2009). For example, crushed voriconazole tablets showed higher drug absorption 
compared to the tablets administered intact (Dodds Ashley et al., 2007).  Additionally, 
the loss of drug during crushing and transferring may also lead to subtherapeutic 
dosing (Manessis et al., 2008; Thong, Manrique, & Steadman, 2018). Furthermore, 
modification of light-sensitive drugs could compromise the stability of the drug 
(Paradiso et al., 2002; Root, Tomlin, Erskine, & Lowey, 2011). 
 
Difficulties in swallowing medicines can be challenging for patients prescribed multiple 
medications. Many older adults are prescribed polypharmacy (average 5 or more 
medications) to treat multimorbidity (two or more disease states) (Hughes, Cadogan, 
Patton, & Ryan, 2016; Morin, Johnell, Laroche, Fastbom, & Wastesson, 2018). The 
pill-burden may complicate adherence particularly in patients with swallowing 
difficulties. Strachan & Greener (2005) reported that 64% of patients in the community 
setting admitted to not taking their medication as a result of swallowing difficulties and 
a study conducted in polypharmacy patients in the community setting (mean age 67 
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years) reported that 23% of patients with ongoing (9.0%) or past (13.4%) swallowing 
difficulties did not take their medication (Marquis et al., 2013). Non-adherence with 
SODF is not just limited to swallowing difficulties.  Individuals without swallowing 
difficulties may have an aversion or anxiety towards swallowing tablets and capsules 
(Schiele et al., 2013). Individual with previous experience of tablets or capsules stuck 
in their throat, choking, gagging, repeated swallowing attempts led to 28.2% of 393 of 
patients fearful of swallowing their medicines (Schiele et al., 2013). Patients 
experiencing pill swallowing discomfort may go unreported out of embarrassment or 
feeling that difficulty in swallowing is normal (Llorca, 2011).  
 
1.8 Other physiological changes with aging 
Apart from changes in absorption and bioavailability from modifications of medicines, 
there are also noteworthy physiological changes during ageing affecting therapeutic 
effects. Pharmacokinetics is a term used to describe physiological processes affecting 
absorption, distribution, metabolism, and excretion (ADME) of the drug. There are 
important physiological changes that occur with aging and changes in ADME that will 
influence the physiological response to the drug treatment (Perrie et al., 2012).  
 
Drug absorption occurs mainly in the small intestine after gastric emptying. Gastric 
motility is reduced with aging which may result in reduced or delayed drug absorption 
(Evans, Triggs, Cheung, Broe, & Creasey, 2015). Gastric pH increases with aging as 
gastric acid production decreases; the increase in gastric pH may affect ionisation and 
solubility of the drug in the stomach and subsequent drug absorption (Baron, 1963; 
Lavan, O’Grady, & Gallagher, 2017). For example, a subtherapetic response may be 
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observed for ketoconazole,  a weakly basic drug, which has low solubility at higher pH 
(Lahner, Annibale, & Delle Fave, 2009). 
 
Drug distribution occurs after drug absorption. The body composition of fat, protein, 
and water differ from older adults (30:12:54) to younger counterparts (18:16.5:60) 
(Piug, 1996). Drug distribution is effected by body composition changes. Lipophilic 
drugs show a higher volume of distribution compared to hydrophilic drugs due to the 
increase in fat (Klotz, Avant, Hoyumpa, Schenker, & Wilkinson, 1975; Robertson et 
al., 1989). This can result in increased elimination half-life for liphophilic drugs and 
therefore a prolonged drug effect and accumulation with the potential for adverse drug 
events and toxicity (Lavan et al., 2017). For example, diazepam is a lipophilic drug 
and has a two-fold increase in half-life in older adults and therefore, a reduced dose 
is required for older adults compared to adult patients (Herman & Wilkinson, 1996). 
The volume of distribiution decreases for hydrophilic drugs and therefore, a higher 
plasma concentration of the drug for older adults which can result in toxicity (Lavan et 
al., 2017). Furthermore, reduced plasma protein levels such as albumin and a-acid 
glycoprotein	 may lead to an increase of unbound drug in the plasma which is 
pharmacologically active increasing the chances of adverse drug events and toxicity 
(Heuberger, Schmidt, & Derendorf, 2013).	
 
Drug elimination is dependent on liver function for drug metabolism followed by 
excretion through the kidneys. Changes in drug metabolism in older adults are 
associated with reduced hepatic blood flow, decreased hepatic function and activities 
of liver enzymes such as the cytochrome p450 system; this reduces the metabolic 
elimination of drugs and results in a prolonged half-life of drugs (Abernethy, 
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Greenblatt, & Shader, 1985; Turnheim, 2003). Higher bioavailability of drugs and 
reduced metabolic clearance may require dose adjustment to avoid adverse events, 
for example for drugs such as morphine and verapamil (Eldesoky, 2007; Guay, 2007). 
 
A decline in glomerular filtration rate and renal plasma flow occurs with age which 
would reduce the rate of clearance for drugs predominantly eliminated by the kidneys  
such as gentamycin and acyclovir (Eldesoky, 2007; Hilmer et al., 2011; Mühlberg & 
Platt, 1999).  
1.9 Dosage form considerations for dysphagic patients 
The shortfall in medicines provision for patient sub-groups such as children and older 
adults is recognised. In 2007, the Paediatric Regulation was enforced in the European 
Union to address the lack of appropriate paediatric medicines (European Medicines 
Agency, 2011b). The objective of this regulation was to improve drug formulations for 
children aged 0-18 years (European Medicines Agency, 2011b). Guidance released 
by the European Medicines Agency (EMA) in 2011 for paediatrics stressed that 
acceptability must be considered in paediatric formulation development and provided 
guidance on considering the appropriateness of the pharmaceutical dosage form for 
paediatrics with consideration of dosing frequency, excipients and packaging 
(European Medicines Agency, 2011b). This guidance was further updated in and 
released in 2014 (European Medicines Agency, 2013b).  
 
The European Medicines Agency (EMA) also recognized that older adults are the main 
users of medications and in 2011, the EMA released Geriatric Medicines Strategy with 
the aim to ensure medicines used by older adults are evidence-based and to improve 
the availability of information for informed prescribing and use of medications 
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(European Medicines Agency, 2011a). The Geriatric Expert group was established in 
2011 to provide scientific advice of the development and assessment aspects of 
medicines and released a concept paper outlining the need of a reflection paper on 
the quality aspects of medicines for older adults (European Medicines Agency, 2013c, 
2013a) . The intention was to identify the limitations of licensed pharmaceutical dosage 
forms in meeting the needs of older adults. Acceptability of dosage forms has been 
defined as the “overall ability of the patient or caregiver to use a medicinal product as 
intended or authorized” and acceptability is an important aspect of pharmaceutical 
dosage form consideration for both paediatric and geriatric patients (Kozarewicz, 
2014).  The EMA Quality Working Party released a draft reflection paper in 2017 
highlighting the distinct needs of older adults for drug products with the reflection of 
advantages and disadvantages of different dosage form preparations with particular 
importance to patient acceptance and willingness to take their medication and 
acceptance by caregivers to administer the medication as authorized (European 
Medicines Agency, 2017).  
 
Aging is associated with multimorbidity and patients can have disabilities that may 
affect the handling and use of dosage forms (Stegemann, 2018). Preparations such 
as buccal or sublingual dosage forms pose a risk for accidental swallowing (European 
Medicines Agency, 2017). This requires particular attention to patients with impaired 
cognition and reduced physical capabilities, both associated with aging (Sino, 
Sietzema, Egberts, & Schuurmans, 2014). Preparations for nasal and inhalation 
administrations require specific skills for usage which again would be challenging for 
patients with difficulties in understanding or cognitive impairment (Iwanaga, Sano, & 
Tohda, 2017). Transdermal patches require reaching the site of administration which 
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may be challenging for patients with reduced physical capabilities and would also be 
limiting for patients with polypharmacy, which would require a number of patches to 
be applied (Kaestli, Wasilewski-Rasca, Bonnabry, & Vogt-Ferrier, 2008). Similarly, 
rectal and vaginal preparations would be challenging for patients with cognitive 
difficulties and patients may also feel embarrassed in asking assistance from 
caregivers to apply these preparations (European Medicines Agency, 2017).  
 
For patients with difficulties in swallowing the obvious route in dosage form 
development may be to avoid the oral route of administration. However, this is the 
preferred route of administration across ages and is the most commonly used and 
convenient for patients (European Medicines Agency, 2017). There are many factors 
such as size, shape, and density of the medication that can affect the ease at which a 
patient swallows their medicines and are discussed below (Channer & Virjee, 1986; 
Perkins et al., 1999). 
 
1.9.1 Tablet and capsule considerations for ease of swallowing 
The transit of tablets and capsules through the oesophagus is influenced by many 
factors; including the size, shape, density and surface characteristics of the dosage 
form (Channer & Virjee, 1986; Perkins et al., 1999). 
 
The size and shape of the tablets and capsules can influence the ease of its transit 
through the oesophagus (Overgaard, Højsted, Hansen, & Christrup, 2001). A study by 
Yamamoto et al. (2013) found that an increase in the size of the tablet requires more 
effort in swallowing and consequently resulted in an increase in a number of swallows 
in fourteen male adults (24-33 years) assessed using electromyographic activity and 
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videofluorographic images. Smaller tablets were found easier and more comfortable 
to swallow by adults than larger ones and the oesophageal transit time was found to 
increase with larger tablets assessed using VFSS and patient preference rating 
(Channer & Virjee, 1986; Overgaard et al., 2001). Oblong and oval tablets transit better 
through the oesophagus compared to circular tablets, and arched tablets pass through 
the oesophagus better than flat tablets in adults assessed using VFSS and patient 
prefererence (Channer & Virjee, 1986, 1985; Hey, Jørgensen, Sørensen, 
Hasselbalch, & Wamberg, 1982; Overgaard et al., 2001). 
 
Gelatine capsules have been reported to have an adhesive nature and are likely to be 
more prone to delayed oesophageal transit (Channer & Virjee, 1985; Hey et al., 1982; 
Osmanoglou et al., 2004). Studies by Perkins et al.,(1994, 1999) found that the 
oesophageal transit time in healthy adults (50-79 years) of the gelatin capsule was 
slower than that of an oblong shaped uncoated tablet and a cellulose film-coated 
tablet. However, contradicting results were found by Channer & Virjee (1986, 1985) 
who reported that the oesophageal transit of capsules was found to be shorter than 
uncoated oval tablets in 115 subjects (aged 17-82 years). 
 
A study in the general practice population found that patients with swallowing 
difficulties preferred tablets over capsules, and round tablets over oval or oblong 
tablets (Schiele et al., 2013). This contradicts the findings presented in the studies of 
oesophageal transit of different solid oral dosage forms (Channer & Virjee, 1986, 1985; 
Hey et al., 1982; Overgaard et al., 2001). The authors speculated that difficulties or 
discomfort in swallowing oval or oblong tablets or capsules might be due to the tablet 
or capsule rotating during deglutition (Schiele et al., 2013). A study assessing the 
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swallowability of medium sized (1-1.5cm diameter) round, oval, oblong tablets and a 
capsule in older adult patients with dysphagia was assessed using FEES and VFSS  
in 41 patients found no significant differences between the type and shape of SODF 
for penetration-aspiration (Schiele et al., 2015).  Patient posture has been considered 
in aiding swallowing of SODF. Postural changes are used as compensatory 
treatments for oropharyngeal dysphagia. Schiele, Schneider, Quinzler, Reich, & 
Haefeli (2014) investigated two methods of swallowing SODF, the pop-bottle method 
for tablets and lean-forward technique for capsules in 151 participants (aged 18-85 
years) with 56% of participants reporting difficulties in swallowing SODF. The pop-
bottle method involved placing placebo tablets (round, oval, oblong) on the tongue, 
followed by closing the lips firmly around the opening of a polyethylene terephthalate 
bottle and swallowing the tablet in a quick suction movement (Schiele et al., 2014). 
The lean-forward method involved swallowing the capsules in an upright position and 
tilting the head forward. Participants swallowed the  SODF using 20mL of water and 
rated the ease of swallowing on an 8-point Likert scale (Schiele et al., 2014).  The pop-
bottle method improved swallowing in 59.7% of patients and the lean-forwad 
technique improved swallowing for 88.6% of patients (Schiele et al., 2014). 
 
1.9.2 Liquid formulation considerations 
Oral liquid dosage forms are advantageous for dosing flexibility and the potential for 
administration via enteral feeding tubes (European Medicines Agency, 2017). 
However, in the older adult population, when administrating liquid medicines, patients 
may experience difficulty in opening the container and shaking the liquid preparation 
for homogeneity increasing the risk of dose errors and spillages (European Medicines 
Agency, 2017; Notenboom et al., 2014). The viscosity of liquid formulations is an 
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important factor to consider for patients with dysphagia particularly if they are at risk 
of aspiration. In some cases, thickeners may need to be added to aid swallowing for 
patients with dysphagia, which may pose difficulties for administration to these 
patients whom dislike thickened fluids (Garcia, Chambers, & Molander, 2005; Murray, 
Miller, Doeltgen, & Scholten, 2014; Shim, Oh, & Han, 2013). If this is outside the 
manufacturers recommendations then this could render the medicine as unlicensed 
(Kelly & Wright, 2009).  
 
The influence of taste of liquids on the ease of swallowing has been investigated. The 
four main taste sensations traditionally recognised consist of; sweet, sour, salty and 
bitter (Chee, Arshad, Singh, Mistry, & Hamdy, 2005; Leow, Huckabee, Sharma, & 
Tooley, 2007). A study by Leow et al. (2007) found that the sour (citrus) taste had the 
shortest oral bolus preparation time, significantly different from that of sweet (glucose), 
salty (saline), bitter (quinine) and neutral tastants. However, no significant differences 
between neutral, salty, bitter tastants for oral preparation times. A combination of sour 
taste and cold stimuli was found beneficial for patients with oropharyngeal dysphagia 
by reducing the pharyngeal transit time (Cola et al., 2010). The use of sour tastant 
(citrus) has also been found to stimulate saliva secretion (Gupta, Epstein, & Sroussi, 
2006). Carbonated water has been reported to reduce aspiration penetration risk and 
improve pharyngeal transit compared to non-carbonated water in 17 adults (18-80 
years) with neurogenic dysphagia (Sdravou, Walshe, & Dagdilelis, 2012). Carbonated 
water is found to chemically stimulate the protective reflexes which protect the airway 
in healthy adults (Miura, Morita, Koizumi, & Shingai, 2009; Sdravou et al., 2012).   
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The influence of postural change on ease of swallowing liquids has also been 
investigated. The chin-down posture (moving the head downwards to touch the chin 
to the neck) and the head rotation posture is reported to aid narrowing of the laryngeal 
entrance and provide a posterior shift of the epiglottis, allowing more enhanced 
protection of the airway (Logemann et al., 2008; Rasley et al., 2013). The head rotation 
maneuver moves the bolus away from the direction of the head turn while swallowing; 
this is useful for patients with neurological damage in the pharynx to enable bypass of 
the effected area during swallowing (Ohmae, Ogura, Kitahara, Karaho, & Inouye, 
1998). The chin-down and head rotation posture have been useful compensatory 
techniques in swallowing liquids and preventing penetration-aspiration in patients with 
dysphagia (Logemann et al., 2008; Rasley et al., 2013; Solazzo et al., 2012; Terré & 
Mearin, 2012).  
 
1.9.3 Dispersible and effervescent tablets 
Dispersible and effervescent tablets are solid oral tablets that are dispersed in a liquid 
to form a solution before administration. Similarly to liquid formulations, thickeners 
may need to be added for patients at risk of aspiration which may render the medicine 
as unlicensed if it is outside the manufacturers’ recommendations. These tablets often 
require a large amount of water to form a solution. This can be problematic for patients 
who are fluid restricted, i.e., patients with cardiac disease and for patients with 
dysphagia who may aspirate with large sip volumes (Butler et al., 2010). These tablets 
also often contain a large amount of sodium, which can be an issue for patients who 
require a reduced salt intake, i.e., patients with hypertension (George, Majeed, 
Mackenzie, Macdonald, & Wei, 2013).  Sodium based formulations of effervescent 
and dispersible nature were found to increase the risk of cardiovascular events; 
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myocardial infarction, stroke and vascular death compared to standard non-
dispersible, non-effervescent and non-soluble formulations of the same drugs (George 
et al., 2013). A study by Ubeda, Llopico, Sanchez, & Al (2009) found a link between 
an increase in blood pressure in the elderly and the use of effervescent paracetamol.  
 
1.9.4 Orally disintegrating formulations 
Orally disintegrating systems include tablets, films, and wafers (also known as 
orodispersible strips) (Kathpalia, Sule, Gupte, 2013). The demand for orally 
disintegrating formulations has increased particularly for the geriatric and paediatric 
populations who experience difficulties in swallowing SODF (Nagar et al., 2011). The 
Food and Drug Administration (2008) define orally disintegrating tablets (ODT) as “a 
solid dosage form containing medicinal substances which disintegrates rapidly, 
usually within a matter of seconds, when placed upon the tongue”.  There have been 
many orally disintegrating tablets developed for age-related conditions such as 
Parkinson’s disease and Alzheimer’s disease (Muramatsu, Litzinger, Fisher, & 
Takeshita, 2010). A multicenter study by (Nausieda et al., 2005) found that patients 
with Parkinson’s disease preferred ODT of carbidopa-levodopa compared to the 
conventional tablet formulation. 
 
ODT’s have the advantages of requiring a fewer number of swallows, less fluid 
requirement, reduced muscular effort and swallowing duration (Carnaby-Mann & 
Crary, 2005). Carnaby-Mann & Crary (2005) investigated the swallowing effectiveness 
of ODT and conventional tablets. The study found that patients with dysphagia 
required higher number of swallows to clear the conventional tablet from the 
oropharynx and more time and larger volume of liquid were required to swallow 
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conventional tablets compared to ODT. The risk of aspiration, however, was found to 
be similar for both ODT and conventional tablets (Carnaby-Mann & Crary, 2005). 
ODT’s also have limitations of difficulty in taste masking, the maximum dose that can 
be incorporated is low and in achieving customized drug release e.g. controlled or 
delay release (Lopez, Ernest, Tuleu, & Gul, 2015; Venkatesh, Stevens, & Lai, 2012; 
Walsh et al., 2014). 
 
1.9.5 Chewable tablets 
Chewable tablets are tablets that are designed to be mechanically disintegrated by 
chewing. Chewable tablets are a choice for patients who find swallowing solid oral 
dosage forms difficult. These are not intended to be swallowed intact and have to be 
chewed completely before swallowing (Gupta, Chidambaram, & Khan, 2013). 
However, for older adults with poor dentition and reduced chewability, this would prove 
difficult (European Medicines Agency, 2017; Liu et al., 2014). There have been reports 
of adverse events as a result of patients swallowing partially chewed or intact 
chewable tablets, resulting in intestinal obstruction, ischaemia, and perforations 
(Gupta et al., 2013). There have also been reports of tooth damage due to hard 
chewable tablets in older adults (Gupta et al., 2013). 
 
1.9.6 Mini-tablets  
Mini-tablets contain a small amount of the required dose  and normally have a 
diameter of 1-4mm in diameter (European Medicines Agency, 2011b; Stoltenberg & 
Breitkreutz, 2011; Tissen, Woertz, Breitkreutz, & Kleinebudde, 2011; Wen & Park, 
2011).  Mini-tablets offer many advantages. They offer high drug loading and have 
good size uniformity, regular shape and a smooth surface (Hadi, Rao, & Firangi, 2012). 
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Liu, Ghaffur, Bains, & Hamdy (2016) assessed the acceptability of mini-tablets in older 
adults using a questionnaire in the community setting; 115 patients were shown 
samples of mini-tablets filled in hard gelatin capsules and patients were asked to 
provide their opinion on acceptance. Seventeen participants were reported to have 
swallowing difficulties and twelve reported ongoing difficulties in swallowing SODF (Liu 
et al., 2016). Participants (dysphagic and non-dysphagic) preferred minitablets over 
granules and chewable tablets but mini-tablets were less favorable than dispersible 
and orally disintegrating tablets (Liu et al., 2016). Mini-tablets offer better dosing 
flexibility compared to granules, however, these dosage forms may result in chewing 
to aid swallowing and thus not suitable for sustained release dosage forms (van Riet-
Nales et al., 2016). However, participants reported that minitablets might be 
challenging for the visually impaired to use and expressed reservations on taste and 
concerns about not receiving the full dose when mixing minitablets with food if the 
meal is not fully consumed (Liu et al., 2016).  
 
1.9.7 Multiparticulate dosage forms 
Multiparticulate dosage forms include granules, powders and pellets (maximum size 
2.8 mm) that are incorporated into capsules or can be sprinkled onto food or 
reconstituted to a solution or suspension (Food and Drug Administration, 2012). 
Multiparticulates can be further processed into conventional tablets, chewable tablets, 
and orally disintegrating tablets.  
 
In the study by Liu et al. (2014), multiparticulates presented in the form of granules for 
sprinkling onto food were least accepted by older adults with and without dysphagia 
compared to minitablets, dispersible tablets, orally disintegrating tablet and chewable 
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tablets (Liu et al., 2016). Similar to mini-tablets, participants favored the 
multiparticulates as useful for those with swallowing difficulties (Liu et al., 2016). 
However, they  expressed dislike of multiparticulates at needing to complete a meal 
for the whole dose and were reserved on mixing the multiparticulates with the food 
with concerns raised to a potential change in flavor of food (Liu et al., 2016). Adults 
and older adults recruited in another study also expressed a preference for chewable 
tablets compared to multiparticulates; multiparticulates were considered more time 
consuming than chewable tablets for administration (Den Uyl et al., 2010). 
Acceptability and palatability of coated and uncoated multiparticulate pellets  with 
particule sizes of 200, 350, 500 and 700µm were studied in 61 adults (18-37 years) 
(Lopez et al., 2018). Acceptability was measured on voluntary consumption of the 
sample, facial observation, ratings using hedonic scale and the willingness to take 
multiparticulates daily (Lopez et al., 2018). Palatability is considered to affect 
acceptability and is the overall appreciation of the dosage form by organoleptic 
properties such as mouth feel, appearance, smell and taste (Kozarewicz, 2014). 
Palatability was assessed based on grittiness perception in this study (Lopez et al., 
2018). Five hunded milligrams of  microcrystalline cellulose pellets were administered 
with 3mL of spring water and palatability was assessed using a 5-point hedonic scale. 
The ability to swallow the pellets was 100% for adults assessed by participants not 
refusing the administration or expelling the placebo pellets. The willingness to take 
multiparticulates daily was 74% of adults. Smaller sizes and coated pellets were more 
favoured by adults (Lopez et al., 2018). Grittiness perception received negative scores 
by 51% of adults (Lopez et al., 2018). 
 
 
 37 
1.9.8 Novel approaches for immediate release dosage form delivery in patients 
with dysphagia  
Several novel technologies have been developed to help patients swallow SODF. 
Okabe et al. (2008) prepared a dry film formulation that turns into jelly by absorbing a 
small amount of water or saliva. Drug elution in the mouth was restrained due to 
gelating layers on either side of the drug-containing layer (Figure 1-4). The 
oesophagus transit time of the film formulation was found significantly quicker than the 
gelatin capsules in 10 healthy volunteers (Okabe et al., 2008). This approach may be 
difficult for patients with xerostomia which is common in older adults (Cassolato & 
Turnbull, 2003). 
 
Figure 1-4: Schematic representation of the film formulation (reprinted with 
permission) (Okabe et al., 2008). 
 
Another approach for easy swallowing is the development of an oral jelly formulation 
developed for older adults for alendronate sodium hydrate in Japan (Imai, 2013). 
These dosage forms have an advantage of easy swallowing, taking medicine without 
water, masking the drug taste and lower risk of accidental ingestion (Imai, 2013). The 
dosage form comprises of a jelly and air portion, allowing the jelly to be pushed out 
when opening the package (Imai, 2013). 
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Innovations have been made in the last two decades in approaches to ease 
swallowing of medicines, such as inventions aiming at enveloping the dosage form 
thereby increasing the size with a gel to assist the movement of the dosage form in 
the throat. Atsuko, Masanori, Takashi, & Mika (2001) developed a swallowing-
assistive jelly (Ryukakusan’s swallowing aid jelly) using natural polymers such as 
agar, locust bean gum, pectin, carrageenan and xanthan gum. The jelly negates the 
use of water for swallowing tablets and capsules. Craig, Wright, Mencarelli, & 
Rogerson (2006) developed a pre-gel mold comprising hydroxypropylmethyl cellulose 
(HPMC) and gelatin which envelopes the SODF in water. A In vivo study of the 
swallowing of the pre-gel mold was conducted with the aim to determine whether there 
is a separation of gel and tablet (participant perception) and visual assessment of 
swallowing of the tablets with the gel using FEES (Mencarelli, 2009). Pre-spillages of 
fluid or gel were seen in two participants when swallowed with and without water. Five 
samples were perceived as fractured and five tablets separated from the gel 
(Mencarelli, 2009). Another pill enveloping material comprising of corn starch, glycerin, 
xanthan gum, agar, and carrageenan becomes slippery on contact with saliva or water 
(Gath, 2016). A lubricating spray for SODF consisting of glycerin, propylene glycol, 
polyethylene glycol, xanthan gum, carboxymethylcellulose, alginate, carrageenan, 
and microcrystalline cellulose were developed to facilitate ease of transit of SODF in 
the oral cavity (David, 2007).  
 
Diamond & Lavallee (2010) described a product called Pill Glide; a flavored spray that 
requires the patient to coat the back of the mouth and tongue by spraying. This creates 
a lubricated surface that facilitates ease of swallowing of solid oral dosage forms. Pill 
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glide was found to reduce medicine taking difficulty in children (6-17 years) assessed 
using self-reporting diaries with 6-point hedonic scale (Jagani et al., 2016).  
Another product developed is the MedCoat, a thin coating (consisting of gelatine, 
sweeteners and flavoring agents) that the patient applies on the tablet before 
swallowing. The coating is used to improve the taste of the tablet, and 97.6% of 41 
healthy volunteers (ages 18 to 64 years) found it easier to swallow than non-flavored 
placebo tablets (Uloza, Uloziene, & Gradauskiene, 2010). An acceptability study in 
children (2-17 years) for MedCoat found that the ability to swallow solid oral dosage 
forms (tablets and capsules) improved in 66 of 67 children assessed using 
questionnaires (El Edelbi, Eksborg, & Lindemalm, 2015). 
 
1.10 Sustained release dosage forms 
Sustained release dosage forms are dosage forms where there is a sustained release 
of the active ingredient compared to the release of the active ingredient from 
immediate release dosage forms administered by the same route (European 
Medicines Agency, 2013a). Sustained release dosage forms are also known as 
controlled release, prolonged release, extended release dosage forms and would 
often have the letters MR, SR, XL and LA in the name of the medicine, for example, 
Dilzem XL.  Conventional immediate release dosage forms are often taken more than 
once a day; this causes sequential therapeutic Active Pharmaceutical Ingredient (API) 
blood peaks and troughs for each dose (Allen, Popovitch, & Ansel, 2005). Sustained 
release dosage forms reduce drug plasma concentration fluctuations thereby reducing 
the intensity of adverse drug reactions. Sustained release dosage forms are often 
taken once or twice daily compared to three or four times daily schedule for immediate 
release dosage forms to achieve the same therapeutic effect. This reduces the 
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frequency of drug administration subsequently reducing the pill burden,  and is 
beneficial to patients with multimorbidities (Allen et al., 2005). Sustained release 
dosage forms have been shown to improve patient adherence by switching dosing 
frequency from twice daily to once daily dosing frequency (Doesch et al., 2010; 
Doughty, Baker, Jacoby, & Lavaud, 2003; Ingersoll & Cohen, 2008; Portsmouth, 
Osorio, McCormick, Gazzard, & Moyle, 2005; Souza, Smith, Miller, Doyle, & Ariely, 
2008). 
 
Sustained release formulations are conventionally designed as a single tablet or 
capsule (Liu et al., 2014). Sustained release dosage forms are usually developed as 
reservoir, monolithic or osmotic delivery systems to control drug release. A reservoir 
drug delivery system consists of a polymer coating around the core containing the API. 
Water-insoluble polymers are used for the coating such as ethylcellulose or acrylate 
and water-soluble components such as sugars, for example lactose or sucrose, or 
water-soluble polymers such as hydroxypropyl methylcellulose (HPMC) are also 
employed in the coating (Liu, McConnell, & Pygall, 2011). The water-soluble 
components dissolve with contact with aqueous fluids, resulting in pores allowing 
liquid flow and facilitating drug diffusion. This method is commonly used for multiple-
unit systems (Liu et al., 2011). Drug release from a reservoir system typically occurs 
via diffusion  and the coating thickness can alter the drug release, for example a thicker 
coating would result in a slow drug release due to an increase in diffusion path length 
(Munday & Fassihi, 1989; Ozturk et al., 1990).   
 
A monolithic matrix system for sustained release consists of API dispersed in a matrix 
(Uhrich, Cannizzaro, Langer, & Shakesheff, 1999). Hydrophillic matrix systems can be 
 41 
composed of polymers such as HPMC and sodium alginate (Hodsdon, Mitchell, 
Davies, & Melia, 1995; Siepmann & Peppas, 2012). Upon contact with fluids, a viscous 
layer is formed around the dosage form, which acts as a barrier for water penetration 
and drug release from the matrix, and the polymer disentangles from the outer surface 
(Li, Martini, Ford, & Roberts, 2005; Siepmann, Kranz, Bodmeier, & Peppas, 1999). 
Drug release is dependent on swelling of the matrix, dissolution of the drug, diffusion 
and erosion of the viscous layer  (Colombo, Bettini, Santi, Ascentiis, & Peppas, 1996; 
Tahara, Yamamoto, & Nishihata, 1995). A hydrophobic or insoluble matrix system 
consists of a porous matrix system using water-insoluble polymers such as polyvinyl 
chloride (PVC) (Desai, Singh, Simonelli, & Higuchi, 1966; Tu, Shen, Mahalingam, 
Jasti, & Li, 2013). Upon contact with aqueous fluids, API located at the surface of the 
matrix is released, termed ‘burst release’ (Allison, 2008; Huang & Brazel, 2001; 
Narasimhan & Peppas, 1997). Subsequently, the API is released at successively 
increasing distances from the surface of the matrix through pores (Narasimhan & 
Peppas, 1997). Drug release is controlled by the initial amount of drug loaded into the 
matrix, the porosity of the matrix, the length of the pores which is dependent on the 
size of the matrix and the solubility of the drug (Freiberg & Zhu, 2004; Higuchi, 1963). 
 
An osmotic pump system consists of a semi-permeable membrane, a tablet core 
containing the API,  osmotic agents  and a delivery orifice (L. Liu, Khang, Rhee, & Lee, 
2000). Osmosis is the movement of water through a semipermeable membrane from 
a region of high water concentration (a dilute solution) to a region of low water 
concentration (a concentrated solution) (Raghunathan & Aluru, 2006). Upon contact 
of the osmotic pump system with aqueous fluids, the surrounding medium permeates 
the semi-permeable membrane, and the drug is driven out from the delivery orifice in 
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the membrane (F. Liu et al., 2011). Osmotic agents such as mannitol or sodium 
chloride may be used for poorly water soluble drugs. A range of polymers are used for 
the semi-permeable membrane such as cellulose derivatives like cellulose acetate 
with high water permeability, or polymers such as ethyl cellulose with low water 
permeability is used depending on the desired dissolution rate (Barzegar-Jalali et al., 
2007; L. Liu et al., 2000; Makhija & Vavia, 2003; Verma, Kaushal, & Garg, 2003).  
 
The size of these sustained release dosage forms can be larger than immediate 
release dosage forms due to the larger drug content and thus are challenging for 
patients who are struggling to swallow SODF. Modification of these dosage forms by 
crushing the sustained release dosage form poses a toxicity risk due to the greater 
API content than conventional immediate release dosage forms. Schier et al., (2003) 
reported the death of a woman as a result of severe hypotension after administration 
of crushed sustained-release nifedipine which resulted in dose dumping of the entire 
nifedipine content designed to be released slowly over a prolonged period. 
1.11 Novel approaches for  sustained release oral drug delivery for patients 
with swallowing difficulties 
Multiparticulate dosage forms for modified release are easier to swallow than single-
unit dosage forms such as tablets, by splitting the full dose into subunits. These were 
first introduced in the 1950s as pellet-filled capsules (Spansules) (Tiwari, DiNunzio, & 
Rajabi-Siahboomi, 2011). The pellets are either coated (reservoir system), or used as 
matrix pellets for modified drug release (Abdul, Chandewar, & Jaiswal, 2010). A crack 
in the coating can result in loss of modified release properties of that subunit (Abdul et 
al., 2010). Multiparticulates disperse easily into the gastrointestinal tract as a result of 
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the small sizes, and display reduced intra- and inter-subject variability compared to 
single unit dosage forms (Rajabi-Siahboomi, 2017). 
 
There have been other novel approaches of modified release oral dosage form 
designs to make administration easier for patients who have difficulties in swallowing. 
El-Gazayerly, Rakkanka, & Ayres (2004) produced a self-sealing chewable tablet of 
verapamil hydrochloride. Beads were coated with multiple layers and then 
compressed into a tablet (Figure 1-5). 
 
Figure 1-5: Cross-sectional view of the multilayered bead (reprinted with permission) 
(El-Gazayerly et al., 2004). 
 
The drug was first dissolved in HPMC binder solution and then sprayed to the beads 
as a first coat. A second coat consisting of a mixture of HPMC and polyethylene oxide 
(Polyox) was dissolved in alcohol and then sprayed to the drug-containing layer. 
Polyox was used as a sealant, due to its swelling property when in contact with water. 
Thus, sealing any cracks that may occur in the coating due to bead compression. The 
third coating was ethylcellulose for controlled release properties. Lactose and sodium 
starch glycolate were also dissolved in water and sprayed onto the beads so that once 
compressed into tablets, the beads can disintegrate into individual units in water. 
Controlled release properties of this formulation were maintained whether the tablet 
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was swallowed intact, chewed or crushed due to the sealant layer in the multilayer 
coating (El-Gazayerly et al., 2004).  
 
Ion-exchange resins have been utilized in suspension form as sustained release 
preparation for drugs such as morphine sulphate and ambroxol hydrochloride (Bhise, 
Thenge, Mahajan, Adhao, & Kadam, 2009; Forman et al., 2007). Examples of 
marketed products include Dyanavel XR (amphetamine extended-release oral 
suspension) and MST Continus suspension for morphine sulphate (Napp 
Pharmaceuticals Limited, 2018; Tris Pharma, 2019). Ion-exchange resins are water-
insoluble polymeric material containing ionic groups (Y. Raghunathan, Amsel, 
Hinsvark, & Bryant, 1981). Drug molecules attach through electrostatic interaction 
onto the ionic groups with the opposite charge (Y. Raghunathan et al., 1981). Drug 
release occurs when drug molecules are replaced with other ions of the same charge 
in the gastrointestinal fluid. The exchange capacity of the ion-exchange resin can limit 
the amount of drug loaded onto the ion-exchange resin; ion-exchange resins for drug 
delivery are also only suitable for ionizable drugs (Guo, Chang, & Hussain, 2009).  
 
Lipid multi-particulates have also been developed using fatty alcohols, fatty acids and 
waxes (Feeney et al., 2016; Mu, Holm, & Müllertz, 2013). Lipid-based formulations are 
used to improve the bioavailability of lipophilic drugs; the presence of lipids mimics 
more or less fed state of the stomach leading to the secretion of bile salts. Bile salts 
cause the emulsification of the poorly soluble drug in the gastrointestinal fluid and thus 
enhances its in vivo solubility subsequently increasing the absorption process of the 
drug resulting in increased bioavailability (Shukla, Chakraborty, Singh, & Mishra, 
2011). Sustained release is achieved as a result of the hydrophobic environment 
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provided by lipids which retard the release of the drug (Shukla et al., 2011). Zmaxâ 
(azithromycin) is a marketed product for extended release suspension using this 
technology (Pfizer, 2017). 
In situ gelling oral liquid formulations have been designed for modified release (Itoh et 
al., 2011; Miyazaki et al., 2009). Miyazaki et al. (2009) described a gel/jelly like 
formulation that is designed to be administered as a liquid and then forms a gel at a 
lower pH in the stomach where sustained release occurs. These formulations contain 
polymers with thermal and ion responsive characteristics (for example, xyloglucan, 
pectin, gelatin, agar) that undergo gelation in the gastric environment  (Itoh et al., 2008, 
2011, Miyazaki et al., 2005, 2009). The formulation (gel) remains intact in the stomach 
for three hours and sustained release occurs over six hours (Itoh et al., 2011). 
Improved sustained release of paracetamol was found in rats for combinations of 
methylcellulose with pectin and methylcellulose with alginate in situ gelling 
formulations (Itoh et al., 2011; Shimoyama et al., 2012). 
1.12 Aim of the study 
As discussed previously older adults are the major users of medicines and can 
particularly benefit from sustained release dosage forms in relieving pill burden and 
side effects commonly associated with immediate release dosage forms. Sustained 
release dosage forms have been shown to improve medication adherence. However, 
these dosage forms are conventionally available as tablets and capsules and are 
challenging to swallow by patients with dysphagia. Modification of sustained release 
dosage forms can result in toxicity due to larger drug content for prolonged release 
compared to conventional immediate release dosage forms.  There have been novel 
approaches to navigate sustained release drug delivery for patients with dysphagia 
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but these have limitations, for example, ionic resin complexes are only suitable for 
ionisable drugs with low dose and lipid particles are primarily applied to poorly water 
soluble compounds. In addition, patients with dysphagia may not be able to swallow 
thin liquids, the consistency of the liquid suspensions and in situ gelling formulations 
needs to be carefully considered to ensure swallowing safety and patient acceptance.   
 
The aims of this study are to understand the practical issues in administering sustained 
relase dosage forms in older patients with dysphagia and develop novel sustained 
release formulations that are safe to swallow and acceptable to these patients. The 
first part of the study focuses on identifying the extent and nature of problems in 
swallowing SODF, with a particular interest in difficulties in swallowing sustained 
release dosage forms in older patients with dysphagia in a secondary care setting.  
This was followed by determination of rheological, textural  and in vitro processing 
properties of products used in dysphagia management, including thickened fluids, 
jellies and yogurt, to reach an understanding in safe swallowing features of these 
products.  Two types of jellies, free-standing jellies (non-flowing jellies that retain its 
shape once cut with a spatula) and granular jellies (free-flowing dosage form 
consisting of granular gels in fluid) were developed without using heat as vehicles for 
drug delivery. Sustained release microparticles containing the antidiabetic drug 
gliclazide were developed using fluidised bed coating and incorporated into the jelly 
vehicles to assess in vitro drug release compared to the reference marketed sustained 
release tablet. 
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Chapter 2 
OLDER ADULTS WITH DYSPHAGIA: ISSUES WITH 
MEDICINES ADMINISTRATION IN A SECONDARY 
CARE SETTING 
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2.1 Introduction 
The global trend towards an aging population and the subsequent increase in demand 
for medicines are well recognized (Department Of Health, 2001; National Institute on 
Aging, 2011). Older adults have a greater need for health care resources,  compared 
to younger counterparts due to increased comorbidities; consequently requiring a 
greater number of medicines (European Medicines Agency, 2012; Jennifer Kelly et al., 
2012). The oral route is the most convenient for medicines administration. Solid oral 
dosage forms (SODF) such as tablets and capsules are preferred due to their 
convenience for patients and cost-effectiveness but it can be challenging to administer 
these dosage forms safely and effectively to patients who have difficulties in 
swallowing. Schiele et al. (2015) found that changing type and shape (round, oval, 
oblong and capsule) of the SODF did not modulate the risk of penetration-aspiration 
and patients with stroke-induced dysphagia had increased risk of penetration-
aspiration when swallowing SODF with spoon-thick consistency thickened fluids. 
Difficulties in swallowing can lead to modification of SODF by tablet crushing or 
capsule opening (Table 2-1). Literature available in English relating to medicines 
modification of SODF in adults and older adults are included in Table 2-1, most of the 
literature relied on surveys and very few studies depended on direct observation (Fodil 
et al., 2017; Mercovich et al., 2014; Paradiso et al., 2002; Stubbs, Haw, & Dickens, 
2008). Two of the four observation studies (Paradiso et al., 2002; Stubbs et al., 2008) 
reported on medicine modification in relation to total number of medicines prescribed 
and patients may have been observed in more than one medicines round. Studies 
relating to surveys provided a general idea of ongoings of medicines crushing in 
various institutions as opposed to number of participants (Nissen et al., 2009; Wright, 
2002) and a survery by Strachan & Greener (2005) enrolled patients assumed to have 
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swallowing difficulties, and thus the high prevalence of modification may be noted for 
these studies. 
Table 2-1: Incidence of SODF modification to facilitate swallowing 
Study 
objective 
Study setting Age group Method Type and prevalence of 
modification 
Reference 
Medicines 
administration 
to patients with 
swallowing 
difficulties  
Nursing 
homes, UK 
Older and 
young 
people 
Self-
administered 
questionnaires 
Crushing tablets or 
opening capsules (61% of 
nurse respondents) 
(Wright, 
2002) 
Extent of 
medicines 
modification 
before 
administration 
Residential 
aged-care 
facilities, 
Austrialia 
Older 
adults 
Observation Crushing tablets or 
opening capsules for 34% 
of medicines in the aged-
care facilities. Modified 
SODF were  mixed with 
jam, vitamised fruit, 
custard, or water 
 
(Paradiso 
et al., 
2002) 
Difficulties in 
swallowing 
SODF in 
community 
Community 
pharmacies, 
UK 
Older 
adults (60-
89 years) 
Survey Crushing tablet or 
opening capsules by 68% 
of 675 patients suspected 
of having swallowing 
difficulties 
 
(Strachan 
& Greener, 
2005) 
Extent of 
medicines 
administration 
errors in old 
age psychiatry 
Independent 
psychiatric 
hospital, UK 
Older 
adults (60-
100 years) 
Observation 26% of SODF were 
modified by crushing 
tablets or opening 
capsules 
(Haw et 
al., 2007; 
Stubbs et 
al., 2008) 
Identification 
of commonly 
modified 
medications 
and method of 
modification 
Hospitals in 
Queensland, 
Austrailia  
Adult and 
child 
Self-report 
survey  
79% of 97 hospitals 
modified SODF by 
crushing tablets and 
mixing with jam, honey, 
custard, food, water, juice 
(Nissen et 
al., 2009) 
Prevalence of 
difficulties in 
swallowing 
SODF 
General 
practices, 
Germany 
Adults, 
older adults 
(18-80 
years) 
Questionnaire 
survey 
58% of 393 patients 
modified SODF by 
splitting and crushing 
tablets, opening 
capsules, dissolving in 
water, chewing and 
mixing with food 
 
(Schiele et 
al., 2013) 
Observation of 
medication 
SODF 
modification in 
aged care 
facilities 
Aged care 
facility, 
Queensland 
Older 
adults 
Observation 18% of 160 older adults 
modified SODF by 
crushing tablets or 
capsule opening and 
mixing with thickened 
pear juice and jam 
(Mercovich 
et al., 
2014) 
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Prevalence of 
dosage form 
modification  
Community 
pharmacy in 
Queensland  
Adults (18 
and over) 
Structured 
interview 
10% of 369 patients 
modified SODF by tablet 
crushing or capsule 
opening 
 
(Lau et al., 
2015) 
Prevalence of 
dosage form 
modification 
Aged-care 
facility, Ireland. 
Older 
adults (65 
years and 
over) 
Prospective 
study using 
drug charts 
35% of 111 patients 
received atleast one 
modified (tablet crushing 
or capsule opening) 
medicine 
 
(Mc 
Gillicuddy 
et al., 
2016) 
Prevalence of 
dosage form 
modification 
Pharmacy, 
Jordan, whom 
experienced  
Adults , 
older 
adukts (18-
90 years) 
Interview 27% of 130 outpatient 
patients whom 
experienced difficulties in 
swallowing SODF, 
modified SODF by cutting 
or crushing tablets  or 
opening capsule  
 
(Tahaineh 
& Wazaify, 
2017) 
Assessment of 
medication 
modification 
Hospitals in 
France 
Older 
adults 
Observation 110 drugs prescribed and 
modified from 143 
prescriptions in17 
geriatric units. Dosage 
forms were modified by 
crushing tablets or 
opening capsules, mixing 
with water, jellified water, 
yogurt 
(Fodil et 
al., 2017) 
 
 
There are very few studies of incidences of dosage form modification conducted in 
hospital (Table 2-1) where it is expected to be less prevalent considering the greater 
access to a multidisciplinary team to optimize medicine prescribing and safe 
administration. For patients with difficulties in swallowing SODF, medicines may be 
crushed and added with thickeners to aid swallowing or may be crushed and given 
through enteral feeding tubes (Barnett & Parmar, 2016). Enteral feeding tubes are 
commonly used for medicines administration for patients that cannot ingest 
substances orally. In hospitals, feeding tubes are particularly used in the care of the 
elderly and surgical wards (Salmon et al., 2013). Crushed tablets are administered 
through enteral feeding tubes when suitable alternatives such as liquids or dispersible 
tablets are not available, and this is the most common cause of occlusion within the 
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feeding tube (Bowman, 2007). Instances of requiring SODF modifcation for 
administration through enteral feeding tubes have been previously reported (Gillicuddy 
et al., 2016; Paradiso et al., 2002; Wright, 2002).  
 
Although the intent behind the modification of SODF is that the medicines are 
administered to the patient without the complications of aspiration, modification of 
dosage forms can be particularly hazardous. Sustained release SODF should not be 
modified before swallowing and if so it can result in dose dumping and fatalities. 
Previous studies where SODF modification occurred reported instances of 
modification of modified release medicines such as oxycodone CR, Paracetamol SR 
(Mercovich et al., 2014), aminophylline MR, diltiazem MR (Stubbs et al., 2008), 
morphine SR, nifedipipine CR, felodipine ER, Verapamil SR, Diltiazem CR and 
lansoprazole EC (Paradiso et al., 2002). Modificatition of these dosage forms can be 
fatal as reported previously (Schier et al., 2003). There are very few studies that have 
reported on medicines modification, especially sustained release SODF, in hospitals 
where multidisciplinary teams in particular pharmacists are easily accessible for 
advice on medicines modification. Modification of sustained release dosage forms in 
hospitals can indicate a wider problem with administration of these dosage forms in 
other environments where specialist advice or timely change of prescription may not 
be available.  
 
The aim of this chapter was to gain information on the extent and nature of problems 
in administering SODF, with a particular interest in the administration of sustained 
release formulations for older adults with swallowing difficulties in a hospital setting 
and the solutions used to overcome administration difficulties.  
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The primary objective of this chapter was to gain a better understanding of problems 
surrounding the use of sustained release dosage forms in older adults with swallowing 
difficulties. 
 
The secondary objectives of this chapter was to: 
• To determine the frequency of prescribing solid oral dosage forms for older 
adults with swallowing difficulties. 
• To determine the frequency of prescribing solid oral dosage forms for 
administration via the oral route and through the enteral feeding tubes. 
• To determine the frequency of prescribing sustained release dosage forms for 
older adults with swallowing difficulties. 
• To determine any changes made in administering or prescribing of sustained 
release dosage forms in older adults. 
 
2.2 Methods 
The study was approved by the NHS South Yorkshire Ethics Committee (REC 
14/YH/1105, protocol LMS/PG/NHS/00161) and was conducted in Addenbrookes 
Hospital, Cambridge, UK throughout two months (between September and November 
2014). Data were collected from a total of 22 wards. These included the stroke and 
rehabilitation unit, respiratory wards, cardiology, and general medicine, medicines for 
the elderly, diabetes and endocrine, neurology and neurosurgery, surgical wards and 
the Intensive Care Unit. 
 
In this prorspective study, all patients (over the age of 65) with swallowing difficulties 
staying in the above wards were identified by ward pharmacists. For this study, 
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swallowing difficulties were defined using the following criteria which were adapted to 
help identify patients (Groher & Bukatman, 1986): 
 
• Difficulty in the oral intake or no oral intake 
• Frequent choking and excessive coughing 
• Need for a diet modified in texture 
• Need for non-oral nutritional support 
• History of aspiration pneumonia 
• Need for individual mealtime supervision 
• Patients that are ‘Nil by mouth’ 
• Refusal of the solid oral dosage form (s) 
 
Informed consent was received for patients who were able to provide informed 
consent. For patients who were unable to provide informed consent, data were 
anonymized by the ward pharmacist before analysis. 
 
Data were collected from patients’ medical notes and drug charts using standardized 
pro forma (Appendix I), including patients’ medical history, any recordings of 
dysphagia in medical notes and medications that were prescribed for oral or enteral 
administration. Any changes to the medications prescribed to help facilitate swallowing 
for the patient, for example, changing to an alternative formulation, modifying solid 
dosage forms by crushing tablets or opening capsules were also documented. Nurses 
were approached for clarification on how SODF were administered when it was not 
clear on the drug chart. 
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2.2.1 Sample size calculation 
Estimation of population proportion was used to calculate the sample size. To enable 
the calculation of the population proportion, the margin of error equation (Equation 2-
1) was used. The margin of error is a measure of accuracy; it provides a limit by which 
the sample proportion differs from the true population proportion (Utts & Heckard, 
2005). 
 
p±Z√(pq/n) = margin of error     [Equation 2-1] 
 
Where Z in the critical value for a 95% confidence interval is 1.96 
p is the expected frequency value, q is 1-p  and n is sample size. 
 
The margin of error was used as 0.05% to provide low error and a reasonable sample 
size for the study to achieve in this investigation.  The primary aim of this study was to 
determine the incidence of sustained release dosage forms prescribed and 
administered to older adults with swallowing difficulties. An estimate of the frequency 
of prescribing these dosage forms to older adults was required as p. 
 
The frequency of prescribing sustained release oral medications in older adults with 
swallowing difficulties is unknown, and therefore, primary care prescription data was 
used to estimate the frequency of prescribing sustained release medications for the 
general public (Health and Social Care Information Centre, 2012). Primary care 
prescription data for medicines prescribed for gastro-intestinal, cardiovascular, central 
nervous and endocrine systems were selected as diseases relating to these systems 
are common in the elderly. A frequency of 3.24% of medicines was prescribed as 
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sustained release dosage forms. Older patients are prescribed on average 5 or more 
medications (Morin et al., 2018), so it was estimated an average frequency of 16.2% 
of older adults with swallowing difficulties prescribed sustained release medications. 
Based on this estimated frequency (p) and a margin of error of 0.05%, a sample size 
of 209 was calculated using Equation 2-1. 
 
2.2.2 Data analysis and evaluation 
All data obtained on the proformas were collated on Microsoft Excel and analyzed for 
frequency of prescribing of dosage forms and dosage form modification. Descriptive 
statistics were applied. 
 
The appropriateness of modifying dosage forms was evaluated using the NEWT 
guideline and Handbook of Drug Administration via Enteral Feeding Tubes (Smyth, 
2012; White & Bradnam, 2015). 
2.3 Results 
2.3.1 Patient characteristics 
Two hundred and nine participants (42% female and 58% male) with dysphagia were 
recruited with a median age of 79 years (range 65-100 years). Eighty-four (40%) of 
these participants had been referred to the Speech and Language therapists and 
dysphagia was documented in patients’ medical notes for ninety-four participants 
(45%). Table 2-2 shows the number of participants showing difficulties in swallowing 
according to the criteria used to identify participants.  
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Table 2-2: Criteria in identifying swallowing difficulty in participants. 
Criteria            Number of participants ( %)* 
Difficulty in oral intake 121 (57.9%) 
Diet modified in texture 78   (37.3%) 
Need for non-oral nutritional support 48   (22.9%) 
Nil By Mouth 48   (22.9%) 
Refusal of solid oral dosage forms 10   (4.8%) 
Need for individual mealtime supervision 7     (3.3%) 
Frequent choking and coughing 3     (1.4%) 
History of aspiration pneumonia 1     (0.04%) 
Total 316 (150.5%) 
• Participants may have more than one indication of dysphagia, and therefore, the total number 
exceeds 209, % calculated based on 209 patients 
 
2.3.2 Medicines management for patients with swallowing difficulties 
A total of 1321 medicines for oral and enteral feed administrations were prescribed 
(an average of 6.3 medicines prescribed per participant). Of these, 268 medicines 
were prescribed to 48 participants for administration through enteral feeding tubes, 
and 1053 medicines prescribed to 161 participants for administration through the oral 
route.  
 
2.3.2.1 Medicines management of immediate release dosage forms 
A total of 1182 (90%) of medicines prescribed were immediate release dosage forms. 
The most commonly prescribed immediate release dosage forms were SODF (tablets 
and capsules, total 947 cases, 80% of all immediate release medicines prescribed) 
(Figure 2-1a).   
 
 57 
Overall, 71% of immediate release tablets and capsules (518/729) administered to 
patients taking medicines through the oral route required some form of change to aid 
swallowing (Figure 2-1b). The most commonly sought change was crushing tablets, 
followed by changing to alternative dosage forms and chewing tablets and capsules 
(Figure 2-1b). Tablets and capsules that were crushed or opened for oral 
administration (n=281) were delivered by either mixing with water (43%, 122/281), 
thickened fluid (6%, 16/281) or yogurt (51%, 143/281). There were also 17 incidences 
of swallowing the immediate release tablet or capsule whole with jelly (Hartley’s ready 
to eat free-standing jelly, Hain Daniels Group, UK) to facilitate swallowing.  
 
All of the tablets and capsules prescribed were changed for patients who were 
administered SODF through enteral tubes; the most common change was tablet 
crushing followed by changing to alternative dosage forms (Figure 2-1b). Out of 416 
incidences of tablet crushing or capsule opening to release contents, only 33% 
(138/416) for oral and enteral administration were authorized by a pharmacist.
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Figure 2-1: a) Most commonly prescribed immediate release dosage forms. b) 
Modification of immediate release dosage forms for patients with swallowing 
difficulties. *In the instances where dosage forms were chewed, the capsules were 
chewed without opening the shell and releasing contents. 
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2.3.2.2 Management of modified release dosage forms 
 
There were a total of 138 (69 sustained release and 69 enteric coated; 10% of total 
medicines prescribed) modified release dosage forms prescribed (Figure 2-2a).  
 
All enteric coated formulations were prescribed to participants in the form of enteric 
coated capsules or dispersible tablets (Table 2-3). Enteric coated capsules were 
administered by opening the capsules and releasing contents (14%, 7 of 50 capsules 
prescribed) and changing to a dispersible tablet for the same drug (24%, 12 of 50 
capsules prescribed) (Table 2-3). The rest of the enteric coated capsules and 
dispersible tablets were swallowed intact. 
 
Figure 2-2b shows that of the 67 sustained-release tablets and capsules prescribed 
94% (63/67) were changed or modified for the administration of the medicine. Similarly 
to immediate release medicines, crushing tablets and opening capsules to release 
content (33 occasions) were the most common modifications to sustained release 
formulations. Only 21% (7/33) of this modification to sustained release formulations 
were authorized by a pharmacist whereby the authorizations were to permit opening 
capsules for patients to swallow the capsule content whole. There were seven 
accounts of chewing sustained release dosage forms (6 accounts of chewing capsule 
contents of Tamsulosin and 1 account of chewing capsule whole with shell for 
venlafaxine) before swallowing. In 11 cases. Sustained release formulations that were 
changed to an alternative dosage form were changed to immediate-release tablets or 
liquids.  
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Figure 2-2: a) Type of modified release dosage forms prescribed. b) Modification of 
sustained release dosage forms.
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2.3.2.3 Evaluation of dosage form modification 
In total, 50% (538/1083) of tablets and capsules prescribed (including immediate 
release, sustained release and enteric coated dosage forms) were modified by 
structural changes, e.g. tablet crushing, opening of the capsule or chewing the dosage 
form. The most frequent classes of medicines that were structurally modified, 
administered with food or changed to alternatives were for the treatment of 
cardiovascular and central nervous system diseases (Table 2-3). 
 
Table 2-3: Disease categories for the most commonly structurally modified 
medicines. 
Disease categories  Number (%) 
Cardiovascular system 285 (35.2%) 
Central Nervous system 258 (31.8%) 
Endocrine system 65 (8.03% 
Gastrointestinal system 85 (10.5%) 
Nutrition 50 (6.2%) 
Malignant disease and immunosuppression 3 (0.004%) 
Musculoskeletal and joint diseases 7 (0.009%) 
Infectious diseases 23 (0.03%) 
Respiratory diseases 11 (0.01%) 
Total 809 (100%) 
 
A review of guidelines accessible in hospitals in the UK for medicines management 
for patients with swallowing difficulties or those taking medicines through the enteral 
feeding tubes showed that 64% (693/1083) of the medicines altered were advised as 
safe to modify (Smyth, 2012; White & Bradnam, 2015). Licensed alternative 
formulations were recommended for 18% (194/1083) of medicines modified. There 
were 9% (97/1083) of medicines modified where tablet dispersal in water was 
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recommended. This modification may be recommended because the therapeutic 
outcome may be compromised from a variable amount of Active Product Ingredient 
(API) being administered (loss of API through crushing and transferring process) or 
many alternatives are available for medicine such as paracetamol (Mercovich et al., 
2014; Paradiso et al., 2002). Modification cases that are contraindicated or permitted 
with caution are shown in Table 2-4.  
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Table 2-4: Modifications that are contraindicated or permitted with caution. 
API Dosage form Frequency 
prescribed 
Modified by 
crushing or 
chewing 
(frequency) 
Recommendations in 
guidelines 
Alendronic acid  Immediate 
release tablets 
16 10 Do not crush, can 
irritate. Use oral solution 
or zoledronic acid 
(administered once 
yearly) (Smyth, 2012) 
 
Nitrofurantoin Immediate 
release tablets 
1 1 Do not crush, can 
irritate. Use oral 
suspension(Smyth, 
2012) 
 
Tamsulosin Capsules with 
slow release 
granules 
24 15 (capsule 
opened to 
release 
contents, 
granules 
chewed by 6 
participants) 
Contents of the capsule 
may be mixed with cold 
water and swallowed 
whole, but not suitable 
for patients unable to 
follow instructions on not 
to chew (Smyth, 2012) 
 
Alfuzosin Slow release 
tablet 
1 1 Do not crush, use 
standard release 
immediate release 
tablets which can be 
crushed or dispersed in 
water (Smyth, 2012). 
 
Felodipine Slow release 
tablet 
6 1 Do not crush, change to 
amlodipine tablets 
(Smyth, 2012) 
 
Venlafaxine Capsule with 
slow release 
granules 
2 1 (capsule shell 
chewed) 
Contents of capsules 
can be released and 
given with smooth food 
such as yogurt. 
Granules must be 
swallowed whole, not 
suitable for patients 
unable to follow 
instructions on not to 
chew (Smyth, 2012). 
 
Slow sodium Slow release 
tablet 
2 1 Should be swallowed 
whole and not chewed 
(HK Pharma Limited, 
2015). 
 
Melatonin Slow release 
tablet 
1 1 Do not crush or chew. 
Use immediate release 
dosage forms (Smyth, 
2012). 
 
Omeprazole Capsule with 
enteric-coated 
granules 
19 11 (4 capsule 
shell chewed 
and 2 capsules 
Can open the capsule 
and swallow contents 
with water, fruit juice, 
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2.4 Discussion 
The findings in this study show that tablets and capsules are commonly prescribed by 
physicians for older adults with dysphagia in a hospital. Tablet crushing or opening 
capsules is a commonly used method for administration to patients with swallowing 
difficulties despite the availability of the multidisciplinary team such as speech and 
language therapists for assessment of dysphagia and pharmacists for easily 
accessible medicines advice for alternative dosage forms  in a secondary setting (Fodil 
et al., 2017; Haw et al., 2007; Gillicuddy et al., 2016).  It was expected that the 
incidence of tablet crushing and capsule opening would be low considering the access 
to specialist advice and the availability of guidelines but our findings showed 49.7% of 
tablets and capsules for immediate and modified release were structurally modified for 
patients with dysphagia via administration through the oral route and enteral feeding 
tube . There are limited studies reporting on overall incidence of modification of SODF 
in hospital, a previous study hospital reported 26% of medicines modification in a 
psychiatric unit for older adults, a lower incidence compared to our findings possibly 
due to the fact that our study is conducted only in patients with dysphagia (Haw et al., 
2007; Stubbs et al., 2008).  
 
contents 
chewed). 
apple sauce or non-
carbonated water. 
Enteric-coated granules 
should not be chewed 
(AstraZeneca UK 
Limited, 2015). 
 
Lansoprazole Capsule with 
enteric-coated 
granules 
31 4 (1 capsule 
shell 
chewed and 1 
capsule content 
chewed). 
Can open the capsule, 
contents must be 
swallowed whole 
(Consilient Health Ltd, 
2012) 
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Although alternative dosage forms such as solutions or suspensions are available for 
most medicines, these are expensive, and thus, tablets and capsules are prescribed 
and modified to facilitate swallowing. For example, the antibiotic metronidazole tablet 
costs £1.70 per pack whereas the liquid suspension version of the drug would cost 
£32.93 per pack (Joint Formulary Committee, 2019a). Lajoinie, Kassai, & Terry (2014) 
evaluated the cost-savings if oral liquid dosage forms were substituted with SODF for 
children over two years. The study found the total cost of dispensing oral liquid dosage 
forms for one week was £8,307 and £11,697 respectively for hospital and community 
charges and substitution of these to SODF would have cost £4,951 and £8,550 for 
hospital and community respectively. Prescribing the SODF would have accounted for 
60% and 73% of the cost for liquid dosage forms. The concern with modification of 
SODF is that dosage forms may be modified without careful consideration and 
authorization, and this can lead to harm. A study in a psychiatric hospital found 44% 
of dosage form modifications by crushing tablets, or opening capsules were 
unauthorized by pharmacists, and another study in a hospital in France found 48% of 
modifications were contraindicated assessed using local guidelines (Fodil et al., 2017; 
Stubbs et al., 2008). In some cases, advisory labels affixed on medicines boxes 
contain the words “swallow the dosage form whole” for enteric and sustained release 
medication or drugs with unpleasant taste (Joint Formulary Committee, 2019c); if the 
practice of modification is introduced for medicines with this labeling in the hospital by 
staff, it may inadvertently lead to this practice being continued at home by patients or 
carers despite label warnings.  
 
Modification of immediate release dosage forms, such as crushing tablets, may lead 
to faster absorption and thus higher bioavailability; on the other hand this may lead to 
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sub-therapeutic API levels due to loss of API through the process of altering and 
transferring the manipulated dosage forms (Dodds Ashley et al., 2007; Manessis et 
al., 2008; Thong et al., 2018). Although altering immediate release dosage forms with 
a wide therapeutic window is considered of low risk, there are instances where this 
may not be appropriate. For example, altering dosage forms of APIs that are light 
sensitive may lead to degradation before administration (Root et al., 2011); modifying 
cytotoxic or hormonal medicines with carcinogenic and teratogenic potential can be 
hazardous due to risk of contact and inhalation of particles and thus posing health and 
safety risks for those modifying and administering these medicines (Haywood & Glass, 
2007; Root et al., 2011).  Alendronic acid and nitrofurantoin are both contraindicated 
for crushing and administration through the enteral feeding tube due to possible 
oesophageal or stomach irritant effects (Smyth, 2012; Root et al., 2011) 
 
Enteric coated dosage forms are designed to pass through the stomach intact and 
release the drug in the intestine; crushing these formulations would reduce efficacy or 
cause stomach irritation (Haywood & Glass, 2007; Root et al., 2011). Modifying enteric 
coated dosage forms for drugs that degrade in acidic conditions can reduce efficacy. 
This can be detrimental for example when proton pump inhibitors such as omeprazole 
or lansoprazole are used to protect the stomach from bleeding when non-steroidal 
inflammatory drugs are used. Lansaprazole is available as oral dispersible tablets 
which are more suitable for swallowing difficulties but despite this, capsules were 
prescribed.  Omeprazole is also available as a dispersible tablet, but capsules were 
prescribed. This may be due to the patient prescribed the capsules prior to admission 
due to cost considerations. Omeprazole (Losec MUPS) for example, costs £9.30 per 
pack compared to the capsules which are £0.75 per pack (Joint Formulary Committee, 
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2019b). Flexible dosage forms are dosage forms that can be administered in more 
than one manner such as dispersal in water or swallowing the dosage form intact and 
have been developed to offer an alternative to patients with difficulties in swallowing 
(Liu & Shokrollahi, 2015; World Health Organization, 2012). In this study enteric 
coated capsules were opened to release the granules and in some cases these enteric 
coated granules were chewed for omeprazole and lansoprazole, which may be a result 
of oral grittiness (‘rough feeling in the mouth’) if the pellets were large leading to 
chewing (Lopez et al., 2016). It has been previously reported that there is a low 
perception of grittiness for particle sizes 90-263 µm (Lopez et al., 2016) and 
lansoprazole and omeprazole granules in capsules are reportedly 750-1400µm  and 
1000-2000 much larger than this size range (Liu & Shokrollahi, 2015). The enteric 
coated granule sizes in dispersible tablets are 352µm and 180-253µm for lansoprazole 
and omeprazole respectively, indicating better acceptance and suitability for these 
patients (Liu & Shokrollahi, 2015). 
 
Despite that it being widely known that sustained release dosage forms should not be 
crushed (Root et al., 2011; Schier et al., 2003), this study showed a surprisingly high 
proportion of sustained release SODF (tablets and capsules) prescribed to patients 
with swallowing difficulties and only a small number of these were authorized for 
modification before administration.  It has been previously reported that prescribers 
are more likely to consider allergies and medical history as important considerations 
than swallowing problems, in contrast to nurses, who are at the forefront of medicines 
administration and are more likely to ask about patients swallowing ability (Nguyen, 
Lau, Steadman, Cichero, Dingle, 2014).  
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Sustained release formulations are designed to release the drug slowly over time and 
are often prescribed to minimalize side effects due to fluctuation in plasma drug 
concentration observed with immediate release dosage forms, or to provide optimal 
control over symptoms to improve disease management, for example, breakthrough 
symptoms such as pain and control of blood pressure. It is well known that structurally 
modifying any sustained release dosage form can be harmful since it often contains a 
greater API content than immediate release dosage forms to reduce dosing frequency; 
modifying this results in immediate release of the dose and can cause toxicity.  The 
majority of the sustained release dosage forms (tablets and capsules) were modified 
by crushing the tablets or opening the capsules to release content to enable 
swallowing rather than changing the dosage form to liquids such as immediate release 
suspensions. Swallowing granules whole may be challenging for patients unable to 
follow instructions, and this is worth considering before permitting this practice. The 
maximum size of granules or pellets incorporated into capsules is 2.8mm 
recommended by the FDA for sprinkling which is greater than the 263µm reported for 
grittiness perception (Food and Drug Administration, 2012; Lopez et al., 2016). Particle 
size of extended release products labelled for use by sprinkling on apple sauce or 
pudding were analysed and found to range from 277 to 1485µm (Nagavelli et al., 
2010). Marconati, Lopez, Tuleu, Orlu, & Ramaioli (2019) found pellets of 891.5µm in  
size were considered more difficult to swallow compared to 325.3µm by healthy adult 
volunteers and the pellets, irrespective of the size, were easier to swallow dispersed 
in polymer solutions (xanthan gum and carboxymethyl cellulose solutions) compared 
to water. The study found water-thin vehicles were not effective for oral transport of 
multiparticulates and left residue of multiparticulates in the mouth (Marconati et al., 
2019). Changing to alternative formulations or drugs, for example, immediate release 
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liquid formulations would obviate the advantages of taking sustained release 
formulations. This can result in losing sustained release properties and increasing 
dosage frequency or pill burden. The opening of capsules to swallow the sustained 
release granules could result in  off-label use; however, even if this is permitted by the 
prescriber or pharmacist, then it is stressed that the granules are not chewed, which 
could result in dose dumping. Structurally modifying these formulations by crushing, 
chewing can result in toxicity due to dose dumping and is perilous to introduce this 
practice to patients who may continue this practice upon discharge. There has been a 
previous case report on patient death as a result of crushing slow release nifedipine 
(Schier et al., 2003). There were incidences of modification of sustained release 
dosage forms in this study without authorization which could have lead to patient harm. 
Previous studies on medicines modification have also reported on modification of 
sustained release SODF occurring in aged-care facilities and hospital (Haw et al., 
2007; Mercovich et al., 2014; Paradiso et al., 2002). Despite the widely acknowledged 
fact by health professionals that sustained release SODF should not be modified, 
modification of these dosage forms has been and still is occurring in practice. This 
indicates the need for serious attention towards handling medicines for patients with 
swallowing difficulties, the need for routine training for administrators on managing 
medicine administration and the need for more suitable dosage forms to be designed 
that provide sustained release and are easy to swallow.  
 
The NEWT guidelines by Smyth, 2012 is based on theoretical, anecdotal and practical 
information from various sources particularly anecdotal reports for medicines 
administration and the Handbook of Enteral feeding by White & Bradnam (2015) is 
based on information from pharmaceutical companies and pharmacist research for 
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medicines administration.  These guidelines are used in hospitals in the UK (UKMI, 
2011) and since the modifications of SODF are likely to be unlicensed, it is a useful 
tool in recognizing whether the modification may be harmful or not from previous 
cases. Evaluation using these resources showed that 9% of SODF were 
contraindicated or recommended to proceed with caution. Previous studies reported 
that 4-48% of alterations were contraindicated (Fodil et al., 2017; Mercovich et al., 
2014; Paradiso et al., 2002; Stubbs et al., 2008). As reported in previous studies, drugs 
prescribed for the central nervous system and cardiovascular system were modified 
the most due to swallowing difficulties (Fodil et al., 2017; Gillicuddy et al., 2016; Stubbs 
et al., 2008).  
 
SODF modified in this study were administered with water, thickened fluid or yogurt, 
and in a few cases, swallowed whole using Hartley’s jelly as a swallowing aid. Using 
thickening agents may alter drug release; previous in vitro studies in simulated gastric 
fluid showed thickened fluids and yogurt could reduce drug release from crushed 
tablets of warfarin and carbamazepine (Manrique-Torres et al., 2014).  
 
This study reports cases of medicines alterations that could have resulted in harm to 
the patient. Pharmacists were involved in the study who have provided feedback in 
cases inappropriate modification took place. This led to training by clinical pharmacists 
to the nurses administrating the medicines on their wards and guidance of medicines 
that should not be modified developed by the Pharmacy department was provided 
where required as a reminder for safe medicines administration. Although greater 
safety of administration of medicines is expected in hospitals, the practice of modifying 
dosage forms is a strategy being used by health care professionals and patients to 
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facilitate swallowing and also in some cases the practice occurred without 
authorization. It is clear from this study that more appropriate dosage forms are 
needed for older adults to prevent this practice particularly for sustained release 
dosage forms where modification can result in toxicity. Swallowing aids such as jellies 
that alter shape during swallowing maybe useful as drug administration vehicle to 
alleviate the instant of chewing, for example granules, and their swallowing safety in 
dysphagia patients needs to be understood.  
 
2.5 Conclusions 
This study found unauthorized medicines modification in secondary care to be 
common practice despite the availability of specialist advice. Modifying SODF during 
hospitalization may result in the same practice being adopted by patients once 
discharged despite that warning labels may be affixed onto dosage form packages 
after dispensing advice to swallow the medicines whole. This is a risky practice and 
unauthorized medicines modification also occurred for sustained release medicines 
which can result in toxicity. The findings reinforce the need for safer, accessible and 
easier to swallow sustained release dosage forms to provide better medicines for 
patients with dysphagia in the future. 
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Chapter 3 
SAFE SWALLOWING FEATURES OF THICKENERS, 
JELLIES AND YOGURT OBSERVED IN AN IN VITRO 
MODEL 
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3.1 Introduction 
Dysphagia is the inability to safely transfer fluids or food boluses from the oral cavity 
to the oesophagus and diet modification is the mainstay of compensatory intervention 
for dysphagia management (Campbell-Taylor, 2008; Ney et al., 2009). Thin fluids 
(e.g., water and beverages) are modified using thickeners (gum or starch based) for 
patients with dysphagia to improve swallowing safety (Garcia, Chambers IV, Clark, 
Helverson, & Matta, 2010). Although the exact mechanism is unknown, it is thought 
that thickened fluids increase viscosity allowing better control of the speed and 
direction of the bolus transiting into the oropharynx, providing greater time for the 
airway to close and preventing spillage into the airway (Campbell-Taylor, 2008; 
Nicosia & Robbins, 2001; Sura et al., 2012).  
 
Thickened fluids are widely used in dysphagia management, but acceptance for these 
products is low due to grainy textures from starch-based thickeners and stickiness 
from gum-based thickeners (Garcia, Chambers, et al., 2005; Murray et al., 2014; Shim 
et al., 2013). Starch-based thickeners are described to have an undesirable grainy 
and ‘lumpy’ texture, and these products are physically unstable and can continue to 
increase in viscosity or thicken over time (Cichero, 2013; Lotong, Chun, Chambers IV, 
& Garcia, 2003; Matta, Chambers IV, Garcia, & Helverson, 2006). On the other hand, 
they can become thinner when mixed with saliva due to digestion by amylase present 
in the oral cavity (Lotong, Chun, Chambers, & Garcia, 2003). Gum based thickeners 
are reported to have an undesirable stickiness; they are more physically stable over 
time (keeping constant viscosity) but need to be shaken vigorously during mixing 
(Lotong et al., 2003; Matta et al., 2006). Starch added to water swells, forming a 
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swollen structure of starch granules whereas gum-based thickeners form a mesh of 
entanglement of polymer chains (Cichero, 2013).  
 
Viscosity is often described as the salient property for safe-swallowing of fluids. 
Although the focus of dysphagia management is modifying the viscosity of liquids, 
other rheological and textural properties such as cohesion and yield stress of fluids 
have also been mentioned in literature, albeit scarcely, that might contribute to safe-
swallowing. Thin liquids with low cohesion between particles can result in spillage into 
the airway in dysphasic patients due to inability to control laryngeal closure (Cichero 
& Murdoch, 2006; Prinz & Lucas, 1997; Tashiro, Ono, Atsuko Tanigome, Kumagai, & 
Kumagai, 2010). An increase in thickener concentration is known to increase viscosity 
and yield stress (Payne, Methven, Fairfield, Gosney, et al., 2011; Popa Nita et al., 
2013). Yield stress described as the minimum stress required to enable flow is 
reported as a potentially relevant parameter in safe swallowing (Cho et al., 2012; 
Payne et al., 2011). A study was conducted in eighteen young students (aged 22-25) 
for sensory analysis of perceived ease of movement of semi-liquid samples (prepared 
using pregelatinized waxy corn starch as a thickener) in the pharynx, comparing to 
videofluoroscopy measurements (Takahashi et al., 2002). A texture analyser was used 
to characterise the semi-liquid samples for hardness, cohesiveness, and 
adhesiveness. Thickened samples showed an increase in hardness and 
adhesiveness with increasing thickener concentration; however, the cohesiveness of 
all samples was similar. The study found that increased hardness resulted in perceived 
difficulty in swallowing and slower bolus transit (Takahashi et al., 2002). 
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The present study uses the in vitro throat model presented by Mackley et al. (2013) 
which is designed for processing of liquids to compare dysphagia thickened fluids 
(starch and gum-based thickeners) to jellies and yogurt for pharmaceutical application 
(Chapter 1, Section 1.6). Patient acceptability for thickened fluids is found to be  low. 
A study testing acceptability by using 9-point hedonic scales for overall liking, taste 
and texture of thickened fluids in healthy volunteers found the rating reduced for 
increased thickening for overall liking and ratings were mostly below average for 
nectar-thick and honey-thick fluids (Jane Mertz Garcia, Chambers, Chacon, & Di 
Donfrancesco, 2015). A retrospective audit of medical records of adults diagnosed 
with dysphagia showed only 56.5% of patients complied with thickened fluids 
consumption (Shim et al., 2013). and thus these products were compared to potentially 
more palatable swallowing aids, jellies, and yogurts which were used as alternative 
swallowing aids (Chapter 2). There is very little scientific evidence on the safety of 
swallowing of these alternative swallowing aids (Sonoi et al., 2016). However, jellies 
that are made from gums are commonly used in Japan and are recommended as a 
transitional food product that change in texture, for example break down quickly in the 
oral cavity and become easier to swallow (International Dysphagia Diet 
Standardisation Initiative, 2016b).  A study conducted in postoperative cancer patients 
has found that jellies are safer than nectar-thick thickened fluids to swallow (Sonoi et 
al., 2016). A study was conducted examining the efficiency of intervention methods to 
prevent aspiration in twenty-five patients with Parkinson’s disease (PD) and 23 
patients with degenerative cerebellar ataxia (CA) (Nagaya, Kachi, Yamada, & Sumi, 
2004). Thirteen PD patients and seven CA patients showed aspiration without 
intervention. Three interventions were used; changing food form to using jelly, chin-
down posture and supraglottic swallow techniques. The study found that changing to 
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jelly was effective and resulted in no aspiration observed in all PD patients and five 
CA patients (Nagaya et al., 2004). The two CA patients that showed aspiration after 
jelly intervention were patients whose feeding was severely impaired and were at the 
end stage of the progressive disease (Nagaya et al., 2004). Kumagai, Tashiro, 
Hasegawa, Kohyama, & Kumagai (2009)  studied the velocity spectrum in the pharynx 
measured using ultrasonic pulse Doppler method for yogurt, water and thickener 
solutions and found that the maximum velocity of water was thrice that of yogurt. The 
velocity spectra for water and thin fluids showed the velocity spectra distributed over 
a wider range than yogurt and more viscous thickened fluids suggesting cohesive and 
thus safer bolus flow for yogurt and thickened fluids with increasing concentration 
(Kumagai et al., 2009).  
  
The aim of this chapter is to compare the acceptability of jellies and thickened fluids 
commonly used for dysphagia management, to characterize rheological, texture and 
in vitro processing properties of thickened fluids and  to compare these with alternative 
products used for dysphagia patients such as jellies and yogurts. 
 
The primary objective of this study is to compare the processing behaviour of 
thickened fluids to jellies and yogurt in the in vitro throat model. 
 
The secondary objectives of this study are to: 
• Compare the acceptability of thickened fluids and jellies in healthy adults 
• Compare the rheological, textural and in vitro processing properties of 
thickened fluids with jellies and yoghurt 
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3.2 Materials and methods 
3.2.1 Materials 
Three commercial thickeners, five commercial jellies, and a smooth yogurt were 
purchased and are shown in Table 3-1 with the main ingredients. Within the 
thickeners, Thick & Easy® (referred to as Thick & Easy in this chapter) is starch-based; 
Resource® ThickenUpTM Clear (referring to Resource Clear in this chapter) is xanthan 
gum-based, and Nutilis Powder contains a mixture of starch and gums. Three of the 
commercial jellies (Hartley’s, Vimto and Peppa pig) are firm, homogeneous and retain 
a free-standing structure when left on a plate; whereas the Ryukakusan jellies (both 
for adults and children) are in a granular form (non-homogeneous in texture) and can 
flow on a plate. 
 
Table 3-1: Products used in the study. 
Product Main ingredients Manufacturer 
Thickeners Thick & Easy® Modified starch Fresenius Kabi, Ireland 
Resource® 
ThickenUpTM Clear  
Xanthan gum Nestle Health Science, 
Switzerland 
Nutilis Powder Modified starch, 
xanthan gum, tara gum, 
guar gum 
Nutilis, The Netherlands 
Jellies Hartley’s strawberry 
ready-to-eat jelly 
Locust bean gum, 
xanthan gum, gellan 
gum 
Hain Daniels Group, UK 
Vimto ready-to-eat jelly Carrageenan, locust 
bean gum 
Caterers choice Ltd., UK 
Peppa pig ready-to-eat 
jelly 
Gelatine Heaven made foods 
Holt Ltd., UK 
Ryukakusan “magic” 
jelly for adults  
Agar  Ryukakusan, Japan 
Ryukakusan “magic” 
jelly for children 
Agar  Ryukakusan, Japan 
Yogurt Ski strawberry yogurt Milk, rice starch, sugar, 
lemon juice, carrot 
concentrate, guar gum, 
milk calcium 
concentrate 
Nestle, Switzerland 
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3.2.2 Preparation of test samples 
Each commercial thickener was prepared using the lowest amount of powder within 
the manufacturer recommended range in deionized water, corresponding to three 
levels of thickening (Table 3-2). The thickening levels comply with the American 
National Dysphagia Diet guideline recommendations for use in patients with different 
stages of dysphagia according to the disease severity, with stage 3 being the most 
severe (National Dysphagia Diet Task Force & American Dietetic Association, 2002) 
(Chapter 1, Table 1-3). To be able to process the three free-standing jellies (Hartley’s, 
Vimto and Peppa pig) for the in vitro swallowing test, they were manually chopped 
(using a spatula) to particles of 4mm diameter. 
 
Table 3-2: Amount of thickeners added to deionized water (100ml) for each level of 
thickening. 
Product Level of thickening Thickener content in deionized water % (w/v)  
Thick & Easy 
 1 4.5 
 2 6.75 
 3 9 
Resource Clear  
 1 1.2 
 2 2.4 
 3 3.6 
Nutilis Powder 1 2 
 2 4 
 3 6 
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3.2.3 Particle size distribution and acceptability study of jellies and thickened 
fluid 
The study was approved by the University of Hertfordshire Ethics Committee 
(LMS/PGR/UH/02759). Twelve healthy volunteers provided informed consent to 
participate in the study. Participants with swallowing difficulties or any allergies or 
restrictions with the ingredients of the test products were excluded from the study. 
 
Participants were given jellies that were firm enough to retain a free-standing structure 
(Hartley’s, Vimto and Peppa pig gelatin jellies) and were asked to chew the jellies (if 
they needed to) until they felt it was ready to swallow the bolus and to expel the bolus 
just before swallowing. The chewing time was not assessed as the aim of this 
investigation was to measure particle size once the bolus was deemed ready to 
swallow. The temperature of the expelled boluses was measured using a digital 
thermometer (Fisher Scientific, traceable pocket-size thermometer) immediately after 
the expulsion of the first three boluses for each jelly product. The particle sizes of 
randomly selected 20 particles for each product for each participant were measured 
using a digital calipher (DML 150mm, Digital Micrometers Ltd). Boluses of similar 
particle sizes for each product from different participants were mixed together and 
used for further testing.  
 
After the particle size distribution study, participants were provided with a 
questionnaire  (Appendix II) to assess the acceptability of the Hartley’s, Vimto, Peppa 
Pig and Ryukakusan’s adult jellies and Thick & Easy stage 3 thickener, in a 
randomized sequence.  The Thick & Easy stage 3 was prepared as described in 
Section 3.2.2. Participants were asked to swallow a spoonful of each product and were 
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asked to answer the questionnaire regarding the acceptability of the product 
straightaway after each swallowing. Participants used water to rinse their mouths after 
consuming each product. Questions included rating ease of swallowing and stickiness 
of the product using a 5-point Likert scale (1 being very easy to swallow or not sticky 
at all and 5 being extremely difficult to swallow or extremely sticky), whether there was 
any residue felt in the mouth or throat, whether samples required chewing and whether 
consistency changed in the mouth prior to swallowing. Participants were also asked 
which product they preferred and disliked the most. 
 
3.2.4 In vitro performance in the “Cambridge throat” (“CT” ) model 
The “Cambridge Throat" (CT) model was used to understand the in vitro swallowing 
of the thickeners, jellies, and yogurt. The “CT” model is a static mechanical model 
designed to simulate the physiological anatomy and dimensions of the human throat 
(Mackley et al., 2013). A five-milliliter test sample was held within a 25mm dialysis 
tube attached to the top of the perpex mouth of the “CT” model, representing the mouth 
(Figure 3-3). The thickeners were used as prepared according to Table 3-2; the 
Ryukakusan jellies (adults and children) were used as directly taken out from package, 
and the three free-standing jellies (Hartley’s, Vimto and Peppa pig) were processed 
both as manually chopped samples (dry jellies), and participant chewed samples 
(chewed jellies) as shown in Section 3.2.2 and 3.2.3. Five replicates were processed 
for each sample. 
 
In the “CT” model, the tongue action is represented by a roller which has an attached 
weight (190g) held by a pin. When the pin is released, the weight provides a constant 
torque which causes the roller to apply a constant pressure (approximately 0.1 bar) on 
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the bolus through the tubing (Mackley et al., 2013). The roller movement ends just 
before the area representing the epiglottis, and the samples then flow under gravity, 
reaching a diversion of the model cavity representing the airway divide (Figure 3-1). 
An iPhone 6S camera was used to capture images of the flow of test samples within 
the throat model at 30fps. The retrieved images were used to calculate the oral transit 
time (OTT) and bolus length (BL) at airway divide of the test sample. The position of 
the bolus in the tubing was previously described by Mowlavi et al. (2016) by measuring 
the angel q between the roller and the horizontal direction. At the initial position (before 
the pin was released), the roller was held at an angle q0 = 45°; at the end of the roller 
movement, the roller reached its final position at qf = 165° (Figure 3-1) (Mowlavi et al., 
2016). The OTT is defined as the time taken for the roller to move from its initial 
position (q0) until reaching qend = 120° (Figure 3-1) (Mowlavi et al., 2016). Image J (Fiji) 
was used to calculate BL at airway divide by capturing the first image in which the 
bolus front can be seen to reach the airway divide. Using this image, the BL was 
measured as the length of the bolus from bolus front to bolus tail (Figure 3-2a).  In 
cases where the bolus tail cannot be clearly seen, the BL was measured from the end 
of the dialysis tubing as the bolus tail to the bolus front (Figure 3-2b).  
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Figure 3-1: CT throat model with measured angles. 
 
 
Figure 3-2: a) Bolus length measurement for boluses with the bolus tail and front. b) 
An example bolus length measurement for boluses where bolus tail is not clearly 
defined. 
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3.2.5 Rheological and textural characterization 
Rheological and textural characterisation was carried out for all products listed in Table 
3-1. The preparation of samples were as described in Section 3.2.2 and 3.2.3.  A TA 
1500 EX controlled–stress rheometer (TA instruments) was used to obtain steady 
shear apparent viscosity and oscillatory viscoelastic data. Measurements were carried 
out at 25°C using parallel plate geometry (diameter: 40mm, gap 650mm) for all 
experiments. For each sample, oscillatory stress sweep (torque 0.01-10,000 micro 
N.m at a frequency of 10 rad/s), frequency sweep (0.1 to 100rad/s) and steady-state 
rate sweep (0.01-100/s) were carried out in triplicate. Apparent viscosity was 
determined at a shear rate of 50s-1 during a steady state rate sweep, and yield stress 
was determined as the linearity limit of G’ from stress (amplitude) sweeps. 
 
Texture characteristics (cohesiveness, surface adhesion and firmness) were 
evaluated using back extrusion tests on a Texture Analyser (TA.XT. Plus, Stable 
Microsystems) applying a 5kg load cell.  An extrusion disc (35mm) was positioned 
centrally over the sample container containing 100ml of the sample; the disc 
penetrates the sample to 20mm at 0.5mm/s test speed. The maximum force (g) used 
to reach this depth is taken as a measurement of firmness or hardness. The maximum 
negative force (when the probe is drawn up at a speed of 0.5mm/s) is an indication of 
cohesiveness. Surface adhesion was determined by drawing the disc at a speed of 
0.5mm/s towards the sample; the disc is then held on the surface of the sample for 30 
seconds and pulled away at 2mm/s. The force (g) for withdrawal of the disc from the 
sample is the indication of surface adhesion (adhesiveness). The measurements were 
carried out at room temperature with triplication for all samples.  
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3.2.6 Data analysis 
Prism Graphpad (Version 7.0) was used to assess if the data relating to ease of 
swallowing and stickiness scores from participant questionnaires was normally 
distributed using the Shapira-Wilk test and normal distribution was rejected (p<0.05). 
The Kruskal Wallis test was applied to determine significant differences for ease of 
swallowing, stickiness scores between the stage 3 thickened fluid and jelly products, 
significant differences were noted if p ≤ 0.05. 
 
Prism Graphpad (Version 7.0) was used to obtain Pearson correlation coefficient for 
OTT and BL against rheological (apparent viscosity and yield stress) and textural 
parameters (cohesiveness, firmness, and adhesiveness) of thickened fluids. Five 
repetitions were performed for in vitro swallowing tests (OTT and BL) and triplicates 
for rheological and textural measurements. To calculate the correlation, three results 
were selected randomly for OTT and BL from the five repetitions to match the three 
results of the rheological and textural measurements. This was repeated ten times to 
obtain ten random combinations, and an average correlation coefficient was obtained 
using the mean value of the ten combinations. Correlation coefficient was graded 
according to Table 3-3.   
 
The OTT and BL were presented as a mean ± confidence interval (CI). CI was 
calculated at 95% confidence using Equation 3-6: 
 
Mean ±  1.96 (s/Ön)                                        [Equation 3-6] 
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Prism Graphpad (Version 7.0) was used to assess if the data relating to OTT times 
and BL was normally distributed using the Shapira-Wilk test and normal distribution 
was rejected (p<0.05). The Mann Whitney U test was applied to determine significant 
differences for OTT and BL between stages of thickening for each thickened fluid 
product and between dry jellies and participants boluses, significance differences were 
noted if p ≤ 0.05. 
 
Table 3-3: Correlation coefficient classification  (Mukaka, 2012). 
Classification Correlation coefficient (R) 
Very high positive or negative correlation ±0.9 - ±1 
High positive or negative correlation ±0.7 - ±0.9 
Moderate positive or negative correlation ±0.5 - ±0.7 
Low positive or negative correlation ±0.3 - ±0.5 
Negligible correlation 0.0 - ±0.3 
 
3.3 Results 
3.3.1 Participant demographics 
Twelve participants took part in the acceptability study (5 females and 7 males) of age 
range 29-44 years (mean 30 years).  
 
3.3.2 Particle size distribution of jelly boluses and acceptability of different 
products  
The mean temperatures of the jelly boluses after chewing and immediately after 
expelling were 24.6 ± 1.9 °C, 25.2 ± 1.9°C and 21.0 ± 2.9°C for Hartley’s, Vimto and 
Peppa Pig jellies respectively, similar to room temperature (21.1 ± 0.2°C) at the time 
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of the test. The particle sizes (mean ± SD) for the expelled jelly boluses were 7.2 (± 
3.5) mm, 6.9 (± 3.6) mm and 4.3 (± 0.8) mm for Hartley’s, Vimto and Peppa Pig jellies 
respectively. Peppa pig gelatin-based jelly was only measured for boluses from 9 
participants due to a change of consistency to liquid after chewing in some paticipants’ 
expelled samples.  
 
All participants commented that the thickened fluid was the product they liked the least 
(Table 3-4), citing ‘sticky’ (5 participants), ‘granular’ (4 participants) and ‘unpleasant’ 
(4 participants) as reasons for disliking the product. The majority of participants (9/12) 
liked Hartley’s jelly as their favorite product for being “soft” (6 participants) and 
“smooth” (9 participants).  
 
Participants rated thickened water (Thick & Easy stage 3) as more difficult to swallow 
(p<0.05) and sticky (p<0.05) compared to jellies. Sixty-seven percent (8) of 
participants felt residue left in their throat and mouth during swallowing of the 
thickened water (Table 3-4). There was no significant difference in ease of swallowing 
or stickiness between jelly products. All participants needed to chew the free-standing 
commercial jellies (Hartley’s, Vimto and Peppa pig) and only two participants needed 
to chew the Ryukakusan jelly for swallowing. 
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Table 3-4: Participant responses on acceptability aspects of products. 
Acceptability aspects Hartley’s 
jelly 
Vimto 
jelly 
Peppa pig 
(gelatin-based) 
jelly 
 
Ryukakusan 
swallowing aid 
Thick and 
easy stage 3 
Ease of swallowing (mean 
score and range) 
 
1.3 (1-2) 1.1 (1-2) 1.6 (1-3) 1.3 (1-2) 3 (1-5) 
 Residue felt in the mouth 
(% (number) of 
participants) 
 
17 (2) 8 (1) 16 (2) 0 (0) 83 (10) 
Residue felt  in the throat 
(% (number) of 
participants) 
17 (2) 8 (1) 33 (4) 25 (3) 67 (8) 
Participants needing to 
chew jellies to enable 
swallow (% (number) of 
participants) 
 
100 (12) 100 (12) 100 (12) 17 (2) 0 (0) 
Stickiness of products 
(mean score and range) 
 
1.4 (1-2) 1.4 (1-2) 1.8 (1-3) 1.2 (1-2) 3.3 (2-5) 
No. of participants noticing 
a change in consistency of 
product in the mouth 
0  0 4 0 0 
 
3.3.3  Viscosity and in vitro swallowing of thickeners 
The commercial thickeners were prepared using the manufacturer recommended 
concentrations to reach expected stages of thickening according to the American 
National Dysphagia Diet guideline (National Dysphagia Diet Task Force & American 
Dietetic Association, 2002). The expected apparent viscosity range (measured at 50 
S-1) for each stage of thickening are marked in Figure 3-5 using the colour boxes. 
However, the actual apparent viscosity of the thickeners measured in the rheological 
test showed differences to the expected stages of thickening (Figure 3-3). Resource 
Clear (xanthan gum-based) showed consistently low viscosity even at stage 2 and 3 
concentrations. Thick & Easy (starch-based) showed higher viscosity than the 
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expected viscosity range at thickening stages 1 and 2, and the viscosity was also in 
the high end of the expected range for stage 3. Interestingly, Nutilis Powder (a mixture 
of starch and gum-based thickener) showed viscosity within the expected range at all 
three thickening stages.  
 
Figure 3-3. A comparison of expected to actual stages of thickening for the 
commercial thickeners. 
 
Figure 3-4 shows images of the thickeners during the in vitro swallowing process in 
the “CT” and Figure 3-5 shows the oral transit time (OTT) and bolus length (BL) at 
airway divide for each expected stages of thickening. For all three thickeners, OTT 
increased with incremental increase in thickening (Figure 3-5a) and BL at airway divide 
decreased for each incremental increase of thickening (Figure 3-5b). Table 3-5a 
shows statistical differences in OTT and BL between stages of thickening for each 
thickener. OTT and BL showed significant differences between different stages of 
thickening at stages, 1, 2 and 3 for all thickeners except Resource Clear (xanthan 
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gum-based) at stages 2 and 3. Table 3-5b shows the comparison between different 
thickeners at each stage. At stage 1, Resource Clear and Thick & Easy did not show 
a significant difference in OTT between each other, but both showed a significant 
difference to Nutilis Powder. There is no significant difference between the thickeners 
at stage 2 in OTT. At stage 3, all thickeners shown significant differences in OTT to 
each other, with a ranking order of Thick & Easy > Nutilis Powder > Resource Clear. 
For BL, there was no significant difference between the thickeners at stages 2 and 3; 
however, at stage 1 a significant difference was detected with a ranking order of Thick 
& Easy > Resource Clear >Nutilis Powder. 
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Figure 3-4. Images of stages 1, 2 and 3 thickened fluids of a) Thick & Easy, b) Nutilis 
Powder and c) Resource Clear at T1 (time taken for the bolus to reach epiglottis) 
and T2 (time taken for the bolus to reach airway divide). 
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Figure 3-5. Oral transit time (a) and bolus length (b) at airway divide of commercial thickeners at each expected stages of 
thickening. 
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Table 3-5: A comparison of statistical differences in OTT and BL  (a) between stages 
of thickening for each thickener (b) between different thickeners at each stage 
(significance was marked as * p ≤ 0.05 and ** p ≤ 0.01). 
(a) 
Product 
Comparison 
stages 
p-value for OTT p-value for BL 
Thick & Easy 1 and 2 0.0079** 0.0079** 
 2 and 3 0.0079** 0.0079** 
Resource Clear 1 and 2 0.0079** 0.0079** 
 2 and 3 0.1508 0.2778 
Nutilis Powder 1 and 2 0.0079** 0.0079** 
 2 and 3 0.0159* 0.0079** 
(b) 
Products 
Comparison 
stages 
p-value for OTT p-value for BL 
Thick & Easy 
and Nutilis Powder 
1  0.0079** 0.0079** 
2  0.7937 0.2857 
 3 0.0079** >0.9999 
Thick & Easy and 
Resource Clear 
1  0.4444 0.0159* 
2  0.8413 0.5000 
 3 0.0079** 0.952 
Nutilis Powder and 
Resource Clear 
1  0.0238* 0.2857 
2  0.5159 0.2143 
 3 0.0159* 0.1508 
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3.3.4 Rheological and textural characterisations  
Three representative oscillatory frequency sweeps are shown in Figure 3-6 for stage 
three thickening of commercial thickeners. The commercial thickeners all show the 
same characteristic features; G’ dominance over G” within the frequency range tested 
and a decline in complex viscosity (Ih*I) over the frequency range. A greater magnitude 
in G’ and G” is shown for Thick & Easy (Figure 3-8a), followed by Nutilis (Figure 3-6b) 
and Resource clear (Figure 3-6c).  
 
The response to the steady state rate test of the thickener products at different stages 
of thickening is shown in Figure 3-7. All three commercial thickeners showed shear 
thinning behavior and an increase in apparent viscosity was observed with each 
incremental stage of thickening. 
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Figure 3-6: Oscillattory frequency sweeps for a. Thick & Easy; b. Nutilis; c. Resource 
Clear at stage 3 thickening. 
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Figure 3-7: Apparent viscosity as a function of shear rate for a. Thick & Easy; b. 
Nutilis; c. Resource Clear at three stages of thickening. 
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Very high or high positive correlations were found between OTT and some of the 
rheological and textural properties of thickeners, including apparent viscosity, yield 
stress, cohesiveness and firmness (Table 3-6, Figure 3-8). Adhesiveness showed 
negligible correlation with OTT. Moderate negative correlations were found between 
BL and cohesiveness, adhesiveness and firmness; while low confidence in the 
correlation between BL and apparent viscosity and yield stress was observed (Table 
3-6, Figure 3-9). 
 
Table 3-6: Pearson’s correlation coefficients between OTT, BL and 
rheological/textural parameters. 
Parameters 
Correlation with OTT Correlation with BL 
R  Correlation R  Correlation 
Apparent viscosity 0.89 High positive  -0.52 Moderate negative  
Yield stress 0.95 Very high positive  -0.52 Moderate negative  
Cohesiveness 0.87 High positive  -0.66 Moderate negative  
Adhesiveness 0.07 Negligible  -0.54 Moderate negative  
Firmness 0.78 High positive  -0.66 Moderate negative  
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Figure 3-8: Correlation graphs between OTT and a) apparent viscosity, b) yield stress, c) cohesiveness, d) adhesiveness and e) 
Firmness. 
 
 
 
 
 
 
 
-20
0
20
40
60
80
100
0 50 100 150 200
O
ra
l t
ra
ns
it 
tim
e(
s)
Firmness (g) 
Thick and easy
stage 1
Thick and easy
stage 2
Thick and Easy
stage 3
Nutilis stage 1
Nutilis stage 2
Nutilis stage 3
Resource Clear
ThickenUp stage 1
Resource Clear
ThickenUp stage 2
Resource Clear
ThickenUp stage 3
e 
 99 
 
       
      
Figure 3-9: Correlation graph between bolus lengths and a) apparent viscosity, b) cohesiveness, c) adhesiveness. 
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3.3.5 In vitro swallowing of jellies and yogurt 
Figure 3-10 and 3-11 shows the transit of jellies and yogurt in the “CT” model.  Figure 3-12 
shows the OTT and BL at airway divide for jellies and yogurt in comparison to Nutilis Powder 
which showed the expected level of thickening at stages 1, 2, and 3. The OTT of manually 
chopped (dry) jellies (Hartley’s, Vimto and Peppa Pig) were significantly longer than chewed 
boluses of the same jelly (Table 3-7). The dry jellies showed much slower transit than stage 
3 Nutilis Powder. The OTT of the chewed jellies and the free-flowing Ryukakusan jellies (for 
adults and children) are comparable to stage 2 Nutilis Powder. Ski yogurt showed similar OTT 
to stage 3 Nutilis Powder.  
 
The BL at airway divide did not show a significant difference between dry and chewed jellies 
for Hartley’s, Vimto and Peppa Pig jellies (Table 3-7). All jelly boluses had BL between the 
BL of stage 2 and 3 Nutilis Powder; however, larger variations (bigger confidence intervals) 
were observed for BL of jelly samples. Ski yogurt showed longer bolus BL than the jelly 
samples, with the mean value bigger than the CI range of the BL of stage 1 Nutilis Powder.  
 
Figure 3-(13-15) show data from the oscillatory frequency sweep and steady-state rate sweep 
rheological tests. The mechanical spectra showed G’ dominance over G” for all jellies. Ski 
yogurt shows more dependence of moduli on the frequency (Figure 3-13f). Shear-thinning 
rheology was observed for the jellies and yogurt (Figure 3-15). 
 
Figures 3-(16-18) show the rheological and textural properties of jelly boluses compared to 
thickened fluids.  Most rheological and textural properties of jellies, including apparent 
viscosity, yield stress, firmness and cohesiveness, were comparable to stage 1-2 thickened 
fluids, except for Peppa pig jelly which showed firmness and cohesiveness similar to stage 3 
 101 
thickened fluids. Adhesiveness for jellies was similar to stage 1 and 2 thickened fluids 
(comparable to Thick & Easy and Resource clear).   
 
 
 
 
Figure 3-10: Transit of jellies and yogurt in the Cambridge Throat towards the epiglottis (T1) 
and airway divide (T2) for a) Ryukakusan jellies and yogurt and b) dry jellies. 
a 
b 
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Figure 3-11: Transit of participants’ jelly boluses in the Cambridge Throat towards 
the epiglottis (T1) and airway divide (T2) for a) 4mm particle size b) 8mm particle 
size. 
 
 
 
 
a 
b 
 103 
  
 
Figure 3-12: The OTT (a) and BL (b) at airway divide for jellies and yogurt. The coloured boxes represent the confidence interval 
range for the thickener Nutilis Powder at stages 1, 2, and 3 for comparison.
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Table 3-7: A comparison of statistical differences in OTT and BL between dry and 
participant bolus jellies (significant differences was marked as *). 
Product Comparison boluses p-value for OTT p-value for BL 
Hartley’s 
 
Dry jelly vs. participants 
bolus 
0.0159* 0.8413 
Vimto 
 
Dry jelly vs. participants 
bolus 
0.0079** 0.6905 
Peppa pig 
 
Dry jelly vs. participants 
bolus 
0.0079** 0.6905 
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Figure 3-13: Oscillatory frequency sweeps for (a) Hartley’s jelly, (b) Vimto jelly, (c) 
Peppa pig (gelatin-based) jelly, (d) Ryukakusan jelly for adults,  (e) Ryukakusan jelly 
for paediatrics and (f) Ski yogurt. 
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Figure 3-14: Oscillatory frequency sweep for participants’ boluses: a) Hartley’s small 
particles b) Hartley’s large particles. C) Vimto small particles d) Vimto large particles 
and e) Peppa pig gelatine bolus. 
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Figure 3-15:  Apparent viscosity as a function of shear rate for dry jellies and yogurt. 
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Figure 3-16: Comparison of apparent viscosity (a) and yield stress (b) between thickened fluids, jellies and yogurt.  
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Figure 3-17: Comparison of firmness (a) and cohesiveness (b) between thickened fluids, jellies and yogurt. 
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Figure 3-18: Comparison of adhesiveness between thickened fluids, jellies and yogurt..
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3.4 Discussion 
The study was conducted to compare processing behaviour in an in vitro throat model 
which was originally designed for processing of liquids and to compare bolus 
characteristics of thickened fluids to alternative swallowing aids; jellies and yogurt for 
pharmaceutical application. Thickened fluids are known to improve the safety of 
swallowing fluids and are also used to administer solid oral medicines (Bisch, 
Logemann, Rademaker, Kahrilas, & Lazarus, 1994; Clavé et al., 2006; Inamoto et al., 
2013). Chapter 2 from this thesis showed thickened fluids are not the only vehicles 
used to administer medicines, jellies and yogurt were also used but the swallowing 
safety of jellies and yogurt is less studied than thickened fluids. 
 
The in vitro throat model used in this study to evaluate the swallowing process does 
not account for chewing, in particular for jellies that need chewing before swallowing. 
The particle size distribution of jellies after chewing and bolus temperature were 
determined in healthy volunteers. This information was used to manually fragment 
jellies to represent chewing and process jelly products and thickening agents in the in 
vitro throat model. Firmer foods tend to have smaller particle sizes after chewing 
compared to softer foods and this is observed with Hartley’s and Vimto jelly having 
similar mean particle size distribution compared to Peppa pig gelatin based jelly which 
has a higher firmness value (from the texture analysis data) and was chewed to much 
smaller mean particle sizes (Chen, Khandelwal, Liu, & Funami, 2013).  
 
The temperature of expelled boluses was also measured to indicate the extent of 
change in bolus temperature after chewing relevant for the in vitro testing of jellies. A 
change (increase) in temperature during chewing may change the jelly texture and 
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gelatin is recognized to have a melt-in-mouth effect (Karim & Bhat, 2008). A previous 
study reported that the average oral residence time of strawberry jellies of varying 
firmness was between 3-5 seconds (Chen & Lolivret, 2011). In this study, there was 
no considerable increase in bolus temperature when the bolus was deemed ready to 
swallow, likely due to the short oral resident time in healthy volunteers. The manually 
fragmented jellies were thus processed at room temperature for the in vitro tests. 
 
Although thickeners (gum or starch based) are commonly used to increase viscosity 
of thin liquids (water and beverages) to aid safe swallowing in patients with dysphagia, 
previous reports show that acceptability of thickened fluids is low (Garcia, Chambers, 
et al., 2005; Murray et al., 2014; Shim et al., 2013). All participants in this study showed 
displeasure with Thick & Easy stage 3 thickened water compared to jelly products. 
Starch-based thickeners such as Thick and Easy have been reported to have a grainy 
texture, and starch flavour which suppresses other flavours, while gum-based 
thickeners have been reported to have an undesirable stickiness (Lotong et al., 2003; 
Matta et al., 2006). For patients with dysphagia where the time required for swallowing 
may be longer, this can be undesirable. Acceptability studies for foods are normally 
conducted by obtaining consumer ratings on appearance, taste, texture, and overall 
acceptability of a product (Garcia, Chambers, Chacon, & Di Donfrancesco, 2015). 
Acceptability of dosage forms has been defined as the “overall ability of the patient or 
caregiver to use a medicinal product as intended or authorized” and acceptability is 
an important aspect of pharmaceutical dosage form consideration (Kozarewicz, 2014).  
This study shows jellies as potentially better accepted to use as delivery vehicles for 
dosage forms than thickened fluids. 
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The volunteers in this small scale pilot study were not trained sensory panellists; 
however, their feedback can be valuable in indicating preference of using these 
products as medication swallowing aids and to guide formulation development for 
acceptable liquid or semi-solid oral medicines for patients with dysphagia. The 
participants found that Thick & Easy stage 3 was more difficult to swallow and there 
were no significant differences in ease of swallowing of jellies. Feelings of residue in 
the throat after consuming Thick & Easy stage 3 was experienced by more participants 
compared to jellies; residue for patients with dysphagia can increase the risk of 
aspiration or choking sensation (Clavé et al., 2006; Rofes, Arreola, Mukherjee, 
Swanson, & Clavé, 2014; Vilardell, Rofes, Arreola, Speyer, & Clavé, 2016). This 
indicates that jellies might potentially be more suited for patients with weak muscular 
contractions such as older patients, as weak contractions could lead to choking or 
sensation of product lodged in the throat (Cichero & Murdoch, 2006; Tracy et al., 
1989). 
 
There has been considerable emphasis on dysphagic patients consuming thickened 
fluids of the correct consistency due to concerns regarding the consumption of too thin 
or thick consistency both of which may result in penetration-aspiration due to spillage 
in the airway or residue in the pharynx (Steele et al., 2015). In this study, the thickened 
fluids were prepared according to manufacturers guidelines; however, the apparent 
viscosity at 50s-1 used to determine the stages of thickening does not correspond to 
the expected stage of thickening. For example, Resource clear  (gum-based thickener) 
thickened to expected stages 1, 2 and 3,  showed measured apparent viscosity 
corresponding to stages 1, 1 and 2. Thick and Easy (starch-based thickener) 
exceeded expected levels of thickening, although there is no upper limit for stage 3 
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(the viscosity range is >1750cP), the apparent viscosity for the starch-based thickener 
was five times greater than this minimum value. Interestingly, Nutilis, a mixture of 
starch and gum thickener met expected levels of thickening.   It has been previously 
reported that both starch and gum-based thickeners prepared using manufacturers’ 
recommendations do not always fall within the viscosity range for the National 
Dysphagia Diet Task Force guidelines and starch thickeners tend to continue to 
thicken over time and less change is observed for gum-based thickeners (Cho & Yoo, 
2015; Garcia, Chambers IV, Matta, & Clark, 2005; Pelletier & Dhanaraj, 2006). 
Numerous factors can affect the viscosity of thickened fluids including the media used 
for example, water and juice, the thickening time, type of thickening agent and solid 
content, which might contribute to the variation of the resultant apparent viscosity 
compared to manufacturers’ recommendations (Garcia, Chambers, et al., 2005; 
Sopade et al., 2008) 
 
The movement of thickened fluids in the in vitro throat model showed slower and more 
cohesive (reduced bolus length) transit with incremental stages of thickening. Each 
incremental level of thickening involved increased solid content of the thickening 
agent. The most critical concern with difficulties in swallowing is to prevent penetration-
aspiration caused by food or drinks entering into the airway. The important feature of 
the safe swallowing is the closure of the airway to enable the passing of food to the 
oesophagus and not the trachea (Logemann, 2007). Penetration-aspiration can occur 
both at the oral stage and pharyngeal stage. If the bolus transit is too fast, for example, 
thin fluids such as water require greater agility to maneuver in the oral cavity and the 
pharynx, the fast oral transit and lack of cohesion between particles can result in 
premature spillage into the airway particularly for patients requiring longer pharyngeal 
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closure times, where their airways may not have sufficiently closed when bolus arrives 
or during transit in the pharynx (Crary & Groher, 2003; Dantas et al., 1990; Tashiro et 
al., 2010).  Additionally, the bolus needs to transit cohesively (as one homogeneous 
bolus without fragmentation) in the pharynx to prevent spillage into the airway 
(Newman et al., 2016). 
 
Although there is a lack of clinical evidence for texture modified food and drinks for 
dysphagia management, the reduced bolus velocity of thickened fluids has been 
linked with swallowing safety (Painter, Le Couteur, & Waite, 2017; Steele et al., 2015). 
Several studies have reported that increasing viscosity of the bolus resulted in 
reduction of aspiration-penetration observed in patients with dysphagia (Kuhlemeier, 
Palmer, & Rosenberg, 2001; Leonard, White, McKenzie, & Belafsky, 2014; Logemann 
et al., 2008; Painter et al., 2017; Rofes et al., 2014; Troche, Sapienza, & Rosenbek, 
2008; Vilardell et al., 2016). Rofes et al. (2014) reported a significant increase in bolus 
transit time between the glossopalatal junction and upper esophageal sphincter when 
the viscosity of a 5mL thin-liquid bolus was increased to spoon-thick for patients with 
oropharyngeal dysphagia. Troche et al. (2008) reported that increasing bolus viscosity 
resulted in a significant reduction in OTT.  Similarly, Dantas et al., (1990) and Reimers-
neils, Logemann, & Larson (1994) reported an increase in oral and pharyngeal transit 
time for viscous paste boluses compared to low-viscosity liquid bolus in healthy 
subjects.  
 
The finding of slow bolus transit in the in vitro model with increasing thickening level 
was consistent with previous in vitro studies using similar in vitro throat models 
(Mackley et al., 2013; Mowlavi et al., 2016). Different commercial thickeners showed 
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different degree of reduction in the velocity of bolus transit. Xanthan gum-based 
thickeners have been previously reported to influence the reduction in the in vitro OTT 
the least (Mackley et al., 2013; Mowlavi et al., 2016). This is particularly notable at 
stage 3 possible due to the greater shear thinning nature of xanthan gum compared 
to starch, resulting in low viscosity at  50s-1 (the shear rate believed to represent oral 
processing) (Cho & Yoo, 2015; Kumagai, Tashiro, Hasegawa, Kohyama, & Kumagai, 
2009; Vickers et al., 2015; Waqas, Wiklund, Altskar, Ekberg, & Stading, 2017). Starch-
based thickeners have shown higher apparent viscosity at 50s-1 and consequently 
showed longer oral transit times particularly at stage 3. This could increase the risk of 
post-deglutitive residue in the pharynx with the potential to cause penetration-
aspiration if the airway is not closed. Residue associated with starch-based thickeners 
has been reported previously particularly in patients with reduced muscle strength and 
reduced ability for bolus propulsion such as older adults (Clavé et al., 2006; Rofes et 
al., 2014; Vilardell et al., 2016). Interestingly Nutilis, a thickener which is a mixture of 
xanthan gum and starch showed intermediate OTT compared to xanthan gum or 
starch used independently, owing to its moderate apparent viscosity at 50s-1 
complying the National Dysphagia Diet Task Force & American Dietetic Association, 
(2002) standard for all three thickening levels. 
 
The association between cohesion of bolus flow and safety of swallowing is less well 
understood in comparison to bolus viscosity. Kumagai et al. (2009) studied the 
relationship between the velocity of polysaccharide based thickeners, including 
xanthan gum, through the pharynx by using the ultrasonic pulse Doppler method. The 
polysaccharide solutions velocity distributed over a narrower range with increasing 
concentration indicating more cohesive bolus flow. Nakauma, Ishihara, Funami, & 
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Nishinari (2011) performed acoustic analysis of the transit of xanthan gum solutions 
in the pharynx and found that the acoustic balance for swallowing sounds shifted to a 
higher frequency indicating xanthan gum flows as one coherent bolus. The cohesive 
nature of the flow of xanthan gum boluses compared to starch can be further 
supported by its extensional flow behavior. Starch-based thickeners stretched 
heterogeneously; this led to premature filament breakage whereas xanthan gum 
solutions showed homogeneous deformation and extended filament thinning (Mackley 
et al., 2013). Mackley et al. (2013) also reported that xanthan gum showed a higher 
extensional viscosity compared to starch at 50s-1 shear rate. The differences in 
extensional flow behavior may be explained by the differences in the microstructure of 
xanthan gum and starch solutions. Xanthan gum solutions show a mesh-like network 
while starch solutions show swollen starch granules (Waqas et al., 2017). Boluses with 
low extensional viscosity may result in bolus fragmentation in the pharynx and 
subsequently result in penetration-aspiration.  
 
In this study, the extensional flow behavior may be reflected in the BL at the airway 
divide. Generally, increasing thickener concentration resulted in a decrease in BL 
indicating cohesive bolus transit, supporting previous in vivo findings (Kumagai et al., 
2009; Nakauma et al., 2011). At lower thickening stages, xanthan gum based 
thickener showed shorter BL at the airway divide compared to the starch-based 
thickener, supporting the higher extensional viscosity reports  of xanthan gum-based 
thickeners (Hadde & Chen, 2019; Waqas et al., 2017). Xanthan gum and starch-based 
thickener showed similar efficiency in vivo in safety of swallowing at spoon-thick 
thickening assessed using videofluoroscopy; however xanthan gum was more 
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effective at lower thickening levels (nectar-thick) in reducing penetration-aspiration 
compared to starch-based thickeners (Leonard et al., 2014; Vilardell et al., 2016). 
 
The swallowing process is complex involving coordinated contractions of muscles. 
The in vitro throat model used in this study mimics the oral phase by using the roller 
to represent tongue peristalsis and unlike muscle contractions found in the pharynx in 
humans. The pharynx (located after the 120° angle and before the airway divide in 
Figure 3-3) in the throat model is static. The flow of bolus along a wall will induce given 
shear stress. The more solid-like behavior of the thickened fluid compared to thin 
liquids results in a reduced shear strain and hence slower transit speed. The wall shear 
rate was assumed as 50s-1 in this in vitro throat model simulating that in the oral cavity 
in vivo  (Hadde, 2017; Mackley et al., 2013). The in vitro model has limitations, for 
example, it does not simulate the chewing process, the interaction of food with 
mucosal surfaces, the conditions operating in the oral cavity such as the mixture of 
the food with saliva, the tongue surface contact with the bolus during peristalsis and 
the extensional shearing of foods that occur in the mouth.  Although the in vitro model 
over simplifies the swallowing process and the throat model cannot replace in vivo 
studies, it is a useful tool to compare the oral transit of fluids and has been consistent 
with reports of increasing oral transit time with increasing thickening. It is also a useful 
tool in comparing how the fluids transit in a static pharynx, i.e., participants with weak 
muscular movement, and whether the fluids move cohesively or loosely (as indicated 
by BL at airway divide in the in vitro thorat model) where more control may be required 
to direct the bolus.   
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In the rheological test, all products showed a G’ dominance over G” indicating solid-
like behaviour; it is clear from the frequency dependency of Thick & Easy compared 
to Nutilis and Resource clear that these are structurally different products, with Thick 
& Easy having a stronger gel structure (modulus are more independent of frequency 
compared to the other two products) (Zhang, Daubert, & Foegeding, 2005). Shear 
thinning rheology was observed for each incremental thickening of fluids as reported 
in previous studies (Mackley et al., 2013; Payne, Methven, Fairfield, & Bell, 2011).  
The shear-thinning feature of the thickened fluids is believed to prevent uncontrolled 
spillover due to higher viscosities at lower shear rates (Mowlavi et al., 2016).  
 
This study showed a correlation between rheological and textural parameters with 
parameters that were measured using the in vitro throat model, i.e. oral transit time 
and bolus length measured in the airway divide. Firmness is the ability of the material 
to withstand stress, cohesiveness is the intermolecular attraction between like 
molecules, or the unity of particles throughout a mass and adhesion is the molecular 
interactions with dissimilar molecules, or the interaction between two interfaces 
(Marshall, Bayne, Baier, Tomsia, & Marshall, 2010). The yield stress is the point at 
which reversible elastic deformation ends and irreversible deformation occurs and 
viscosity is the internal friction of the fluid. All of the parameters; viscosity, yield stress, 
cohesiveness, firmness related to the structural integrity of the material. An increase 
in the concentration of thickener understandably increased apparent viscosity, 
cohesiveness, yield stress, and firmness and showed correlations to in vitro OTT and 
BL.  
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Although the central focus for dysphagia food and drink management has been 
viscosity, other physical properties can also be influential for safe swallowing such as 
cohesiveness and yield stress, both properties influenced by the binding force 
between the particles in a bolus (Marcotte & Hosha, 2015; Steele et al., 2015). 
Rheological and textural parameters such as firmness, cohesiveness, and 
adhesiveness of food have also been given importance for food management for 
dysphagia by the National Rehabilitation Center for Persons with Disabilities Japan 
(2015). However, the effect of properties other than viscosity is not widely studied. 
Tsukada, Taniguchi, Ootaki, Yamada, & Inoue (2009) found an increase in firmness, 
cohesiveness, and adhesiveness with an increase in agar solid content corresponding 
to an increase in oral ejection time in healthy subjects. Funami, Ishihara, Nakauma, 
Kohyama, & Nishinari (2012) compared the sensory properties of polysaccharide gels 
and acoustic analysis for swallowing performance and found that gels that were scored 
higher in sensory cohesiveness also showed a shorter transit time in the pharynx, 
indicating the bolus transiting as one ‘coherent’ bolus. However, high cohesiveness is 
associated with residue in the pharynx in older adults with post-stroke dysphagia 
(Momosaki, Abo, & Kobayashi, 2013). In this study, parameters of cohesiveness, yield 
stress, firmness, and viscosity was found to have high correlations to OTT, while low 
correlations were found for adhesiveness. Only moderate correlations were obtained 
between these parameters and BL. It was expected that all the parameters associated 
with structural integrity (viscosity, yield stress, cohesiveness, firmness) would show a 
strong association with bolus length.  
 
The in vitro swallowing behavior of jellies and yogurt were tested in this study due to 
the findings in Chapter 2 as both were used as vehicles for medicine management in 
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dysphagic patients. The confidence intervals of Nutilis stages one to three were taken 
forward to compare with our alternative swallowing aid products since Nutilis showed 
consistent thickening with expected stages. There is limited literature on the safety of 
swallowing of jellies and yogurts. The transit of the Ski yogurt in the in vitro model 
showed the spread of yogurt across the pharynx wall (as indicated by the long bolus 
length when reached the airway divide), which was also observed for stage 1 
thickened fluids. However, the oral transit of yogurt in the in vitro model was 
comparable to stage 3 thickened fluids. This is in agreement with Kumagai et al. (2009) 
reported yogurt to have similar velocity spectra in the pharynx to higher thickening 
concentrations and as a lower risk of aspiration than water, due to the reduced velocity 
spectra, which is believed to aid safe swallowing.   
 
The term jelly is often used interchangeably with gels which form a three- dimensional 
matrix interlocking solvent (Satyanarayana, Kulkarni, & Shivakumar, 2011). The dry 
jellies showed slow transit, and the participant boluses which were lubricated by saliva 
were faster in the in vitro transit as expected. The BL was similar for dry and chewed 
jellies showing cohesiveness in the flow. Ryukakusan jellies are presented as free-
flowing granular jellies (Tsuji, Uchida, Fukui, Fujii, & Sunada, 2006). This product is 
used in Japan as a swallowing aid (Tsuji et al., 2006). Tablets and capsules are added 
to a layer of jelly and then covered further with more jelly before being swallowed. The 
cohesive nature of the jelly bolus (shorter BL at air way divide) could help to reduce 
spillage into the airway, which could be the reason that aspiration-penetration is 
reduced when jellies were swallowed by patients with oesophageal cancer (Sonoi et 
al., 2016). These findings indicate jellies to have similar safety features to thickened 
fluids stages 2 and 3, consistent with a study comparing the safety of swallowing of 
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thin, nectar thick, stage three thickened water and jelly in 42 oesophageal cancer 
patients (mean age 68 years), and 43 control hospitalised patients (mean age 69 
years). Puree consistency and jelly were the safest to swallow, laryngeal penetration 
was not observed for patients taking puree consistency and occurred in only one 
patient for jelly (Sonoi et al., 2016). The safety of puree consistency and jelly was 
considered a result of easy flow of the bolus from the pharynx to the oesophagus and 
a lower chance of flow into the trachea before transiting to the pharynx. This is 
consistent with the findings of the current study of a more cohesive flow (shorter BL) 
of jellies and stage 3 thickened fluids compared to thinner liquids (stage 1 and 2 
thickened fluids). However, starch-based thickeners, such as at the puree consistency 
reported above,  transited too slowly which may increase the risk of residue. 
 
A comparison of rheological and texture parameters of jellies and thickeners showed 
parameters such as apparent viscosity, firmness, cohesiveness, yield stress and 
adhesion of jellies to be similar to stage 1 or 2 thickened fluids but safety features 
(slow transit, cohesive bolus flow) closer to stage 3. Rheological characterization 
showed that jelly products have stronger gel network compared to thickened fluids (a 
greater magnitude of  G’, which was dominant over G” over a frequency range), which 
may explain structural integrity in the throat model and thus shorter bolus length. 
Yogurt showed a greater dependency of G’ over the frequency range, indicating a 
weaker structure and hence the spreading of flow across the pharynx. Thickened 
fluids, jellies and yogurt are all produced differently. Thickened fluids involve 
entanglement of polymers (for xanthan-gum based thickeners), jellies including the 
Ryukakusan jelly involve heating followed by cooling to form an ordered structure and 
yogurt is the coagulation of protein (Atsuko et al., 2001; Sandoval-Castilla, Lobato-
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Calleros, Aguirre-Mandujano, & Vernon-Carter, 2004). A set of rheological and textural 
parameters that contribute to safety of swallowing for thickened fluids did not influence 
the processing of  jellies and yoghurt  in the throat model. It is speculated that it would 
be easier to deform an ordered structure (as in jellies after fragmentation or chewing) 
than entangled composition (such as in thickened fluid) during oral processing, which 
may have resulted in lower apparent viscoisity at the shear rate relevant to oral 
processing, cohesiveness, firmness, yield stress of jellies compared to stage three 
thickened fluids. 
 
This is the first study to systematically compare thickeners composed of different 
materials with a focus on BL to indicate cohesive bolus movement in addition to OTT 
which was investigated in previous studies (Hayoun et al., 2015; Mackley et al., 2013; 
Mowlavi et al., 2016). This is also the first study to investigate products other than 
liquids for the processing in the in vitro throat model for pharmaceutical application. 
The rheological and textural parameters showed a correlation for thickened fluids, 
however, this study showed that these parameters may not be appropriate in 
predicting the movement of other products in the “CT” model due to structural 
differences. The in vitro throat model is a useful tool to compare the OTT and BL of  
jellies, yogurt and thickened fluids and further investigation would be required to 
establish a in vitro-in vivo correlation for the processing of these products. 
 
3.5 Conclusions 
Acceptability of jellies was better than thickened fluid. Although viscosity has been 
used as an indicator for the safety of swallowing of fluids and has been the central 
focus for dysphagia product development, a more holistic approach using rheological 
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and textural parameters is  needed. Our study has shown that viscosity is not the only 
feature contributing to the safety of swallowing; cohesiveness, yield stress, firmness 
are also factors that influenced transit time and bolus length (an indicator of 
cohesiveness) of flow of thickened fluids. 
 
Jellies showed similar safety features as thickened fluids; slow transit and cohesive 
bolus flow, which prevents premature spillage.  There was greater variability in the 
processing of some jelly products and a further investigation is required to correlate in 
vitro-in vivo results. The in vitro throat model proved to be a useful tool in evaluating 
the processing behavior of thickened fluids, jellies, and yogurt, to assess whether the 
bolus moves as a unit mass or cohesively and can be used in the future as a tool to 
help the selection or design of safe food or drink for patients with dysphagia. 
 125 
 
 
 
 
 
 
Chapter 4 
DEVELOPMENT OF INSTANT JELLIES WITH SAFE 
SWALLOWING FEATURES IN AN IN VITRO THROAT 
MODEL TO USE AS DRUG ADMINISTRATION 
VEHICLES TO PATIENTS WITH DYSPHAGIA 
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4.1 Introduction 
It is well recognised that patients with dysphagia find solid oral dosage forms (SODF) 
difficult to swallow (Fodil et al., 2017; Schiele et al., 2015; Strachan & Greener, 2005; 
Wright, 2002). However, patients still consume food and drinks in a modified form to 
allow safe swallowing. SODF such as tablets and capsules are commonly prescribed 
and although liquid alternatives are available for many of these SODF these still can 
be challenging to swallow for patients with dysphagia whom are unable to safely 
swallow fluids. Liquid dosage forms sometimes require further modification by using 
thickened fluids to ease swallowing which may pose difficulties for patients whom 
dislike the thickened fluids (Garcia, Chambers, & Molander, 2005; Murray, Miller, 
Doeltgen, & Scholten, 2014; Shim, Oh, & Han, 2013). Countries such as Japan include 
jellies in their dysphagia diet. Jellies made from gelatin are recognised to potentially 
cause aspiration due to a change in consistency from a gel to liquid at body 
temperature (National Rehabilitation Center for Persons with Disabilities Japan, 2015). 
However jellies made from other polysaccharides such as carrageenan are 
recognised to hold together in the oral phase mitigating aspiration risks (International 
Dysphagia Diet Standardisation Initiative, 2016a). Chapter 3 showed that jellies were 
better accepted and presented similar safety features of cohesive bolus flow in the 
pharynx and reduced oral transit, similar to stage three thickened fluids performance 
in the in vitro throat model. 
 
Jellies are potentially useful for drug administration to dysphagia patients, however, 
jellies require heating to form which can affect drug stability. Jellies presented in pre-
prepared form with water can also affect drug stability.  An instant (jelly forming in less 
than 10 minutes) preparation for safe-to-swallow jelly that would not require heating to 
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form the jelly for older adults with swallowing difficulties would obviate drug stability 
issues with heating storage in ready-made jellies.  
4.1.1 Gelation 
The terms gel and jelly is often used interchangeably, and their distinction is not clear 
by definition. Both ‘gel’ and ‘jelly’ can be traced back to the Latin term ‘gelare’ meaning 
to ‘congeal’, suggesting the idea of a liquid congealed in a semisolid material, elastic 
and retaining liquid characteristics (Satyanarayana et al., 2011). Martin (1993) 
describes gels as “a solid or semisolid system of at least two constituents, consisting 
of a condensed mass enclosing and interpenetrated by a liquid.” A matrix rich in the 
liquid is often called a jelly or gel, and when the liquid is removed, it is called xerogel 
(Martin, 1993). There is no literature information on the difference between gels and 
jellies, but a qualitative or an objective description of a food jelly is ‘will quiver, not 
flow…a product with a texture so tender that it cuts easily with a spoon, yet so firm 
that the angles produced retain their shape; a clear product that is neither syrupy, 
gummy, sticky or tough; neither is it brittle and yet it will break” (Bourne, 2002; 
Goldthwaite, 1909). 
 
The process of gelling involves an association between segments of polymers or 
proteins in a dispersion so that a three-dimensional network is formed (Saha & 
Bhattacharya, 2010). The greater the regions of association or junction zones, the 
more rigid the gel (Saha & Bhattacharya, 2010). Gels can be classified as physical or 
chemical gels; Chemical gels involve covalent cross-linkage between polymers 
swollen in a solvent.  Physical gels are formed by the physical association of polymer 
chains in water through hydrogen bonding, cation-mediated cross-linking and 
hydrophobic interactions (Saha & Bhattacharya, 2010).  
 128 
4.1.3 Existing swallowing aids and instant jellies 
Chapter 2 and 3 show that food jellies have better acceptability and are used as 
swallowing aids for medicine administration in older patients with dysphagia. An 
instant jelly dosage form would be useful for patients with dysphagia. There are a 
number of literature on use of sodium alginate-calcium gelation  for capsule shell, film 
formation, in situ gels and gel beads (Al-Kassas, Al-Gohary, & Al-Faadhel, 2007; P. 
Aslani & Kennedy, 1996; Pafisa Aslani & Kennedy, 2006; Blandino, Macias, & Canter, 
1999; Kubo, 2003; Miyazaki, Kubo, & Attwood, 2000; Pawar, Lalitha, & Ruckmani, 
2015). There are also patents in using sodium alginate-calcium gelation to form jelly 
without heating which are summarised in Table 4-1. 
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Table 4-1: A summary of patents for instant jellies and swallowing aids. 
Inventor and 
year 
Target product Ingredients Method for jelly formation Time reported for 
jelly formation 
(Yasushi, 
Kentaro, Yoshida, 
& Yuichi, 2016) 
 
Jelly containing 
foaming bubbles 
Sodium alginate, tribasic calcium phosphate, bicarbonate, 
organic acid (citric acid, malic acid, tartaric acid), a polymer 
compound (egg white) 
Sodium alginate, sodium 
carbonate, calcium phosphate 
mixed together. Acidic 
component added. 
Not reported 
(Masumoto, 
Yuichi, & 
Nakamura, 2016) 
 
Instant foaming 
solid jelly dessert 
powder 
Sodium alginate, calcium sulfate, calcium sequestering agent, 
sodium hydrogen carbonate or organic acid, egg white 
 Not reported  Not reported 
(Hong et al., 
2012) 
Sodium alginate 
jelly powder and 
application 
Sodium alginate, calcium carbonate, sodium 
hexametaphosphate (or sodium tripolyphosphate, or sodium 
pyrophosphate), citric acid 
Dissolve these ingredients and 
add juice, stir and place 1.5-2 
hours for jelly formation. 
1.5-2 hours 
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In the in vitro studies described in Chapter 3 both the free-standing jellies (Hartley’s, 
Vimto, Peppa pig) and granular jelly that flows (Ryukakusan’s jelly) showed promise 
showing slow oral transit time and cohesive bolus transit in the pharynx. Instant jellies 
that do not need heating to form and show these consistencies (free-standing and 
granular) could be useful as medication delivery systems. There are patents 
attempting to produce these type of instant jellies; however, the consistency of the 
resultant jellies and their safe swallowing features are not clear.  
 
This study aims to develop instant free-standing and granular jellies that resemble 
closely to commercial jellies (i.e. wobbly for free-standing jellies) and do not require 
heat to form.  The jellies will be used as a vehicle to safely administer medicines to 
older patients with dysphagia and may benefit other patient groups who find it difficult 
to swallow SODF such as children. The safe to swallow features of these instant jellies 
will be evaluated using the in vitro “Cambridge Throat” (“CT”) model and textural and 
rheology properties, compared to commercial products.    
 
The primary objective of this study is to form an instant (less than 10 minute formation 
time) free-standing and granular jelly that requires no heat. 
 
The secondary objectives of this study are to: 
• Compare the textural and rheological profile of developed jellies with 
commercial jelly products. 
• Assess the processing of the developed jellies in the CT model and compare 
the processing behaviour to commercial jelly products. 
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4.2 Materials and methods 
4.2.1 Materials 
Gelling agents used in this study are listed below in Table 4-2. 
Table 4-2: Gelling agents used in this study. 
Gelling agent Grade and supplier 
Sodium alginate Protanol GP 1740, FMC Biopolymer, UK 
Gellan gum Low acyl gellan gum, CP Kelco, UK 
 High acyl gellan gum, CP Kelco, UK 
Pectin HM pectin pure, CP Kelco, UK 
LM pectin pure, CP Kelco, UK 
Carrageenan Kappa, CP Kelco, UK 
 Iota, CP Kelco, UK 
 Lamda, CP Kelco, UK 
Guar gum B&V, Italy 
Locust bean gum Genu GUM type RL-200Z 
CP Kelco, UK 
Gum tragacanth Thew Aarnott, UK 
Gum karaya Thew Aarnott , UK                                        
Gum ghatti Thew Aarnott, UK 
Gum arabic Thew Aarnott, UK 
Agar Special Chem, UK 
Xanthan gum Keltrol 
CP Kelco, UK 
 Keltrol advanced performance CP Kelco, UK 
Maize starch Roquette, UK 
Egg protein Bodybuilding Warehouse, UK 
Soya protein Pro-Fit SI90, Roquette, UK 
Whey protein Simplesse Microparticulated whey protein, 
Roquette, UK 
Pea protein Cel-Fit QM3, Roquette, UK 
Hydroxypropyl methyl cellulose E5 Methocel, Premium LV, Colorcon litd, UK 
Polyethylene oxide Sentry Polyox WSR N10 LEO NF, Colorcon 
Ltd, UK 
 
Dicalcium phosphate dihydrate and calcium carbonate were purchased from Sigma 
Aldrich, UK. Citric acid, calcium chloride was purchased from Fischer Scientific UK. 
Hartley’s ready to eat jelly (locust bean gum, xanthan gum, gellan gum), Hain Daniels 
Group, UK,  Vimto’s ready to eat jelly (carrageenan, locust bean gum), Caterers 
Choice Litd, UK and Peppa pig ready to eat jelly (gelatin), Heaven Made foods Hold 
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Ltd, UK was used in this study. Ryukakusan “magic jelly” (agar based) was purchased 
from Ryukakusan, Japan. Ski yogurt (milk, rice starch, sugar, lemon juice, carrot 
concentrate, guar gum, milk calcium concentrate) from Nestle, Switzerland was used 
in this study.  Nutilis Powder (starch, xanthan gum, tara gum, guar gum), Nutilis, 
Netherlands was used in this study. Harrogate still bottled water was purchased from 
a local supplier, and deionised water was prepared using a water purification system 
(Purite Select Analyst A80 system, Purite Ltd, UK) at the University of Hertfordshire, 
UK. 
4.2.2 Summary of developing instant jellies 
Instant jellies for this study are jellies that form in less than 10 minutes. There were 
two important factors predominantly considered for developing Instant jellies; one was 
time to form the jellies which were considered at the early stages of development and 
secondly, testing these jellies in an in vitro throat model to ensure safe swallowing. 
Rheological and textural properties were also investigated to compare with existing 
commercial jelly products. 
A summary of steps to develop two forms of instant jellies; a free-standing jelly and 
granular jelly is shown in Figure 4-1. 
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   Figure 4-1: Summary of steps in jelly development.   
 
4.2.3 Visual assessment of commercial jellies and thickened fluids 
In order to visually characterise the products formed during jelly development, visual 
criteria of assessment were formed to distinguish differences between thickened fluid, 
granular jelly and free-standing jellies. Products were assessed for: 
1. Flow when the container is inverted 
2. Granular gels immersed in fluid 
3. Homogeneous consistency 
4. Cuts easily with a spatula, but firm enough that the angles produced retain its 
shape (Goldthwaite, 1909) 
5. Quivers or wobbles when held on a spatula 
6. Smooth surface  
 
Nutilis, Hartley’s ready-to-eat jelly, Ryukakusans ‘magic’ jelly for adults was used to 
assess these visual characteristics. 
 
Visual 
characterisation of 
commercial products 
Hydration time and visual 
assessment of polymer hydration 
in water at room temperature  
Development of free-
standing and granular 
jellies  
 Rheological and textural 
characterisation for comparison 
with commercial products 
 In Vitro 
assessment of 
jellies 
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Table 4-3  and Figure 4-2 shows the visual assessment of commercial products used 
for development of vehicles. There are clear differences between stage 1 and stage 3 
thickened fluids (Nutilis), the first easily flowing with inversion of the container and the 
latter not flowing at all. The granular (Ryukasuan’s) jelly has granular gels in fluid and 
flows, and the free-standing jelly (Hartley’s) does not flow, retains its shape when cut 
with a spatula and wobbles. 
 
Table 4-3: Visual assessment of commercial products.  
Criteria Stage 1 or 2 
thickened  
fluid 
Stage 3 
thickened 
fluid 
Granular 
jelly 
Free-
standing  
jelly 
Flow when the container is inverted Ö x Ö x 
Granular jelly with fluid. x x Ö x 
Homogeneous consistency  Ö Ö X Ö 
Cuts easily with a spatula, but firm 
enough that the angles produced retain 
its shape 
x x x Ö 
Quivers or wobbles when held on a 
spatula 
x x x Ö 
Smooth surface Ö x x Ö 
 
 
 
Figure 4-2: Visual appearance of products scooped with a spatula. 
 
4.2.4 Initial scoping study: polymer hydration times 
Polymers listed in Table 4-2 were added slowly to 20mL deionised water and were 
mixed using a cylindrical magnetic stirrer at 180rpm at room temperature.   A range of 
concentrations  of polymers (0.15, 0.5, 1, 2, 3, 4% w/v) were tested. Hydration time 
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was determined as the time taken for the polymer to fully dissolve or disperse. The 
end product after hydration was determined using the criteria in Section 4.2.3 and 
characterised against the most closely resembled commercial product, e.g. thickened 
fluid, free-standing or granular jellies 
 
Polymers that form gels with ions (sodium alginate, low acyl gellan gum, carrageenan 
(kappa and iota) and low methoxy pectin at 0.5% w/v were dissolved in 10mL 
deionised water and mixed with calcium chloride aqueous solution (0.5% and 2% w/v).  
4.2.5 Development of free-standing jellies 
Sodium alginate and dicalcium phosphate dihydrate were added to 20mL deionised 
water and stirred at 180rpm using a cylindrical magnetic stirrer until the mixture was 
hydrated. Citric acid powder was then added to this mixture and allowed to mix for 30 
seconds before leaving this mixture to set for 5 minutes (Figure 4-3). 
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Figure 4-3: Summary of sodium alginate free-standing jelly steps. 
 
Free-standing jellies were developed using sodium alginate (0.5, 1% w/v), dicalcium 
phosphate dihydrate (0.1, 0.2, 0.3, 0.4, 0.5, 1% w/v) and citric acid (1, 2, 3, 4, 5, 10% 
w/v). The jellies were assessed using the visual criteria outlined in Section 4.2.3. Any 
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residual water was measured by pouring all residual water from the jelly container into 
a measuring cylinder.  
 
Further experiments were conducted to improve jelly hydration time using Formulation 
1 (F1) - sodium alginate 0.5% w/v, dicalcium phosphate dihydrate 0.4% w/v and citric 
acid 2% w/v. For this different stirring methods involving shaking the beaker, stirring 
with a rod, were investigated. Guar gum was used as an additional polymer to sodium 
alginate to improve jelly formation time, residual water and visual appearance using 
F1. Guar gum was selected due to its short hydration time (less than 10 minutes) 
assessed in Section 4.2.4.   
 
Three ratios of sodium alginate to guar gum (75:25, 50:50 and 25:75) were 
investigated. The maximum total polymer concentration was kept at 1% w/v to achieve 
good hydration time. The concentration of dicalcium phosphate dihydrate was 
calculated in proportion to sodium alginate. The composition of the three polymer 
ratios used are shown below:  
 
75: 25 sodium alginate to guar gum: 0.75% w/v sodium alginate, 0.25% w/v 
guar gum, 0.6% w/v dicalcium phosphate dihydrate, 3% w/v citric acid 
 
50:50 sodium alginate to guar gum: 0.5% w/v sodium alginate, 0.5% w/v guar 
gum, 0.4% w/v dicalcium phosphate dihydrate and 2% w/v citric acid. 
 
25:75 sodium alginate to guar gum: 0.25% w/v sodium alginate, 0.75% w/v 
guar gum, 0.2% w/v dicalcium phosphate dihydrate and 1% citric acid. 
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The resultant jellies were assessed using the visual analysis criteria (4.2.3).  Other 
polymers that showed short hydration times (less than 10 minutes) assessed in 
Section 4.2.4 were investigated in the same way as guar gum including egg white 
protein, LM pectin, maize starch, polyethylene oxide, HPMC, carrageenan (kappa) 
and low-acyl gellan gum, at 50:50 ratio.   
 
The volume (15, 20 and 25 mL) and hardness of water used for jelly formation were 
varied and any changes in visual assessment (Section 4.2.3) and time taken for jelly 
to form were determined. Harrogate still bottled water (soft water 98g calcium 
carbonate/L) and tap water (very hard, 358g calcium carbonate/L) were used as 
alternatives to deionised water to determine the effect of water hardness on jelly 
formation. 
 
4.2.6 Development of granular jellies  
Sodium alginate and calcium chloride were used to develop granular jellies that flow.  
Sodium alginate of varying concentrations (0.1, 0.2, 0.5, 1, 1.5, 2, 2.5% w/v) was 
dissolved in 10mL  deionised water using a cylindrical magnetic stirrer at 180rpm. The 
resultant solution was added to 10mL calcium chloride solution (0.1, 0.2 and 0.3% w/v 
of calcium chloride in 10mL deionised water) (Figure 4-4). The mixture was then mixed 
for 5 seconds using a spatula. 
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Figure 4-4: Summary of granular jelly formation. 
 
Formulation 2 (F2)  containing sodium alginate 2% w/v and calcium chloride 0.3% w/v 
was selected for further investigation. Additional polymers (egg protein, LM pectin, 
guar gum, maize starch, polyethylene oxide, hydroxyl propyl methyl cellulose, kappa 
carrageenan, and low acyl gellan gum)  were added to F2 to determine the time for 
the jelly formation and for assessment against the visual criteria (Section 4.2.3). Three 
ratios were investigated with additional polymers at 75:25, 50:50 and 25:75.   
 
The maximum total polymer concentration with additional polymers for F2 was kept at 
1% w/v to achieve good hydration time. The concentration of calcium chloride was 
calculated in proportional to sodium alginate. The composition of the three polymer 
ratios used are shown below:  
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1. 75:25 sodium alginate to other polymer: 0.75% w/v sodium alginate, 0.25% 
w/v other material and 0.11% w/v calcium chloride 
2. 50:50 sodium alginate to other polymer: 0.5% sodium alginate, 0.5% other 
material and 0.075% calcium chloride. Low acyl-gellan gum was also trialled 
with 0.15% calcium chloride. 
3. 25:75 sodium alginate to other polymer: 0.25% w/v sodium alginate, 0.75% 
w/v other material and 0.0375% w/v. 
 
The additional polymer was added using two approaches: 
 
Method A: Additional polymer and sodium alginate were mixed together and dissolved 
in deionised water. 
 
Method B: Additional polymer and calcium chloride were mixed together and dissolved 
in deionised water. 
 
Polymers such as LM pectin, kappa carrageenan, and low-acyl gellan gum were only 
added using method A due to the interaction between calcium and these polymers. 
 
4.2.7 Rheological and textural characterisation of free-standing and granular 
jellies 
Commercial jellies (Hartley’s, Peppa pig and Vimto jelly) and the developed free-
standing and granular jellies (F1 – F3, Table 4-4) were characterized using texture 
analyzer and rheometer.  
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Table 4-4: Formulation and composition. 
Formulation Jelly and composition 
F1 Free-standing: Sodium alginate (0.5% w/v), 
dicalcium phosphate dihydrate (0.4% w/v) and 
citric acid (2% w/v). 
 
F2 Granular jelly: Sodium alginate (2% w/v) and 
calcium chloride (0.3% w/v) 
 
F3 Granular jelly: Sodium alginate (0.5% w/v), low 
acyl gellan gum (0.5% w/v) and calcium chloride 
(0.15% w/v). 
 
A TA 1500 EX controlled–stress rheometer (TA instruments) was used to obtain 
steady shear apparent viscosity and oscillatory viscoelastic data. Measurements were 
carried out at 25°C using parallel plate geometry (diameter: 40mm, gap 650mm) for 
all experiments. For each sample, oscillatory stress sweep (torque 0.01-10,000 micro 
N.m at a frequency of 10 rad/s), frequency sweep (0.1 to 100rad/s) and steady-state 
rate sweep (0.01-100/s) were carried out. 
 
For texture analysis, the gel strength test was used for free-standing jellies and the 
back extrusion test was applied for granular jellies. These tests gave comparison of 
the developed “instant” jellies to commercial ready-made jellies. The gel strength test 
used is a penetration test and is useful for determining gel characteristics before 
chewing. The gel strength test was used for free-standing jellies to determine the 
firmness and adhesiveness of gels and compare with commercial jellies. A Texture 
Analyser (TA.XT. Plus, Stable Microsystems) with an attached cylindrical (P/0..5) 
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probe was used to depress 4mm into spherical jellies gel of diameter 4.5cm and height 
2cm. Texture characteristics (cohesiveness, surface adhesion and firmness) were 
evaluated using back extrusion tests on a Texture Analyser (TA.XT. Plus, Stable 
Microsystems) applying a 5kg load cell. The same test conditions were applied as 
described in Chapter 3, Section 3.2.5. The measurements were carried out at room 
temperature with triplication for all samples.  
 
4.2.8 In vitro characterisation of jellies using the “CT” model 
F1-3 (Table 4-4) were tested in the CT model. The free-standing (F1) jellies were 
manually chopped to 4mm pieces to account for chewing. A 5mL sample of each was 
placed carefully with a spatula into the dialysis tubing attached in the CT model.  
In the “CT” model was used as described in Chapter 3, Section 3.2.4 
4.3 Results 
4.3.2 Initial scoping: polymer hydration times 
Polymers that hydrated under 10 minutes are presented in Table 4-5. Ten minutes 
was selected as the maximum time for full hydration; this is due to the consideration 
of convenience for patient preparation. Materials taking longer than 10 minutes to 
hydrate where gum ghatti, karaya, Arabic, tragacanth, carrageenan iota, carrageenan 
lamda, pea protein, soya protein, whey protein, locust bean gum, xanthan gum, HM 
pectin (with and without sucrose), LM pectin with calcium chloride, carboxymethyl 
cellulose and agar. Low-acyl gellan gum, sodium alginate, guar gum and maize starch 
showed hydration times under 5 minutes at the concentrations investigated. Kappa 
carrageenan, high-acyl gellan gum, LM pectin, HPMC, polyethylene oxide showed 
hydration times that extended to over 5 minutes but less than 10 minutes. 
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Sodium alginate and low-acyl gellan gum both showed potential with calcium salts in 
forming jelly-like structures. Sodium alginate-dicalcium phosphate dihydrate formed 
jellies that met the full criteria for free-standing jellies.  Sodium, alginate (0.5-1.5% 
w/v)-calcium chloride combinations (0.5-1.5% w/v) at high concentrations also formed 
a free-standing structure but do not meet all visual assessment criteria for free-
standing jellies. The jellies did not quiver, did not retain the angles once cut with a 
spatula and a rubbery, string like texture was observed once the jelly was cut. This 
combination at low concentration range showed potential to form granular jellies. Low-
acyl gellan gum (0.15-0.5% w/v) – calcium chloride (0.5-2% w/v) also formed gels with 
a free-standing structure but do not meet all visual assessment criteria for free-
standing jellies. The jellies did not quiver, did not retain angles once cut with a spatula 
and a rubbery, string like texture was observed once the jelly was cut. In addition, the 
low-acyl gellan gum crosslinked with calcium salt gels showed large volume of residual 
water (8-13mL) and thus were not investigated further.  
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Table 4-5: Materials with hydration times under 10 minutes. 
Material Concentration 
w/v (%) 
Time taken to 
hydrate (min) 
                               Visual assessment of end product  
Thickened fluid 
stage 1 or 2 
Thickened fluid 
stage 3 
Ryukakusan 
jelly 
Free-standing jelly 
Carrageenan (kappa) 1-4 4-8 √* (2 ) √*   
Low acyl gellan gum 0.15-1 2-4 √* (2 ) √*   
High acyl gellan gum 0.5-1 4-6  √   
Guar gum 1-4 1-3 √ (1)    
Maize starch 1-4 1-3 √ (1)    
Egg protein 0.5-1.5 3-7 √ (2)    
LM pectin 0.5 9 √ (1)    
HPMC 0.5 8 √ (1)    
Polyethylene oxide 0.5 9 √ (1)    
Sodium alginate 0.5-2 1-5 √ *(1, 2)    
Sodium alginate and 
calcium chloride 
-* 4-8   √* √** 
Sodium alginate and 
dicalcium phosphate 
dihydrate 
-* 6-9    √ 
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Low acyl gellan gum 
and calcium chloride ** 
-* 6-9    √** 
Low acyl gellan gum 
and dicalcium 
phosphate dihydrate 
*     √** 
*Properties vary depending on the concentrations used.  
**Formed a free-standing structure but did not meet the full visual assessment criteria
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4.3.3 Development of free-standing jellies 
As shown in Section 4.3.2 (Table 4-5), sodium alginate-dicalcium phosphate dihydrate 
formed the most promising free-standing jelly structure and was investigated further 
by varying the concentrations of the ingredients. The visual appearance, gel strengths 
and adhesion of the developed jellies were compared with commercial products. A 
variation of gel strengths was observed for the commercial jellies (Table 4-6) ranging 
from 13g to 30g and adhesion ranging from 3g to 6g. 
 
Table 4-6: Gel strength and adhesiveness of commercial jellies. 
Commercial ready-made jelly Gel strength (g) Adhesion (g) 
Hartley’s  jelly 13.36±1.5 2.8±0.6 
Vimto jelly 27.78±1.09 6.071±0.28 
Gelatine  peppa pig jelly 29.34±0.28 4.079±0.18 
 
An increase in citric acid concentration increased gel strength of the resultant jellies 
until 4% w/v citric acid was utilised (Table 4-7). A decline in gel strength was observed 
with further increase in citric acid concentration. Additionally increasing citric acid 
concentration to above 2% w/v increased hydration time; therefore sample number 2 
was selected to further evaluate the effect of changing dicalcium phosphate dihydrate 
concentration on jelly formation. An increase in dicalcium phosphate dihydrate 
concentration also resulted in an increase in gel strength; furthermore, a concentration 
lower than 0.4% w/v did not result in the formation of jelly and a concentration of 1% 
w/v resulted in a rigid gel not fulfilling jelly criteria (Table 4-7). In comparison sample 
10 showed quicker hydration time and higher gel strength than sample 2 and thus 
taken for further evaluation. An increase in sodium alginate concentration from 0.5% 
w/v to 1% w/v  increased gel strength but again the resultant jelly was rigid. An 
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increase in hydration time was observed for all incremental increase in the 
concentration of the ingredients and due to an increase in hydration time above 10 
minutes, no further concentration increase was investigated after sample 12. No clear 
pattern was observed for adhesiveness with changes in the concentration of the 
ingredients; however, the adhesiveness of the alginate jellies were generally lower 
than commercial jellies. Table 4-7 shows a green highlight for the promising jelly 
sample selected by taking into consideration texture analysis results, residual water 
and final jelly formation time (relevant columns highlighted). 
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Table 4-7: Development of sodium alginate and dicalcium phosphate dihydrate jellies (triplicate samples). 
 
Sample 
number 
 
Sodium 
alginate 
(% w/v) 
 
Dicalcium 
phosphate 
dihydrate 
(% w/v) 
 
Citric 
acid 
(% 
w/v) 
 
Time 
taken to 
hydrate 
(min) 
magnetic 
stirrer 
method 
 
Final jelly 
formation 
time  
after 
setting  
(5 min) 
 
Visual assessment 
 
Texture analysis 
Gel strength 
 
Whether or 
not free-
standing 
jelly formed  
 
Other information  
 
Residual 
water 
(mL) 
 
Gel 
strength 
(g) 
 
Adhesiveness 
(g) 
 
1 
 
0.5 
 
0.5 
 
1 
 
8 
 
13 
 
x 
 
Does not retain shape 
 
4 
 
2.8±0.8 
 
0.3±0.05 
 
2 
 
0.5 
 
0.5 
 
2 
 
7 
 
12 
 
Ö 
 
Slight quiver 
 
7 
 
10.6±0.3 
 
1.03±0.2 
 
3 
 
0.5 
 
0.5 
 
3 
 
11 
 
16 
 
Ö 
 
Very slight quiver 
 
6 
 
14.3±0.6 
 
1.3± 0.3 
 
4 
 
0.5 
 
0.5 
 
4 
 
14 
 
19 
 
Ö 
 
Very slight quiver 
 
8 
 
12.7±2.3 
 
1.8±0.05 
 
5 
 
0.5 
 
0.5 
 
5 
 
12 
 
17 
 
Ö 
 
Very slight quiver 
 
8 
 
3.2±0.6 
 
0.4±0.04 
 
6 
 
0.5 
 
0.5 
 
10 
 
13 
 
18 
 
x 
 
Doesn’t retain shape 
 
8 
 
0.2±0.06 
 
0.9±0.3 
 
7 
 
0.5 
 
0.1 
 
2 
 
4 
 
9 
 
x 
 
Doesn’t retain shape 
 
8 
 
0.2±0.1 
 
0.7±0.2 
 
8 
 
0.5 
 
0.2 
 
2 
 
5 
 
10 
 
x 
 
Doesn’t retain shape 
 
8 
 
1.9±0.5 
 
1.02±0.0.4 
 
9 
 
0.5 
 
0.3 
 
2 
 
5 
 
10 
 
x 
 
Doesn’t retain shape 
 
9 
 
3.7±0.6 
 
0.6±0.07 
 
10 
 
0.5 
 
0.4 
 
2 
 
6 
 
11 
 
Ö 
 
Quivers 
 
6 
 
12.3±1.5 
 
 
0.9 ±0.2 
 
 
11 
 
0.5 
 
1 
 
1 
 
6 
 
11 
 
x 
 
no quiver 
 
5 
 
12.3±1.5 
 
0.9±0.2 
 
12 
 
1 
 
0.5 
 
1 
 
14 
 
19 
 
Ö 
 
Firm, very slight quiver 
 
4 
 
55.2±3.8 
 
0.77±0.18 
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Sample 10 showed the quickest hydration time out of samples that met the visual 
assessment criteria, and showed gel strength and adhesiveness similar to Hartley’s 
jelly. Hydration time for this jelly sample 10 (Table 4-7, Figure 4-10a) was thus tested 
using shaking the beaker method gave an overall jelly preparation time of 6 minutes 
(hydration time 1 minute, jelly formation 6 minutes), stirring using a glass rod resulted 
in 2 minutes hydration time 7 minutes for jelly formation. 
 
The effect of variation of the volume and hardness of water on jelly formation is shown 
in Tables 4-8 and 4-9. A reduction in water volume from 20 mL to 15 mL increased the 
gel strength of the jelly and time taken to form the jelly. An increase in the volume of 
water to 25 mL resulted in a weak gel that did not retain its shape, with low firmness. 
Soft (bottled water) and hard (tap) water increased the time to form the jelly and gel 
strength compared to deionised water. 
 
Table 4-8: The effect of variation in water volume for the jelly formation (sample 10). 
Volume of 
water 
Jelly formation time  
after setting (5 min) 
Jelly formed Gel strength (g) Adhesion (g) 
15ml 17 Ö 20.7±2.9 0.99±0.83 
25ml 9 x 1.9±1.3 0.39±0.105 
 
Table 4-9: The effect of water hardness on the jelly formation. 
Water hardness Jelly formation time  
after setting (5 min) 
Jelly formed Gel strength (g) Adhesion (g) 
Soft 15 Ö 12.3±1.5 0.9±0.2 
Very hard 18 Ö 14.3±0.6 1.3± 0.3 
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All variations of sample 10 using different volumes and hardness of water showed G’ 
dominance over G” (Figure 4-5). Both G’ and G” reduced with using 25ml of deionised 
water (Figure 4-5b) indicating lesser elastic properties for a greater volume of 
deionised water. The magnitude of G’ increased at low frequency for sample 10 jelly 
developed using less volume (15mL) of deionised water (Figure 4-5c). Both G’ and G” 
increased for soft and hard water prepared jellies (Figure 4-5d and e).  
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Figure 4-5: G’ and G” represented as a function of frequency for a) Sample 10 
sodium alginate dicalcium phosphate dihydrate b) sample 10 formed in 25ml of 
deionised water, c) sample 10 formed in 15ml of deionised water, d)sample 10 
formed using soft water, e) sample 10 formed using hard water.  
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Additional materials that showed hydration times under 10 minutes for free-standing 
jelly development were guar gum, polyethylene oxide, HPMC and low-acyl gellan gum 
(Table 4-10, Figure 4-16). Egg protein, LM pectin, carrageenan kappa resulted in 
substantial preparation time. Low-acyl gellan gum combination was quick to prepare 
but resulted in a lot of residual water (Table 4-10, Figure 4-6). 
 
Gel strength was comparable to sodium alginate-dicalcium phosphate dihydrate jelly 
(sample 10)  after the addition of guar gum, polyethylene oxide and kappa 
carrageenan (Table 4-11). Polyethylene oxide jellies showed considerably lower gel 
strength or firmness than the sodium alginate-calcium phosphate jelly (sample 10).  
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Table 4-10: Development of sodium alginate and dicalcium phosphate dihydrate jellies with the additional polymer at 50:50 ratio. 
 
Sample 
number 
 
Additional 
polymer 
 
Time taken to hydrate 
(min) 
Shaking beaker 
method 
 
Jelly formation time  
after setting (5 min) 
 
Visual assessment 
 
Jelly formed 
 
Other information 
 
Residual water (mL) 
 
13 
 
Egg protein 
 
>15 
 
NA 
 
x 
 
clumps 
 
NA 
 
14 
 
LM pectin 
 
>15 
 
NA 
 
x 
 
clumps 
 
NA 
 
15 
 
Guar gum 
 
1 
 
6 
 
Ö 
 
Wobbly, pale yellow 
 
3 
 
16 
 
Maize starch 
 
>15 
 
NA 
 
x 
 
clumps 
 
NA 
 
17 
 
HPMC 
 
4 
 
9 
 
Ö 
 
Wobbly, transparent 
 
7 
 
18 
 
Polyethylene 
oxide 
 
3 
 
8 
 
Ö 
 
Wobbly, transparent 
 
7 
 
19 
 
Carrageenan 
(kappa) 
 
>15 
 
NA 
 
x 
 
clumps 
 
NA 
 
20 
 
Low-acyl 
gellan gum 
 
50 secs 
 
5 minutes 50 seconds 
 
Ö 
 
Wobbly, transparent 
 
9 
 
21 
 
High-acyl  
gellan gum 
 
>15 
 
NA 
 
x 
 
clumps 
 
NA 
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Table 4-11: Gel strength and adhesiveness of free-standing jellies. 
Sample number              Additional polymer  
Gel strength (g) 
 
Adhesiveness (g) 
15 Guar gum 11.1±0.4 1.9± 0.9 
17  HPMC 16.1±0.3 1.3±0.3 
18 Polyethylene oxide 0.8±0.3 0.3±0.1 
20  Low-acyl gellan gum 13.1±0.5 0.4±0.0.05 
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Figure 4-6: a) Sodium alginate jelly, (sample 10) b) Sodium alginate and guar gum 
jelly (sample 15, F1) c) Sodium alginate and HPMC jelly (sample 17) 50:50 ratio d) 
Sodium alginate, polyethylene oxide jelly, 50:50 ratio (sample 18), and sodium 
alginate, low-acyl gellan gum jelly, 50:50 ratio (sample 20).  
 
 156 
A comparison of the frequency dependence of G’ and G” of sodium alginate- guar gum 
jelly (F1, sample 15, Figure 4-7c) to commercial products (Hartley’s and Vimto jellies, 
Figures 4-7a and b shows a greater magnitude of G’ and G” for sodium alginate-guar 
gum jelly and a lower magnitude of G’ and G” to sample 10 (sample without guar gum, 
Figure 4-5a). The finding indicates greater structural strength compared to commercial 
products.  
 
 
Figure 4-7: Frequency dependence of G’ and G” for a) Hartley’s, b) Vimto jellies and 
c) F1 (sample 15). 
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4.3.4 Granular jelly formation 
Sodium alginate, dicalcium phosphate dihydrate and citric acid were not appropriate 
for the granular jelly formation as a free-standing jelly begins to form over a short 
period of time. Sodium alginate and calcium chloride combination formed granular 
jellies at low concentrations. Low concentrations of sodium alginate (0.1-2.5w/v)and 
calcium chloride (0.1-0.3 %w/v) were trialled to form a granular jelly and the majority 
formed a thickened fluid.  Granular jelly was formed using sodium alginate 2% w/v and 
calcium chloride 0.3% w/v (F2, Figure 4-13) and further increase in concentration of 
sodium alginate resulted in little flow. Back extrusion results for F2 showed 
considerable increase in firmness (238.7±22.2g) compared to Ryukakusan jelly for 
adults (32.7g ± 0.2g), low cohesiveness of 5.29±0.09g compared to the Ryukakusan 
jelly (14.89 ± 0.03g) and slightly greater surface adhesiveness 13.73±1.2g compared 
to the commercial product (8.24 ± 0.3).   
 
Adding some of the additional polymer to F2 kept the jelly appearance meeting the 
visual criteria for granular jellies, including polyethylene oxide, HPMC, carrageenan 
kappa and low acyl gellan gum (Table 4-12). Time taken to hydrate and visual 
assessment (columns highlighted in Table 4-12) were used to select jellies that met 
the criteria (highlighted rows in green in Table 4-12). Low acyl gellan gum was the 
additional polymer that had the quickest jelly formation (F3). All materials that were 
successful as additional polymers for forming granular jelly were added using Method 
A by mixing the additional polymer with sodium alginate and dissolving together. Table 
4-13 shows the results of texture analysis of granular jelly formed with additional 
polymers which were more comparable in firmness to Ryukakusan jelly for adults with 
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sample 55 (F3) (highlighted green) showing the closest resemblance in firmness, 
cohesiveness and adhesiveness. 
 159 
 
Table 4-12: Sodium alginate-calcium chloride jelly development with other polymers. 
Sample 
number 
Additional material Method of adding 
additional material 
Time taken to 
hydrate 
Visual assessment 
Ryukakusan 
jelly 
Reasons 
Ratio 75 sodium alginate: 25 other material 
43 Egg protein 
 
A 14 x Thickened fluid stage 1, granular 
gels not formed 
44 B 8 x Thickened fluid stage 1, granular 
gels not formed 
45 LM pectin A 14 x Thickened fluid stage 1, granular 
gels not formed 
46 Guar gum 
 
A 5 x Very watery, and no granular 
gels, sludge-like  
47 B 4 x Mostly water 
48 Maize starch A >15 x Mostly water 
49 B 5 x Thickened fluid 
50 Polyethylene oxide A 8 Ö Large granular gels 
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51  B 6 x Sludge like 
52 HPMC A 8 Ö Large granular jellies 
53  B 7 x Sludge like 
54 Carrageenan (kappa) A 14 Ö Large granular jellies 
55 Low-acyl gellan gum A 6 Ö Large granular jellies 
Ratio 50 sodium alginate: 50 to other material 
56 Polyethylene oxide A 12 x Fluid, granular gels not formed 
57 HPMC  A 13 x Fluid, granular gels not formed 
58a Low-acyl gellan gum with 0.075% 
calcium chloride 
A 9 x Sludge like with few granular 
jellies. 
58b Low-acyl gellan gum with 0.15% 
calcium chloride 
A 9 Ö Granular jelly formed 
59 Kappa carrageenan A 13 Ö Granular jelly formed 
Ratio 25 sodium alginate: 75 other material 
60 Polyethylene oxide A >20 x Clumps 
61 HPMC  A >20 x Clumps 
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62 Low-acyl gellan gum A 11 x Sludge like but few granular 
jellies formed 
63 Kappa carrageenan A >20 x Clumps 
 
 
Table 4-13: Textural characteristics (back-extrusion tests) after addition of polymers (method A) for granular jelly. 
Sample 
number 
Additional polymers Firmness Cohesiveness Adhesiveness 
 Ratio 75 sodium alginate: :25 other material 
50 Polyethylene oxide 27.5±3.5 6.4±0.4 6.1±0.1 
52 HPMC 30.6±4.1 5.9±0.1 6.05±0.6 
55 Low-acyl gellan gum 28.4±1.4 16.05±0.3 10.5±0.69 
 Ratio 50 sodium alginate: :50 other material 
58b Low-acyl gellan gum 28.9±1.4 14.2±2.7 6.7±0.1 
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Figure 4-8: a) Sodium alginate 2% calcium chloride 0.3% w/v (sample 41, F2). b) 
Sodium alginate 75 parts: polyethylene oxide 25 parts granular jelly (sample 50) c) 
Sodium alginate 75 parts: HPMC 25 parts granular jelly (sample 52) d) Sodium 
alginate 75 parts: Low-acyl gellan gum 25 parts granular jelly (sample 55, F3) e) 
Sodium alginate 50 parts: Low-acyl gellan gum 50 parts granular jelly (sample 58b).
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The frequency dependency of moduli for sample 41 (F2, sodium alginate and calcium 
chloride) and 58 (F3, sodium alginate, low acyl gellan gum (50:50 ratio) and calcium 
chloride) is shown in Figure 4-9. A frequency dependence profile for sodium alginate 
and calcium chloride showed a greater magnitude of G’ and the difference with G”, 
indicating a stronger network (Figure 4-9b) compared to Ryukakusan jelly for adults 
(Figure 4-9a). Sodium alginate-low acyl granular gel showed G’ dominance over G”. 
The profile is similar to Ryukasun’s jelly for adults frequency spectre (Figure 4-9c). 
 
 
Figure 4-9: Frequency dependence of G’ and G” for a) Rukakusan jelly for adults, b) 
sodium alginate and calcium chloride granular jelly (F2, sample number 41) and c) 
sodium alginate-low acyl gellan gum granular jelly (ratio 50:50) (F3, sample number 
58).  
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The response to the steady state rate test of promising jellies (F1-3; sample numbers 
15, 41, 58) is shown in Figure 4-10. All the jellies showed shear-thinning rheology. A 
much greater apparent viscosity for all shear rates was observed for sodium alginate 
granular jelly (F2, sample number 41). 
 
 
Figure 4-10: Apparent viscosity as a function of shear rate for promising jellies (F1, 2 
and 3). 
4.3.5 In vitro processing of “instant” jellies 
Figure 4-11 shows the transit of F1, 2 and 3 in the in vitro ‘CT’ model. All three jellies 
showed fast transit (Figure 4-12a) comparable to stage 2 thickened fluids and 
cohesive bolus movement comparable to stage 3 and 2 thickened fluids (Figure 4-
12b).  
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Figure 4-11: : Transit of participants bolus jellies in the Cambridge Throat towards 
the epiglottis (T1) and airway divide (T2) for a) F1; sodium alginate- guar gum free 
standing jelly, (manually chopped) b) F2; sodium alginate granular jelly, c) F3; 
sodium alginate-low-acyl gellan gum granular jelly. 
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Figure 4-12: The OTT (a) and BL (b) at airway divide for jellies. The coloured boxes 
represent the confidence interval range for the thickener Nutilis Powder at stages 1, 
2, and 3 for comparison.  
4.4 Discussion 
The purpose of this study was to develop jelly formulations that take less than 10 
minutes to form without requiring heat in order to present a sachet product that patients 
can add to water and form a jelly for medication administration. The time of less than 
10 minutes was chosen for patient convenience, a jelly that requires a lot of 
preparation time may not be accepted by the patient. A number of materials have met 
this hydration criteria including  carrageenans (kappa), guar gum, gellan gum, sodium 
alginate, maize starch, egg protein, LM pectin, which all have good water-binding 
properties. Water binding occurs by hydrogen bonding with hydroxyl groups on guar 
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gum and sodium alginate,  charged carboxyl groups and hydroxyl groups on low 
methoxy pectin, negatively charged sulphate groups and hydrogen bonding with 
kappa carrageenan (Fisher, 2009; Tripathy & Das, 2013; Vaclavik & Christian, 2008; 
Venugopal, 2011). Hydrogen bonding occurred between water and charged amino 
acid groups on egg protein(Zayas, 1997).  Longer hydration times were expected for 
other materials such as locust bean gum, gum ghatti, gum tragacanth and agar which 
are known to be partially soluble or not soluble in cold or room temperature water 
(Dakia, Blecker, Robert, Wathelet, & Paquot, 2008; López-Franco, Higuera-Ciapara, 
Goycoolea, & Wang, 2009). Differences in hydration times were observed for LM and 
HM pectins as expected, due to the carboxylic acid and hydroxyl groups on the LM 
pectin allowing hydrogen bonding with water molecules.  
 
Generally, in rank order for carrageenans, lamda>iota>kappa are expected to dissolve 
in room temperature deionised water from quickest to slowest. Lamda carrageenan is 
highly sulphated, consists of hydroxyl group and is void of hydrophobic 3,6 anhydro- 
D- galactose subunits (ADG). Kappa carrageenan contains the ADG subunits as a 
repeating unit and has fewer sulphate groups. Iota carrageenan is expected to be 
intermediate and more hydrophilic than the kappa carrageenan due to the presence 
of 2-sulphate which also counteracts the ADG group. However, the kappa 
carrageenan showed quicker hydration in this study as the product was presented as 
a sodium salt form of the sulphated group increasing is water solubility (CP Kelco, 
2001).  
 
Most of the materials formed thickened fluids which occurs due to entanglement of 
polymer chains (Saha & Bhattacharya, 2010). Sodium alginate showed potential to 
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form jellies as reported previously (Hong et al., 2012; Masumoto et al., 2016; Yasushi 
et al., 2016). Low-acyl gellan gum also showed potential for jellies using the same 
method but showed greater residual water possibly due to greater binding with calcium 
and stronger gel contractions resulting in syneresis. Syneresis of water is when the 
unbound water is expelled from the gel matrix (Banerjee & Bhattacharya, 2011). 
Gellan gum has reported to form brittle texture and therefore is commonly blended 
with other polymers to form softer, elastric textures, brittle gels are reported to be 
susceptible to syneresis compared to elastic gels (Mao, Tang, & Swanson, 2000; Valli 
& Clark, 2009). Two different methods of introducing calcium crosslinking ions were 
used to prepare free-standing jellies and granular jelly. Calcium chloride is commonly 
used for sodium alginate gelation, however, calcium chloride is highly water soluble in 
cold water (40% w/v) compared to dicalcium phosphate dihydrate (0.02% w/v) which 
results in an instantaneous reaction between alginate and calcium (Draget, 2009; 
Helgerud, Gåserød, Fjæreide, Andersen, & Larsen, 2009; Lee & Mooney, 2012).  
Calcium chloride was used for the free standing jelly but the rapid interaction can result 
in the inhomogeneous distribution of calcium due to a sharp gelling zone forming at 
the surface and decrease towards the center of the gel (Helgerud et al., 2009). This 
resulted in a rubbery and string-like texture inside the jelly and didn’t retain angles 
once cut with the spatula. Since dicalcium phosphate dihydrate is less soluble in cold 
water than calcium chloride, the low solubility allows  the dicalcium phosphate 
dihydrate and sodium alginate to be mixed and added together to the deionised water 
for in situ gelation (Helgerud et al., 2009). Controlled release of calcium ions was 
achieved by a change of pH using citric acid for the free-standing jelly. The citric acid 
in the formulation helps to dissolve the calcium phosphate which is less soluble in 
neutral pH, thereby increasing the presence of calcium ions  (Draget, 2009).   
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The firmness of supermarket jellies was tested to compare with the free-standing jelly 
formulation to maintain similarity of the ease of chewing. An increase in firmness was 
observed with increasing calcium concentration or citric acid concentration. An 
increase in calcium or sodium alginate concentration is expected to increase the 
firmness of the sample as a result in increased binding between G units of sodium 
alginate and calcium ions (Lee & Mooney, 2012). Sodium alginate and calcium gels 
are known to retain water through hydrogen bonds, and during gel contraction, release 
water known as syneresis (Draget, 2009). Greater residual water was observed with 
increasing citric acid (which would increase calcium content) or calcium content.  
 
The volume of water for jelly preparation was altered considering potential instances 
whereby patients and health care professionals may accidentally use a different 
volume than advised. As expected, an increase in volume resulted in softer jellies as 
a result of the lower concentration of gelling agent and calcium, and a reduction in 
volume increased firmness of the jellies. An increase in water hardness increased the 
firmness of the jellies and the time for jelly formation. Water hardness is normally 
expressed in terms of the concentrations of calcium and magnesium ions in water as 
equivalent to calcium carbonate (Rubenowitz-Lundin & Hiscock, 2005). An increase 
in these ions which contribute to gel formation of alginates is expected to increase the 
firmness of the gels. This was further reinforced with the frequency spectra. A greater 
magnitude of G’ and dominance over G” was observed throughout the frequency 
range showing an increase in the concentration of calcium ions resulted in a stronger 
gel network. The presence of these ions also delays the hydration time of alginate as 
clumps started to form. The effect of water volume and hardness indicates the need 
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for the correct volume and type of water to be used in jelly formation. It would be 
recommended that the correct volume of deionised water is supplied with the sachet 
containing dry materials of the jelly which would increase the cost of the dosage form, 
however, it is expected that a safe-to-swallow sustained release dosage form would 
have long-term cost benefits by reducing pill burden, facilitating compliance with 
dosage form administration, reduced missed doses, reducing subtherapeutic dosing 
and better therapeutic management. 
 
Additional polymers were added to improve time for the jelly formation and reduce 
residual water. Guar gum improved the time for jelly formation and reduced residual 
water. The use of multiple gelling agents is believed to reduce syneresis (Banerjee & 
Bhattacharya, 2011). Guar gum is known to increase the viscosity of solutions at low 
concentrations, due to intermolecular chain interaction or entanglement which 
enhances viscosity (Mudgil, Barak, & Khatkar, 2014). Guar gum is used for controlling 
water migration in bakery products due to its water binding properties (Ward, Hanway, 
& Ward, 2005). However, more residual water was observed with using HPMC and 
polyethylene oxide in the jelly composition. The reasoning for more residual water with 
HPMC and polyethylene oxide may be due to the lower water binding of HPMC and 
polyethylene oxide. HPMC has ether groups preventing intermolecular association 
with water (BeMiller, 2019). The ethylene oxide units in polyethylene oxide prevent 
intermolecular association with water (Graham, 1992). Low-acyl gellan gum also 
showed larger residual water; this may be a result of an excess of calcium in the jelly 
and the interaction between calcium and low-acyl gum potentially resulting in gel 
contraction and extruding liquid out of the jelly.  
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A different method approach was used for forming the granular jelly. The sodium 
alginate- dicalcium phosphate dihydrate method results in a non-flowing, free-standing 
jelly formed over a short time and was not appropriate for granular jelly. Sodium 
alginate and calcium chloride at low concentrations formed a granular jelly. The 
sodium alginate-calcium chloride trials for very low concentrations of both component 
only resulted in a thickened fluid with none, or a low number of granular gels. 
Increasing the concentrations provided granular jelly, but increasing it further, resulted 
in a jelly with little flow. Sodium alginate-calcium chloride showed a much larger 
firmness compared to Ryukakusan’s granular jelly. This combination met the visual 
criteria for granular jelly; however, the greater firmness of the granular jelly compared 
to the commercial product, Ryukakusan jelly. However, the “instant” granular jelly was 
less firm than Thick and Easy stage 3 (Chapter 3). Chapter 3 showed that firmness 
did not influence the safety of swallowing features that were observed in the in vitro 
throat model for jelly. Further development of this granular jelly with other polymers 
showed much lower firmness which may be due to the lower amount of sodium 
alginate and calcium chloride used and loosening of the structure of sodium alginate-
calcium chloride formed jelly. The presence of other polymers may be entangled with 
the sodium alginate and restricting cross-linkage with calcium ions. 
 
Frequency spectre showed a greater magnitude of G’ and G”  sodium alginate-calcium 
chloride granular jelly (F2) compared to Ryukakusan’s granular jelly, reinforcing the 
greater firmness observed using the texture analyser due to greater proportions of the 
polymer and calcium ions. The greater magnitude of G’ and G” for the  F3 compared 
to the Ryukakusan ‘s granular jelly yet similar firmness to commercial products show 
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potential for in vivo studies in retaining cohesive bolus during peristaltic contractions 
in the pharynx.   
 
There were clear differences in hydration time between mixing methods using a 
magnetic stirrer at a low speed, shaking by hand and mixing with a rod. Mixing with a 
magnetic stirrer provided agitation at the bottom of the beaker, and thus results of jelly 
formation were much slower. The speed was kept very slow to simulate the potential 
difficulties in hand movement older patients may have. Shaking of the beaker by hand 
and glass rod provided quicker jelly formation time potentially due to greater agitation 
and that the agitation was throughout the fluid which helps homogenous hydration of 
the polymer. 
 
The three jellies (F1, 2 and 3) that met the visual criteria for free-standing jellies and 
granular jellies and were the quickest to prepare were selected for In vitro testing using 
the CT model. Although gels and jellies are used interchangeably, the visual criteria 
were used to mimic commercial jelly products in terms of overall appearance. The 
reason for this consideration is that patients whom are already familiar with jellies from 
the supermarket and enjoy these products as dessert are likely to accept the jellies as 
dosage forms. Thickened fluids which are safer to swallow than thin water are not well 
accepted (Garcia, Chambers, et al., 2005; J. Murray et al., 2014; Shim et al., 2013), 
Japan includes jelly in the dysphagia diet and have jellies as swallowing aids to help 
swallow tablets and capsules intact without needing water for swallowing (International 
Dysphagia Diet Standardisation Initiative, 2016a; National Rehabilitation Center for 
Persons with Disabilities Japan, 2015; Tsuji et al., 2006). Japan also has a marketed 
oral immediate release jelly dosage form for Donepezil for Alzeimer’s disease (Aricept 
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oral jelly) to help patients with swallowing difficulties (Elsai, 2009). Although the focus 
of this thesis is developing an instant jelly dosage form for older adults, jellies may be 
beneficial for the younger cohort and for patients with a psychological aversion to 
swallowing SODF. Previous incidences of children choking with jelly were associated 
to aspiration related to konjac-based jellies which are known to swell (Seidel & 
Gausche-Hill, 2013). However, Kluk & Sznitowska (2014) observed 83% of children 
(2-3 years) were able to swallow five or ten 2-3mm minitablets with jelly on a spoon, 
although only 57% of children were capable of swallowing without prior chewing.  
 
The jellies selected for in vitro testing showed similar safety features of slow transit 
and coherent bolus movement as observed for commercial jellies in Chapter 3. 
Although this drug delivery vehicle was developed for older adults, jellies are also 
useful as swallowing aids for children (Kluk & Sznitowska, 2014).  
 
The free-standing jelly and granular jelly are prepared differently, and there is an 
influence of water volume and hardness. These considerations affect the design and 
selection of the final jelly product presentation, the deionised water needs to be 
provided and the polymer powder needs to be provided and then prepared by the 
patient or administrator of the dosage form. The free-standing jelly requires the 
addition of powders from two sachets, one sachet for the polymers and one sachet for 
the citric acid, in addition to providing  the deionised water. The granular jelly would 
requires deionised water to be provided, and one sachet of powder for polymer and 
calcium chloride solution. The granular jelly would be more challenging to prepare and 
likely to be bulky. The preparation of these jellies and ease of preparation may be 
facilitated with bespoke packaging design. 
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There has been an increase in development of novel administration designs for 
paediatrics (Lopez et al., 2015; Walsh, Bickmann, Breitkreutz, & Chariot-Goulet, 
2011). For example, dose sipping technology (XStrawTM) is a ready-to-use pre-dosed 
straw containing granulated dosage form (Raumedic, n.d.; Walsh et al., 2011). The 
straw containing a filter (controller) is placed in a drink, and the end-cap is taken off 
and the drink with the full dose is swallowed through the straw. The product is for thin 
fluids and therefore not useful for the jelly formulations developed in this study. 
Packaging containers for jellies in Japan include a single serve type, which is a 
container with a jelly, a stick type which involves squeezing the jelly from the 
packaging container and an air-extruded type packaging which comprises of a jelly 
and air portion which allows smooth discharge of the jelly (Imai, 2013). A bespoke 
packaging design may reduce having different containers and packages and may 
facilitate preparation of the jellies with ease. A potential package for F1, for example, 
having a small central container attached with a small tube of sodium alginate and 
guar gum and another separate small tube with citric acid on one side of the container. 
The central container can be rotated and the relevant tube can be pressed to dispense 
the powder into the central container. The central container can be shaken to mix the 
powder contents with deionised water. The top of the container can then be opened 
using a peel or lid and the jelly can be pushed out on the patients hand or the jelly can 
be consumed using a spoon. For F2, using the same principle, the centralised 
container can include the polymer in one tube and a calcium chloride solution in the 
other tube and pressure can be applied on the tubes to release the relevant powders 
in order to prepare the jelly.  
 
 175 
4.5 Conclusions 
Two forms of jelly were developed, a free-standing jelly and two granular jellies using 
sodium alginate. The sodium alginate jellies developed in this study form relatively 
quickly without the requirement of heat and showed promise as swallowing aids for 
patients with dysphagia in the in vitro throat model. The jellies showed slow oral transit 
times and cohesive bolus movement in the pharynx, the safety features that were 
observed for stage 3 thickened fluids in Chapter 3. The developed jellies (F1 anf F2) 
also showed reduced variability in the In vitro model compared to the commercial jelly 
products but this would need further investigation and validation using in vivo studies. 
The jellies would, however, require a supply the correct volume of deionised water to 
ensure that the desired consistency is formed and would require a bespoke packaging 
design to ease preparation of jellies for  patients.  
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Chapter 5   
SUSTAINED RELEASE COATING OF 
MICROPARTICLES AND THE EFFECTS OF 
INTEGRATING INTO “INSTANT” JELLIES ON IN 
VITRO DISSOLUTION 
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5.1 Introduction 
Solid oral dosage forms (SODF), particularly conventional immediate release dosage 
forms are popularly prescribed, however as described in Chapter 1, these dosage 
forms have limitations compared to sustained release dosage forms. Sustained 
release dosage forms exist predominantly as tablets and capsules and can be 
challenging to swallow by patients with swallowing difficulties. Novel approaches such 
as multiparticulate dosage forms which involve splitting the full dose into subunits were 
first introduced in the 1950’s as pellet-filled capsules (Spansules) (Tiwari et al., 2011). 
Multiparticulates obviate the challenges associated with swallowing SODF (e.g. 
tablets) and are also less likely to be chewed compared to mini-tablets due to its size 
and are therefore more suitable for patients with dysphagia. However, taking 
multiparticulates alone without a delivery vehicle can be challenging to these patients. 
For example, patients with dysphagia may not be able to swallow thin fluids to help 
administer the pellets or granules and thickened fluids for administration of 
multiparticulates may not be acceptable to patients therefore more palatable and safe-
to-swallow delivery vehicles are needed.  
 
5.1.1 Sustained release multiparticulates 
Multiparticulates disperse easily into the gastrointestinal (GI) tract as a result of the 
small sizes, and display reduced intra- and inter-subject variability compared to single 
unit dosage forms and less likelihood of dose dumping due to the spread of the units 
in the GI tract (Rajabi-Siahboomi, 2017). Active pharmaceutical ingredients (API) can 
be included within a granule using processes such as extrusion spheronisation. The 
API can also be layered onto an inert core. The inert core for extended release is 
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typically sugar spheres or microcrystalline cellulose (Sidwell, Hansell, Rane, & Rajabi-
Siahboomi, 2017). Sugar cores or pellets which contain 62.5-91.5% dried sucrose are 
widely available but have limitations. Sucrose has high osmolality, and any presence 
of residual moisture after the manufacturing process can result in drug dissolution in 
the residue water during storage  as a result of osmotic pressure (Kállai et al., 2010; 
Sidwell et al., 2017). In addition, sucrose may be unsuitable for patients with sugar 
restrictions (Kállai et al., 2010). Microcrystalline cellulose is insoluble in water and thus 
advantageous as the inert core for sustained drug release (Kállai et al., 2010).  
Microcrystalline cellulose although widely used does have disadvantages such as 
drug adsorption on its surface which can affect bioavailability of drugs (Al-Nimry, 
Assaf, Jalal, & Najib, 1997; Okada, Nakahara, & Isaka, 2011). 
 
5.1.2 Sustained release coating of multiparticulates 
Film coating consists of a dry, outer material (thin membrane) on the surface of the 
dosage form to achieve specific benefits; for sustained release, it is to allow the drug 
to release slowly from the dosage form for an extended period (Skalsky & Stegemann, 
2011). Film formers normally comprising of polymers are important components in the 
coating (Skalsky & Stegemann, 2011). The coating can be applied in aqueous 
dispersions or polymer solutions using organic solvents. Water or aqueous 
dispersions are more popular due to environmental and toxicity concerns regarding 
the use of organic solvents (Lecomte, Siepmann, Walther, MacRae, & Bodmeier, 
2004; Ozturk et al., 1990). Coating with aqueous solutions involves the process of 
continued solvent evaporation, droplets of coating solution are allowed to build up on 
the substrate and continued solvent evaporation results in immobilization of polymers 
due to continued solvent loss (Lecomte et al., 2004;  Porter, Sackett, & Liu, 2017).  
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The coating process for polymer dispersions involves the atomization of the coating 
solution or dispersion into small droplets using spray atomization. The polymer 
particles pack closely onto the surface of the inert core or substrate and move closer  
during water evaporation during drying due to the cohesive forces between the 
polymers which coalesce to form a homogeneous film (Eckersley & Rudin, 1994; 
Lecomte et al., 2004). The minimum film forming temperature is the temperature 
above which a homogeneous film is formed, and the product temperature is normally 
kept 10°C above the minimum film forming temperature during coating (Eckersley & 
Rudin, 1994; Skalsky & Stegemann, 2011). Curing after the coating process is also 
applied to promote coalescence of the film (Felton, 2013). 
 
Polymers used in coatings are classified according to their origin as natural, synthetic 
and semi-synthetic. Natural polymers, for example, include alginate and pectin 
(Abletshauser, Schneider, & Rupprecht, 1993; Semdé, Amighi, Devleeschouwer, & 
Moës, 2000). Methacrylic acid and co-polymers are example of synthetic polymers 
(Savage & Rhodes, 1995) and semi-synthetic polymers include ethylcellulose (S. C. 
Porter, 1989), hydroxypropyl methylcellulose (HPMC) (Wan & Lai, 1991), cellulose 
acetate (Shivanand & Sprockel, 1998).   
 
Multiparticulate sustained release dosage forms are usually designed as a reservoir 
drug delivery system. A reservoir drug delivery system consists of a polymer coating,  
around the core containing the API and water-insoluble polymers such as 
ethylcellulose or acrylate are typically used for the coating (Liu et al., 2011).  Water-
soluble components such as lactose or sucrose, or HPMC  are also used as pore 
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formers to facilitate drug release (Liu et al., 2011). Drug release from a reservoir 
system typically occurs via diffusion  and the coating thickness can alter the drug 
release, for example a thicker coating would result in a slow drug release due to an 
increase in diffusion path length (Munday & Fassihi, 1989; Ozturk et al., 1990).   
 
Apart from film-forming polymers, other common components of coating include a 
plasticizer, an anti-tacking agent, pore formers to provide aqueous channels for drug 
release (Porter et al., 2017).  Plasticizers are used to lower the minimum film forming 
temperature by weakening the intermolecular attractions between the polymer chains, 
increasing flexibility (Felton, 2013). Common plasticizer examples are citrate esters 
such as triethyl citrate, glycol derivatives such as propylene glycol and even water 
(Okarter & Singla, 2000). Anti-tacking agents are used to preventing agglomeration of 
the pellets during the coating process (Wan & Lai, 1993); typical examples include talc 
and magnesium stearate (Wan & Lai, 1993). 
 
Water soluble additives or pore formers may be added to increase the rate of drug 
release from the sustained release coating. Typical water-soluble low-molecular 
additives include sucrose, lactose, calcium phosphate, sodium chloride which leach 
out from the coating layer into the aqueous media forming pores during dissolution. 
High molecular weight pore formers include polyvidone, HPMC which hydrates in 
aqueous media forming channels for drug release (Tang, Chan, & Heng, 2005).  
 
5.1.2.1 Fluidised bed coating 
Fluidised bed processing has been around since the late 1960s and the technology is 
widely used for coating multiparticulates (Kuntz, Weisbrod, Chakraborty, & Skalsky, 
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2017). Inert cores used for coating are usually 100 µm and above; particles smaller 
than this size are cohesive and agglomerate during coating, resulting in poor film 
formation (Werner, Jones, Paterson, Archer, & Pearce, 2007b). 
 
Fluidised bed coating can be configured to top spray, bottom spray, and tangential 
spray. The top spray process is mainly used for drying, spray granulating and may 
also be used for core material manufacture by solution or suspension layering (Jones, 
1994). The nature of an open vessel for top spraying results in the non-uniform coating 
and thus  this process is not preferred for film coating (Jones, 1994). Tangential spray 
involves a rotating disc and spraying of liquid concurrently with the flow of the inert 
core, commonly used for dry powder layering (Jones & Rajabi-Siahboomi, 2017).  
 
The bottom spray was introduced in 1959, at the University of Wisconsin by Dr. Dale 
Wurster (Jones & Godek, 2017). Hence the technique is known as the Wurster system. 
The Wurster system is the most popularly used for coating for sustained release due 
to the specially designed air distribution plate and nozzle location (Teng & Qiu, 2010). 
The air distribution plate is specially designed with large holes around the center, small 
holes outside the center (Figure 5-1a). At the center of the air distribution plate is a 
nozzle, and surrounding this is a partition, or the Wurster column (Figure 5-1b). There 
is a gap between the column and the air distribution plate, allowing particles to be 
drawn towards the center of the plate where the nozzle is located and accelerated in 
the gap (Cheng & Turton, 2000). The coating solution or suspension is sprayed 
upward from the nozzle. As the particles move upwards in the spray zone, they are 
decelerated in the chamber outside the Wurster column and the process continues in 
a loop. The process allows more uniform film formation than the top spray process 
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due to the recurring flow of substrates through the spray zone (Jones & Rajabi-
Siahboomi, 2017).  
 
 
Figure 5-1: Image of (a) the air distribution plate and nozzle and (b) image of the 
Wurster column and nozzle.  
 
5.1.2.2 Coating processing variables 
Fluidised bed coating involves control of spray rate, atomization air pressure, inlet air 
temperature, inlet air volume, product temperature and curing to ensure product 
quality and consistency (Cheng & Turton, 2000; Maa, Nguyen, & Hsu, 1996; Shah, 
Mehta, Aware, & Shetty, 2017) (Table 5-1). 
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Table 5-1: Processing variables for fluid bed coating. 
Processing variable Effect of variable  
Spray rate The spray rate is the rate of liquid coating application to the substrate. If the spray rate 
is too high, agglomeration can occur (S. K. Singh, Reddy, & Khan, 1996). Too low 
spray rate results in too few droplets and drying of the sprayed coat before coalescing 
(Singh et al., 1996). 
Atomisation air 
pressure 
Atomisation air pressure is important in controlling droplet size distribution and velocity, 
This helps to prevent overwetting and spray drying (Werner, Jones, Paterson, Archer, 
& Pearce, 2007a). An increase of this parameter would increase volume and velocity 
of air passing through the nozzle reducing the air-droplet size, leading to spray drying 
and subsequently incomplete coating due to the prevention of coalescence of polymer  
(Werner et al., 2007a). Too little pressure can lead to agglomeration as a result of 
larger spray droplets bridging between particles (Werner et al., 2007a) 
Inlet temperature This is the temperature of the air before it enters the product chamber. The inlet 
temperature is set low compared to drying, a high inlet temperature can result in 
agglomeration during coating due to increased polymer stickiness or film softening 
(Teng & Qiu, 2010). 
Air volume Too high air volume can result in particles trapped in the filter housing, and too low can 
result in overwetting of particles passing through the spray area due to insufficient 
drying (Teng & Qiu, 2010). 
Product temperature The product temperature needs to be above the minimum film-forming temperature to 
allow coalescence of polymer to avoid discontinuous porous films (de Oliveira, Freire, 
& Coury, 1997). Higher temperatures allow enhanced mobility of particles and faster 
drying. However too high temperature can result in drying of the atomized droplets 
before reaching the inert cores (de Oliveira et al., 1997). An increase in the inlet 
temperature and air volume can increase the product temperature whilst an increase 
in spray rate can decrease the product temperature (Jones & Godek, 2017).  
Curing Coated particles are cured to allow further evaporation of water and complete polymer 
coalescence (Williams & Liu, 2000).  The curing temperature should exceed the 
minimum film forming temperature but not the glass transition temperature (the 
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temperature at which the film changes from hard and brittle to elastic and soft), beyond 
which the polymer coating would become soft, and sticky and may result in 
agglomeration (Williams & Liu, 2000). 
 
5.1.3 Gliclazide  
Gliclazide (Figure 5-2) is a second generation sulfonylurea used for the treatment of 
type II diabetes mellitus. Gliclazide is a weak acid (pKa 5.8) and reported to have poor 
water solubility (55 µg/mL) (Allaboun, Alkhamis, & Almomani, 2003; Skripnik, Riekes, 
Pezzini, Cardoso, & Stulzer, 2017). Gliclazide is formulated as immediate release and 
sustained release tablets. The immediate release tablets can be taken once to twice 
daily, and the sustained release tablet is taken once in the morning with breakfast 
(Joint Formulary Committee, 2019d). 
 
 
 
Figure 5-2: Chemical structure of gliclazide (Al-Kassas et al., 2007). 
 
Diabetes is reportedly a growing health burden in older adults and almost one-third of 
over-65’s in the US are reported to have diabetes (Kirkman et al., 2012; Narayan, 
Boyle, Geiss, Saaddine, & Thompson, 2006). Modification of sustained release 
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gliclazide may lead to hypoglycemia which can subsequently result in coma (Joint 
Formulary Committee, 2019d). Gliclaizde is not the first line treatment for diabetes in 
the UK and was selected as a model drug for this study for proof of concept. Absorption 
of gliclazide was not considered for this study. 
 
The aims of this study are therefore to develop sustained release microparticles for 
gliclazide and integrate the sustained release microparticles into the “instant” jellies as 
delivery vehicles and test the influence of jellies using in vitro dissolution.  
 
The primary objective of this study was to develop sustained release microparticles 
for gliclazide with a dissolution profile similar to the reference marketed product 
(Diamicron). 
 
The secondary objective of this study was to integrate the microparticles into the 
developed instant jellies to gain an understandaing of the potential influence of the 
jellies on drug release from sustained release microparticles.  
 
5.2 Materials and Method 
5.2.1 Materials 
Gliclazide was purchased from Sinobio Chemistry Co Ltd, China. Diamicron sustained 
release 30mg tablets manufactured by Servier (pack size 56) were ordered from AAH 
pharmaceuticals, UK. Microcrystalline cellulose microspheres (Cellets 100) was 
obtained from IPC Process-Centre GmbH & Co, Germany, Eudragit NM30D 
(Poly(ethyl acrylate-co-methyl methacrylate) was purchased from Evonik AG, 
Germany. Magnesium stearate was ordered from Acros Organics, Belgium. Talc was 
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purchased from Imerys Talc, Italy.  Hydroxypropyl methylcellulose (Methocel E5) was 
ordered from Colorcon, UK. Silicon dioxide (Aerosil 200 Pharma) was purchased from 
Evonik AG, Germany. 
 
Sodium alginate (Protanol GP 1740) was kindly gifted by FMC Biopolymer, UK. Low 
acyl gellan gum (Kelcogel F) was gifted by CP Kelco, UK and guar gum was gifted by 
B&V, Italy. Calcium chloride and citric acid were purchased from Fischer Scientific, 
UK and dicalcium phosphate dihydrate was purchased from Sigma Aldrich, UK.  
5.2.2  Drug layering and sustained release coating of microparticles using 
fluidised bed 
Gliclazide was layered onto microcrystalline cores (Cellets 100) using a fluidized bed 
coater with Wurster insert (Mini-Glatt, Glatt GmbH, Germany). Gliclazide was milled 
for two hours using a mini ball mill (160g of gliclazide with 60 x 10mm, 19 x 20mm and 
24 x 10mm mini balls at 450 rpm) (Copley Scientific). Gliclazide suspension for drug 
layering was prepared by dissolving HPMC (1% w/v) in water and the milled gliclazide 
(10%w/v) was then added into the HPMC solution, followed by adding talc (1.9% w/v) 
to form a suspension.   
 
The batch size for the drug layering was 100g (Cellets 100 starting core) and the 
process followed parameters shown in Table 5-2.  
 
The sustained release coating dispersion was prepared by dispersing talc  (7.5% w/v) 
in water using a magnetic stirrer and the resultant dispersion was homogenized at 
10,100 rpm for 20 minutes (Silverson L4RT, Silverson Machines, UK). The talc 
dispersion was added to Eudragit NM (30%) dispersion (7.5% w/v) and stirred using 
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a magnetic stirrer for 20 minutes. The final coating dispersion was sieved using a 250 
µm mesh sieve before the coating process (Table 5-2) to remove any aggregates.  
 
Small aliquots (1.5g) of magnesium stearate was added every 15 minutes throughout 
the coating process into the fluidized bed coater through an external feeding port. 
Silicon dioxide (1g) was added into the coating chamber and allowed to mix for 20 
minutes before the coated  microparticles were collected and cured in the oven at 
40°C for 24 hours.  
 
Table 5-2: Processing parameters for drug loading and polymer coating are shown.  
Processing conditions Drug layering Sustained release coating 
Amount of starting material (g) 100g 100g  
Nozzle size (mm) 0.5 0.5 
Inlet air temperature (°C) 70 - 80 30-35 
Product temperature (°C) 40 – 45 18-20 
Atomization pressure (bar) 2 1.5 
Fluidisation air velocity (m3/hr) 18 ±0.5 18 ± 0.5 
Spray rate (g/min) 2-2.5 1.8-2 
Weight gain (%) 50 16, 25, 40 
 
After curing, the sustained release microparticles were weighed and placed in a sieve 
shaker with meshes placed in order of 710µm, 255µm, 250µm, 180µm, 125µm and 
90µm and shaken at 70 amplitude for 10 minutes. The portion of sustained release 
micropellets in the size range of 125-250µm were weighed and the percentage yield 
was calculated (Equation 5-1). The sze of 125-250µm was selected for non-
agglomerates of the sustained release micropellets which was confirmed with light 
microscopy. 
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Percentage yield = !"#$%&	()	*(+&",	-#*.(/+.&#*0"1	#2	3456457µ-	1#8"	.+2$"92&#+#0	:"#$%&	()	-#*.(/+.&#*0"1	;")(."	*(+&#2$ x100 [Equation 5-1] 
 
5.2.3 Light microscopy and particle size measurement by laser diffraction 
Coated microparticles were observed for morphology and aggregation using light 
microscopy (GXCAM-5, 0.5x CCD adapter, GT vision ltd. the UK). The sample was 
mounted onto slides before observation using objective lens PL 5/0.2 and a 
magnification of 50. 
 
Particle size measurements of the sustained release microparticles were made using 
a Sympatec HELOS/RODOS (Sympatec GmbH, Germany) using R5 lens. The cellets 
100 and sustained release microparticles were depressed with compressed air at 2.0 
bar pressure to obtain particle size measurements. The average particle size was 
described as D50 to correspond to the particle size bellow which 50% of the particles 
by volume are smaller. 
 
5.2.4 Incorporation sustained release microparticles into jellies 
Three jellies were prepared, formulations 1-3 according to Chapter 4 (Section 4.2.7, 
Table 4-3) . Preparation of jellies containing coated gliclazide microparticles at coating 
level 25% (CL25) are shown below. 
 
Formulation 1 (F1; free-standing jelly): Dry powder mixture of sodium alginate (0.5% 
w/v), guar gum (0.5% w/v), coated microparticles (0.71% w/v) and dicalcium 
phosphate dihydrate (0.4% w/v) were added to 20mL of deionized water and mixed 
 189 
using a spatula. The concentration of the ingredients indicates the concentration in the 
final jelly formulation. The mixture was stirred until the polymer was dissolved and 
particles dispersed. Citric acid powder (2% w/v) was then added to the above 
dispersion and mixed for 30 seconds before leaving the jelly to set for 5 minutes. 
 
F1 was also manually fragmented to 4mm pieces using a spatula to account for 
chewing for dissolution testing. 
Formulation 2 (F2; granular jelly): Dry powder mixture of sodium alginate (2% w/v) and 
coated microparticles (0.71% w/v) were added to 10mL of deionized water and mixed 
using a spatula. The concentration of the ingredients indicates the concentration in the 
final jelly formulation. The mixture was stirred until the polymer was dissolved. Calcium 
chloride aqueous solution (0.3% w/v) was then added to the above dispersion and 
stirred for 10 seconds until a granular jelly consistency was obtained. 
 
Formulation 3 (F3; granular jelly): Dry powder mixture of sodium alginate (0.5% w/v), 
low-acyl gellan gum (0.5% w/v) and coated microparticles (0.71% w/v) were added to 
10mL of deionized water and mixed using a spatula. The concentration of the 
ingredients indicates the concentration in the final jelly formulation. Calcium chloride 
solution (0.15% w/v)  was added to the above dispersion stirred for 10 seconds until a 
granular mix was obtained. 
 
5.2.5 Ultraviolet-visible spectroscopy analysis of gliclazide  
A standard Ultraviolet-Visible (UV)  calibration curve for gliclazide in phosphate buffer 
pH 7.4 (PB 7.4); 50mL of 0.2M of potassium dihydrogen orthophosphate and 39.5 mL 
of 0.2M sodium hydroxide (NaOH) were mixed and diluted to 200mL with water) and 
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Simulated Gastric Fluid (SGF); 250mL of 0.2M sodium chloride and 425mL of 0.2M 
hydrochloric acid (HCl) were mixed and diluted to 1000mL with water) (British 
Pharmacopoeia, 2018a, 2018b). Gliclazie test solutions (0.0016 to 0.053mg/mL were 
prepared by diluting a stock solution (0.067mg/mL) of gliclazide in dissolution media 
PB 7.4 or SGF. A UV-spectrophotometer (T80; PG Instruments Ltd., UK) was used to 
analyse each sample with buffer media PB 7.4 and SGF used as blank at 226nm 
wavelength. Absorbances obtained for each known concentration were plotted to 
obtain a calibration curve covering the dissolution concentrations (5% - 200% of drug 
release).  
 
The influence of jellies on gliclazide UV absorbance was investigated by dissolving 
the three jellies (prepared as described in Section 5.2.4 but without the sustained 
release microparticles) in  900mL of PB 7.4 and a UV spectra scan (400-190nm) is 
performed using UV-spectrophotometer (T80; PG Instruments Ltd., UK).  Each 
component of the jellies (sodium alginate, guar gum, dicalcium phosphate dihydrate, 
citric acid) was also dissolved separately in 900mL PB 7.4 and UV spectra scans 
performed.  
 
5.2.6 Determination of solubility of gliclazide 
The equilibrium solubility of gliclazide was determined using the shake-flask method. 
A series of aqueous solutions with pH levels ranging from 1-12 were prepared using 
serial dilutions of 0.1M HCl (pH 1-7) and 1M NaOH (pH 13-8) with deionized water. 
The pH was measured using a pH-electrode (WTW inoLab pH 720 with WTW pH-
electrode SenTix 42, WTW GmbH; Germany) before and after addition of excess 
amount of gliclazide. After the addition of gliclazide, the pH level of the solutions was 
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adjusted using HCl (0.1M or 1M) and NaOH (0.1M or 1M) and measured every 24 
hours to maintain the desired pH. The sample was left on the shaker (Roller Mixer 
SRT9, Stuart, manufactured in PRC) with amplitude 16 mm and frequency 20 min-1) 
for a total of 72 hours. Two-milliliter samples were taken from each solution at different 
pH levels and centrifuged (MiniSpin Plus, Eppendorf AG, Hamburg) at 14500 rpm for 
15 min. Aliquots of 1mL or 0.1mL of the supernatant were placed in 25mL or 100mL 
volumetric flask and made to volume using PB 7.4. The concentration of dissolved 
gliclazide was determined at 226nm using UV-spectroscopy (T80; PG Instruments 
Ltd., UK). Measurements were made in triplicates. 
 
5.2.7 Dissolution testing of coated gliclazide microparticles with and without 
jellies  
All dissolution tests were conducted in triplicate using apparatus II dissolution with a 
paddle rotation speed of 100rpm (DIS 6000, paddle apparatus NE4-COP, Copley 
Scientific, UK). The dissolution tests were performed in 900mL PB 7.4  or SGF for 14 
hours at 37°C. UV-spectrophotometer (PG Instruments Ltd., UK) at wavelength 
226nm was used for detection of released gliclazide.   
 
Commercial gliclazide SR 30mg tablet (Dimicron, Servier) was used as a reference 
for dissolution testing. Dissolution testing was carried out using the coated sustained 
release gliclazide microparticles (equivalent to 30mg of gliclazide) at varying coating 
levels (CL16, CL25, and CL60). Milled gliclazide, a physical mixture of milled gliclazide  
and Cellets 100, and gliclazide layered Cellets 100 were also tested for drug release. 
Coated gliclazide microparticles at CL25 were incorporated in the three jelly F1-3 
(prepared as described in Section 5.2.4) and tests for drug release in PB 7.4. Placebo 
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jellies were prepared without the sustained release microparticles and subjected to 
dissolution testing to obtain baseline dissolution profiles. Drug release from jellies 
containing the microparticles was calculated by deducting the jelly baseline 
absorbance from the total UV absorbance value at each sample time points. In an 
alternative method, placebo jellies were placed in the dissolution bath with PB 7.4 and 
SGF and were allowed to dissolve completely. Coated gliclazide microparticles (CL25) 
was then placed in the dissolution bath for drug release testing. The UV absorbance 
of the placebo jelly solutions were auto-zeroed before dissolution testing began for  
coated microparticles.  
 
The pH change of the dissolution media PB 7.4 during dissolution testing of placebo 
jellies was measured using an ELIT PH2011 pH electrode (NICO2000 Ltd, UK.) and 
recorded using NICO2000 software and 6-channel pH monitor (NICO2000 Ltd, UK). 
 
 5.2.8 Data analysis 
The similarity factor is used to determine the closeness between two dissolution 
profiles; this was calculated using Equation 5-2 (Food and Drug Administration, 1997). 
 
   [Equation 5-2] 
Where n corresponds to the number of time points and Rt corresponds to drug release 
of Diamicron reference at time t, and Tt corresponds to drug release of the test product 
at time t. The closeness of the dissolution profile is indicated when f2 is between 50 
and 100. 
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Prism Graphpad (version 7.0) was used to assess normality of dissolution profiles; 
normal distribution was rejected (p<0.05). The Mann-Whitney U test was applied to 
compare significant differences between dissolution profiles and significance 
differences was noted for p ≤ 0.05. 
5.3 Results 
5.3.1 Light microscopy and particle size distribution 
Successful drug layering and coating processes were achieved for the microparticle 
coating using a fluidised bed coater. The yields for polymer coatings at coating levels 
(CL) CL16, CL25 and CL60 were 99.5%, 99.0% and 79.0% respectively and 
agglomerates (sieve fractions above the size of 250µm confirmed using light 
microscopy) was 0.5%,  1.0% and 21.0% respectively. It can been seen that at higher 
coating level (CL60), particles started to agglomerate during coating.  
 
A representative light microscopy image of coated microparticles at CL25 is shown in 
Figure 5-3; mostly spherical particles with smooth surfaces is observed. The D50 of the 
coated microparticles at CL25 were 198µm ± 4.3 and for Cellets 100 were 160.33 ± 
2.1 µm. 
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Figure 5-3: Light microscopy results of sustained release CL25. 
 
5.3.2 Calibration curve and solubility profile of gliclazide 
A representative calibration curve is shown for gliclazide in PB pH 7.4 (Figure 5-4a), 
and good linearity was obtained (R2=0.9997). The equilibrium solubility of gliclazide 
shows that the solubility is dependent on pH and increases with increasing pH level 
from pH 6 (Figure 5-4b). 
 
Figure 5-4: Graphical representation of a) Calibration of gliclazide in PB 7.4 (n=3), b) 
equilibrium solubility of gliclazide at different pH levels (n=3). 
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5.3.3 Gliclazide release from  sustained release microparticles 
Figure 5-5 shows the drug release profile for coated microparticles at coating levels 
CL16, CL25 and CL60,  milled gliclazide, gliclazide Drug Layered (DL) Celles 100, a 
physical mixture of gliclazide and Cellets 100 and Diamicron in PB 7.4. The dissolution 
of milled gliclazide, drug layered Cellets and physical mixture of milled gliclazide and 
Cellets showed similar dissolution profiles. A ranking order of drug release is DL 
Cellets 100 > gliclazide > physical mixture of gliclazide and Cellets 100 > CL16 > CL25 
> Diamicron > CL60.  Microparticles at coating level CL16 showed a much faster drug 
release than Diamicron (f2 18.5, p<0.0001) while at CL60 (f2 23.3, p<0.0011) showed 
a much slower drug release than Diamicron. Coated microparticles at CL25 showed a 
f2 value of 54.2 (p=0.6653)  to Diamicron, demonstrating equivalent drug release 
according to Food and Drug Administration (FDA) guideline (Food and Drug 
Administration, 1997).  
   
 
Figure 5-5: A comparison of drug release for commercial reference tablet Diamicron, 
milled gliclazide, physical mixture of milled gliclazide and Cellets, DL Cellets, and 
coated microparticles at CL16, CL25 and CL60 in PB 7.4 (n=3). 
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5.3.4 Gliclazide release from  sustained release microparticles incorporated in 
jellies 
UV spectrum scans of placebo F1 in PB 7.4 showed a peak in the same UV 
wavelength expected for gliclazide (226nm) (Figure 5-6a), and citric acid was found to 
be the main ingredient in F1 to contribute to this peak (Figure 5-6b). The absorbance 
for gliclazide appeared without interference from F2 and 3 (Figure 5-6c and 5-6d). 
 
Figure 5-6: UV spectra scans for glicllazide, placebo jellies and mixture of gliclazide 
and placebo jelly for a) Placebo F1, b) the excipients contributing to peak in placebo 
F1, c) Placebo F2 and d) Placebo F3, in PB 7.4. 
 
Figure 5-7 showed drug release from coated gliclazide microparticles at coating level 
CL25 incorporated into jellies. Dissolution profiles of the microparticles incorporated 
in jellies show much slower release compared to microparticles without jellies. A 
ranking order of drug release was CL25 > Diamicron> F3> F2> F1 small subunits > 
F1 intact. The similarity factor between drug release of CL25 and the three 
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formulations and between F1 intact and fragmented are shown in Table 5-3. Drug 
release for CL25 and F1 (intact and fragmented), F2 showed significant differences. 
No significant differences were found for drug release for CL25 and F3. F1 intact and 
fragmented showed f2> 50 demonstrating equivalent drug release (Table 5-4) (Food 
and Drug Administration, 1997).  Monitoring of pH changes during the dissolution test 
of placebo jellies without microparticles shows that pH level of the dissolution media 
decreased considerably with F1 from pH 7.4 to 7.0 and no apparent changes were 
noticed for F2 and 3  (Figure 5-8). 
 
 
Figure 5-7: A comparison of drug release for Diamicron, coated microparticles at 
CL25 and F1-3 incorporated with CL25 in PB 7.4 (n=3). 
 
Table 5-3: A comparison of similarity factor and statistical differences between drug 
release for CL25 and F1-3 (significance was marked as * p ≤ 0.05 and ** p ≤ 0.01). 
Comparison Similarity factor  p-value 
CL25 and F1 19.9 <0.0018** 
CL25 and fragmented F1 20.4 <0.0004** 
CL25 and F2 27.4 0.0425* 
CL25 and F3 38.4 0.0623 
F1 intact and fragmented 84.4 0.2523 
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Figure 5-8: The effect of jelly dissolution on the pH level of PB 7.4  
 
Figure 5-9 shows gliclazide release from microparticles CL25 after placebo jellies were 
dissolved in the dissolution media (PB 7.4) before dissolution test commenced. Similar 
to microparticles incorporated into the jellies for dissolution testing, slower dissolution 
rates were noted compared to microparticles alone (without jellies). Significant 
differences were observed for placebo F1 and placebo F2 compared to drug releases 
for CL25 (without jellies) (Table 5-4), at ranking order for drug release, CL25 > 
Diamicron > dissolved placebo F3>  dissolved placebo F2> dissolved placebo F3. For 
each jelly, there is an increase in release rate from coated microparticles in PB 7.4 
with pre-dissolved jelly compared to microparticles incorporated into jelly before 
dissolution testing; however, the difference was not significant (Figures 5-7 and 5-9). 
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Figure 5-9: A comparison of drug release for Diamicron, coated microparticles at 
CL25 and CL25 after placebo F1-3 were dissolved in the media (PB 7.4) before 
testing (n=3). 
 
 
Table 5-4: A comparison of similarity factor and statistical differences between drug 
release for CL25 and placebo F1-3 (significance was marked as * p ≤ 0.05 and ** p ≤ 
0.01). 
Comparison Similarity factor  p-value 
CL25 and placebo F1 23.9 <0.0018** 
CL25 and placebo F2 36.5 <0.0425* 
CL25 and placebo F3 40.3 0.0623 
 
Figure 5-10 shows gliclazide release from microparticles CL25 after placebo jelly 
formulations were dissolved in the dissolution media SGF. There is no significant 
difference in drug release profiles for gliclazide release from CL25 alone and after 
placebo F1-3 were dissolved. Drug release in SGF was lower than in PB 7.4 (Figure 
5-9). 
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Figure 5-10: A comparison of drug release for coated microparticles at CL25 and 
CL25 after placebo F1-3 were dissolved in the media (SGF) before testing (n=3). 
 
5.4 Discussion 
The sustained release coated microparticles showed low aggregation at coating levels 
16% and 25%; increased aggregation was noted with increased coating level (60%). 
Larger particles are expected to elutriate up in the fluidised bed column at a slower 
velocity than smaller particles, the slower velocity of particle movement for higher 
coating level (60%) may have resulted in greater proximity between the particles and 
thus liquid binding amongst the particles during coating (Iley, 1991). Light microscopy 
showed mostly spherical particles with a smooth coating surface at 25% coating level 
which is desirable for achieving uniform dissolution characteristics. The average 
particle size produced for coating level at 25% was less than 200 µm. Reports on 
perceptibility by adults of micropellets in gels prepared with carboxymethyl cellulose 
or carbomer, suggests that pellet sizes less than 350 µm are imperceivable or have 
low perception in the oral cavity regardless of the polymer concentrations (Kluk & 
Sznitowska, 2014). Another study tested acceptability of gels of HPMC containing 
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MCC Cellets in adults and found that oral grittiness (rough mouthfeel) increased with 
increasing particle size; the study concluded that particles below 263 µm showed low 
perception of grittiness (Lopez et al., 2016). Increasing viscosity of the gel also 
reduced perceived grittiness (Lopez et al., 2016).  A rough mouth feel of the coated 
microparticles  can result in poor patient acceptability; the prepared sustained release 
gliclazide are much smaller than the threshold size described in these studies, 
indicating they will likely have good patient acceptability.  
 
The solubility of gliclazide increased with increasing pH due to the weakly acidic nature 
of gliclazide (pKa 5.8) (Jondhale, Bhise, & Pore, 2012). Higher pH levels result in 
greater ionisation of gliclazide and thus an increase in solubility is observed (Skripnik 
2016). The solubility data also showed that a slight change in pH level in the range of 
pH 6-10 will result in a large difference in the solubility of gliclazide. 
 
The Food and Drug Administration (1997) guidance advises three dissolution media 
to be tested for BCS class II drugs (applicable to gliclazide as a poorly water soluble 
drug). In this study only one dissolution media (phosphate buffer pH 7.4) was used for 
the primary dissolution tests considering the low solubility of gliclazide at low pH levels 
such as pH 4.5 and pH 1.2 relevant to simulated fed and fasted stomach conditions. 
No official dissolution test was recorded in the pharmacopeia at the time of this study 
for sustained release gliclazide dosage forms; therefore the dissolution method 
recommended for immediate release formulations was taken forward to attain an 
indication on comparative dissolution profiles of coated microparticles with and without 
incorporation into jellies.  
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Gliclazide layered onto Cellets showed rapid release and almost superimposed 
dissolution results to milled gliclazide indicating that the sustained release coating is 
the only contributor to differences observed in dissolution for varied coating thickness 
levels. Coating thickness is known to influence the rate of dissolution. Diffusion from 
a sphere is described by Fick’s law of diffusion (Laghoueg, Paulet, Taverdet, & 
Vergnaud, 1989).  The drug release is determined by surface area, thickness of the 
transport barrier such as the film coat and the concentration gradient between the drug 
concentration on the substrate surface and the surrounding medium. The thickness of 
the film coat determines the length for drug diffusion pathway, thinner coats result in 
a faster dissolution and thicker coats result in slower dissolution, as observed in this 
study in drug release from coated microparticles of different coating levels (Ozturk et 
al., 1990).  
 
The potential influence of jellies on gliclazide UV detection was determined.  Citric acid 
(used in F1) is reported to absorb and produce broad UV bands due to the presence 
of unionised or ionised carboxyl groups. The presence of this jelly influenced the UV 
absorption of gliclazide (Krukowski, Karasiewicz, & Kolodziejski, 2017). This influence 
was mitigated by obtaining a baseline dissolution profile of the placebo jelly to account 
for the increase in UV absorbance during dissolution testing of  sustained release 
microparticules.  
 
Retardation of gliclazide dissolution was observed through the entire dissolution 
duration in phosphate buffer media when the microparticles were incorporated into the 
jelly formulations. The jelly formulations were prepared using sodium alginate cross-
linked with calcium.  The jelly formulations immersed in phosphate buffer result in ion-
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exchange between sodium in the phosphate buffer media and calcium in the jelly 
matrix, a process which loosens the structure of the gel network and over time to 
facilitate the dissolution of the jellies (Bajpai & Sharma, 2004; Voo, Ooi, Islam, Tey, & 
Chan, 2016). In this study, the jelly formulations were observed to completely dissolve 
within two hours. The jelly matrices are expected to provide an additional barrier for 
drug release possibly through a combination of drug diffusion through the jelly network 
and jelly dissolution/erosion similar to hydrophilic matrix systems for sustained drug 
release. For this reason, alginate is used for encapsulation of drugs for controlled 
release drug delivery (Voo et al., 2016). Manrique-Torres et al. (2014) found 
retardation of atenolol, amlodipine, carbamazepine, and warfarin with the use of gum 
and starch-based thickening agents. Slower dissolution was observed with greater 
thickening, indicating greater entanglement network or solid-like behavior impairing 
drug release (Manrique-Torres et al., 2014). 
 
The extent of drug release retardation by the three jellies was different; at pH 7.4, the 
rank order of drug release from incorporated microparticles was F3> F2> F1. This can 
be linked to the different preparation methods and jelly compositions especially the 
amount of calcium salt in the jelly formulation. F1 has the highest calcium salt 
concentration and showed slowest drug release, due to a higher level of ion exchange 
between sodium (in the phosphate buffer) and calcium (in the jelly) being required for 
jelly dissolution. In addition, previous reports show that an increase in calcium 
concentration resulted in slower drug release from calcium alginate beads due to an 
enhanced structural network, reduced water intake and subsequently greater drug 
entrapment (Bajpai & Sharma, 2004; Pawar et al., 2015; Voo et al., 2016). It has been 
previously reported with increasing cross-linkage of alginate with calcium, water 
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uptake decreases (Bajpai & Sharma, 2004). The jellies prepared with lower calcium 
concentration (F2 and 3) showed  lower magnitude of G’ (Chapter 4) indicating weaker 
gel structure and internal crosslinking, thus allowing faster gliclazide release from 
incorporated microparticles.  
 
Another potential reason for the slow drug release from F1 is the inclusion of guar gum 
in the jelly composition. Galactomannans such as guar gum  are reported to increase 
the entrapment efficiency of drug and thereby to enhance sustained release (Pawar 
et al., 2015). In addition, F1 was shown to lower the pH of dissolution media during 
jelly dissolution (due to the presence of citric acid in the jelly composition), which would 
further explain the retarded release of gliclazide considering its pH-dependent 
solubility. The pH level of the dissolution media maintained the same level during the 
dissolution of F2 and 3.    
 
It was postulated that smaller subunits of F1 in the fragmented jelly to account for 
chewing was expected to increase gliclazide release by reducing the diffusion pathway 
in contrast to gliclazide release from intact jelly. However, dissolution of gliclazide in 
the unfragmented F1 and smaller subunits of fragmented F1 showed similar drug 
release. It was reported that reducing droplet sizes of xanthan gum thickening agent 
resulted in faster atenolol release in simulated gastric acid (Manrique, 2015). 
However, in this study, drug release from the fragmented and intact F1 may be 
predominantly based on dissolution of the jelly rather than diffusion of fluids and drug 
through pores in the jelly matrix. Since the dissolution of jellies in phosphate buffer pH 
7.4 is ion-exchange mediated there may not be a significant difference in the 
dissolution of fragmented jelly compared to intact jelly F1, resulting in similar drug 
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release. This similarity of drug release in intact and fragmented jellies indicates that 
chewing may not impair the gliclazide release from microparticles incorporated in F1; 
however, it needs to be taken into caution that chewing might cause impairment to the 
coating of the sustained release microparticles and increase drug release. This effect 
needs to be investigated in future studies, possible mitigation strategies if chewing of 
microparticles does occur is presenting the jelly in a smaller easy to swallow size. 
 
Dissolution testing of coated gliclazide microparticles in dissolution media containing 
dissolved jellies showed slower drug release compared to the sustained release 
microparticle alone without jelly. This could be due to the increase in the viscosity of 
the dissolution media and decrease in media pH in the case of F1. However the extent 
of drug release retardation was lower in dissolved jellies than microparticles 
incorporated in intact jelly, although the difference in drug release was not statistically 
significant.  Gliclazide release from coated microparticles with and without jellies were 
very low in simulated gastric fluid. This was predominantly due to the low solubility of 
gliclazide at low pH levels.  
 
Gliclazide release from microparticles incorporated in jellies, especially F1, was slower 
compared to drug release form Diamicron; this can be rectified by using lower coating 
thickness beneficial for cost saving during production. This study has shown sodium 
alginate-calcium jellies decreased gliclazide release from sustained release 
microparticles in phosphate buffer medium. However the extent of this release 
deduction needs further investigation in dissolution media that better simulate the in 
vivo small intestinal fluids than phosphate buffer, for example using bicarbonate 
buffers that have lower buffer capacity.  This would allow better comparison with the 
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reference product Diamicron and subsequently provide insight into in vivo 
performance of the novel drug delivery systems. The dissolution apparatus II is limited 
in reproducing fluid mechanics in vivo. The influence of hydrodynamics varies 
according to the position of the dosage form in the vessel and the paddle speed is set 
to 50rpm to allow discrimination power between drug release profiles (Armenante & 
Muzzio, 2001). The dissolution of jelly is likely to vary with varying shear rates and 
hence the absorption of gliclazide may vary in patients. This would require further 
investigation in vivo. Furthermore, varying of chewing patterns for jelly 1 may also 
result in variation in dissolution in vivo but this requires further investigation of whether 
the extent chewing would influence gliclazide dissolution.  
 
Dissolution testing in this study using UV detector has provided an insight on potential 
influences for drug dissolution such as slower drug release with jelly vehicles. 
However, a more accurate quantification for gliclazide is required using HPLC and the 
acceptability, palatability and ease of swallowing of the developed instant jellies  for 
needs further investigation in vivo. 
 
5.5 Conclusions 
Sustained release gliclazide microparticles were developed and “instant” jellies were 
used as delivery vehicles. All three jelly formulations contributed to decreased drug 
release from the sustained release microparticles, with F1 (free-standing jelly) 
showing the greatest effect on drug release retardation compared to F2 and 3 
(granular jellies). F1 showed similar drug release between intact jelly and fragmented 
jelly indicating chewing will not affect drug release from incorporated microparticles. 
The decrease in drug release from sustained release microparticles in jellies could 
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reduce the coating level required and thus achieving cost saving in production. The 
novel drug delivery system using “instant” jellies incorporating sustained release 
microparticles offer a promising solution for medication administration in patients with 
dysphagia.  
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Chapter 6 
GENERAL DISCUSSION
209 
 
The safe administration of tablets and capsules in patients with dysphagia can be 
challenging and medicines modification (tablet crushing and capsule opening) is 
sometimes used to facilitate administration (Paradiso et al., 2002). Older patients are 
often prescribed multiple medicines (Hughes et al., 2016; Morin et al., 2018) and can 
benefit from sustained release dosage form to reduce pill burden, however, medicines 
modification of sustained release dosage forms can be dangerous and result in toxicity 
(Schier et al., 2003). The aim of the study was to understand the practical issues in 
administering sustained release dosage forms in older patients and develop novel 
sustained release dosage forms that are safe to swallow and acceptable to these 
patients.  
 
Existing literature explored medicines modification and the occurrence of sustained 
release dosage form modification was recognised, however, the extent of modification 
occurring for these dosage forms was not reported (Fodil et al., 2017; Mc Gillicuddy et 
al., 2016; Paradiso et al., 2002; Stubbs et al., 2008). The study of medicines 
modification (Chapter 2) focused on difficulties in administering  sustained release 
dosage forms to older adults with dysphagia. The study highlighted that sustained 
release dosage forms are  prescribed to patients with dysphagia (10% of medicines 
prescribed) and were modified by tablet crushing or capsule opening to aid swallowing 
(49%). The population is aging and prescribing and incidences of modification of 
sustained release dosage forms in this cohort may grow. The study also showed 
swallowing aids were sometimes used to facilitate swallowing of modified dosage 
forms such as thickened fluids, yogurt and jellies. There were also cases of swallowing 
the dosage form whole with jelly. This study was designed as a prospective study 
involving medicines charts to enable data to be obtained across wards and relied on 
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the nurses input on details of medicines modification, in hindsight, an observation 
study may have given first-hand insight into the clinical situation. 
 
Swallowing aids such as thickened fluids, yogurt and jelly were used in the medicines 
modification study but whilst there was literature supporting improvement of safety of 
swallowing with thickened fluids (Clavé et al., 2006; Logemann et al., 2008) there was 
little or no information for jellies and yogurt (Nagaya et al., 2004; Sonoi et al., 2016). 
An in vitro throat model was used to assess processing of these products and compare 
findings with rheological and textural characteristics of the thickened fluids, jellies and 
yogurt to determine if there are universal parameters that can predict in vitro 
performance (oral transit time and bolus length). At the time of this study, previous 
literature used the throat model for the processing of thickened fluids (Hayoun et al., 
2015; Mackley et al., 2013; Mowlavi et al., 2016). This was the first study that explored 
application of the in vitro throat model for processing of semi-solids for pharmaceutical 
application and the first study that considered the combination of in vitro oral transit 
time and bolus length in the airway divide as  in vitro markers of velocity and 
cohesiveness of bolus transit. Previous studies showed, an increase in oral transit 
time was observed with increased thickening (Clavé et al., 2006; Dantas et al., 1990; 
Tashiro et al., 2010). In vitro processing of thickened fluids in this study showed 
increase in oral transit time and reduced bolus length in the airway divide with 
increasing thickening indicating slow and cohesive bolus transfer as important 
considerations for safety of swallowing. Increasing in oral transit time and reduced 
bolus length correlated with viscosity, yield stress firmness and cohesiveness of 
thickened fluids. Jellies paralleled processing findings in the in vitro throat model of 
honey and spoon thick thickened fluids for oral transit time and reduced bolus length 
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but show lower viscosity, yield stress, firmness and cohesiveness instrumental values 
compared to the thickened fluids. The rheological and textural characterisation of 
products used in this study cannot be used to predict in vitro processing behaviour, 
the throat model did however, show potential in differentiating the processing 
behaviour of different products. The in vitro throat model is a static model whereas the 
in vivo  swallowing mechanism is complex, for example, peristaltic contractions in the 
pharynx help to move the bolus towards the oesophagus (Chadwick & Jolliffe, 2009), 
which cannot be simulated using the in vitro model. Further investigation is needed 
into the correlation between in vivo and in vitro results and possibly calibrate the in 
vitro throat model accordingly. A acceptability study (Chapter 3) conducted in healthy 
volunteers using 5-point likert scale for rating showed commercial free-standing and 
granular jellies were found easier to swallow than thickened fluids in healthy volunteers 
and the in vitro findings for jellies showed potential for jellies to be assessed further in 
vivo for safety of swallowing. 
 
The findings from the in vitro study and medicines modification led to development of 
instant jellies (forms in less than 10 minutes) to use as vehicles for the administration 
of sustained release microparticles for older adults with dysphagia. Sodium alginate 
and calcium salts were the primary components used to develop free-standing and 
granular jellies without heat. The combination of sodium alginate and calcium salt is 
listed in existing patents  (Hong et al., 2012; Masumoto et al., 2016; Yasushi et al., 
2016) but the quality of the final products and safety of swallowing is unknown. The 
combinations of sodium alginate and calcium salt jellies were assessed according to 
a visual criteria for commercial products, any residual water due to gel contractions 
and time taken for final product to form. The jellies were compared using texture and 
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rheological analysis to mimic the properties of commercial jelly products which are  
familiar to patients as desserts or used as swallowing aids for tablets and capsules in 
Japan (Tsuji et al., 2006) and in our clinical study (Chapter 2). The final jellies 
developed in this study mimicked the behaviour of commercial jellies (slow oral transit 
and cohesive bolus movement) in the in vitro  throat model. The study found variation 
in water hardness and volume can compromise jelly formation in terms of quality and 
time for the jelly to form which would result in additional costs of providing deionized 
water for the dosage form. The jellies require multiple sachets of components which 
may be challenging and bulky for patients, however, this may be mitigated using 
bespoke packaging. These additional costs however, may be less than the costs 
incurred for missed doses, subtherapeutic dosing as a result of swallowing difficulties 
and manipulation of dosage forms.   
 
The jellies developed in Chapter 4 were used as a delivery vehicle for sustained 
release microparticles for older adults with swallowing difficulties. Simply mixing 
microparticles with existing commercial jellies may compromise the jelly performance 
for swallowing and would not allow integration of the microparticles sufficiently into the 
jelly structure for complete and safe delivery. Although microparticles were not 
favoured by patients due to potential impact on taste when consuming with meals and 
the use of mini-tablets poses the risk of chewing due to sensation of grittiness reported 
in sizes above 263 µm (Liu et al., 2016; Lopez et al., 2016). The sustained release 
microparticles (198µm) developed in this study were smaller than the reported sizes 
for grittiness (above 263 µm) to reduce the risk of chewing (Kluk & Sznitowska, 2014; 
Lopez et al., 2016). The sustained release microparticles developed using cellet 100 
and coated with gliclazide and sustained release coating consisting of Eudragit NM 
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and talc using fluid bed technology for model drug gliclazide showed similar drug 
release compared to the marketed reference drug Diamicron in phosphate buffer pH 
7.4. The jellies however, sustained gliclazide release further. Sodium alginate and 
calcium combination is previously reported to retard drug release (Bajpai & Sharma, 
2004; Pawar et al., 2015; Voo et al., 2016) and this study validated these findings with 
increasing sustained release observed with increased calcium concentration. The 
free-standing jelly was expected to show faster gliclazide release upon fragmentation 
to account for chewing, similar to the findings by (Manrique, 2015). However, both 
chewed and whole forms of the free-standing jelly showed similar drug release profiles 
potentially due to ion-mediated dissolution (Bajpai & Sharma, 2004; Voo et al., 2016). 
This study was a proof-of-concept and requires further investigation with biorelevant 
dissolution media that better simulates the in vivo small intestine fluids such as 
bicarbonate buffers and there is also a requirement of more accurate quantification of 
gliclazide with HPLC to eliminate potential influence of jelly. The jellies integrated with 
sustained release microparticles offer a novel platform for drug delivery for patients 
with swallowing difficulties. A further investigation is however required for patient 
acceptability and palatability for these jelly dosage forms similar to previous 
acceptability and palatability study performed by Lopez et al. (2018).  
 
6.1 Final conclusions 
The study found challenges in administration of sustained release dosage forms for 
patients with swallowing difficulties and hazardous practices of administration by 
crushing tablets and opening capsules to facilitate administration. The developed 
jellies showed similar safety features to thickened fluids in the in vitro throat model but 
requires validation from in vivo studies. The jellies with sustained release 
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microparticles can be potentially useful platform of dosage forms for older adults with 
swallowing difficulties and may also be suitable for paediatrics. 
 
6.2 Future work 
The swallowing process is much more complex than the static throat model used in 
this study and a correlation needs to be established between in vivo and in vitro throat 
model to provide validation for results that are obtained from the in vitro throat model 
and for further investigation using the developed jellies with integrated microparticles. 
The throat model is designed for liquids and jelly products did show variable results, 
this would require further investigation in vivo, particularly the effect of chewing 
variability on cohesive bolus transit and safety of swallowing for the free-standing jelly.  
 
A acceptability and palatability study is required for the instant jelly with sustained 
release microparticles to establish whether older patients would accept these dosage 
forms. A acceptability study is also required for preparation of the dosage form and 
ease of use of potential packaging options. The ease of swallowing in vivo needs to 
be investigated for the developed jellies. Although the focus of this thesis is older 
adults, these dosage form may be potentially useful for the paediatric population. 
 
Further studies into in vitro drug release in biorelevant media would be worthwhile for 
in vivo predictions and better quantification of gliclazide drug release is required using 
HPLC to eliminate potential jelly influences in quantifying gliclazide using UV. The in 
vitro dissolution study showed chewing may not effect dissolution of gliclazide but the 
effect of chewing of jellies and microparticles needs further investigation  in vivo. 
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SYNOPSIS 
 
Title An investigation into the use of modified release medications in older adults 
with swallowing difficulties 
 
Chief Investigator Miss Simmi Patel– University of Hertfordshire 
Principal Investigator Mr. Narinder Bhalla- Cambridge University Hospitals NHS Foundation Trust. 
Aim The aim of this study is to determine the extent and nature of problems with 
administration of modified release oral medications in older adults with 
swallowing difficulties and how these problems are solved in practice. 
 
Objectives • To find out the frequency of prescribing modified release medications 
for older adults with swallowing difficulties.  
• To find out if any changes are made in administering or prescribing of 
modified release medication in this patient population. 
• To analyse the problems associated with changes that are made with 
modified release medications to aid administration for older adults with 
swallowing difficulties. 
• To determine the types of modified release oral medication and the 
disease categories that causes the most concerns for administration of 
modified release medications in older adults with swallowing 
difficulties. 
Setting Secondary care- Cambridge University Hospitals NHS Foundation Trust. 
Sample size estimate A sample size of 209 was calculated using a population proportion estimate. 
Eligibility criteria • Patients must be aged 65 or over 
• Patients with swallowing difficulties  
• Medicines reconciliation must be complete. 
 
Summary of method This is a prospective study using medical notes and drug charts to collect 
information on the use of modified release oral medications in older adults with 
swallowing difficulties. A data collection pro forma will be used to determine 
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whether the patient is prescribed any modified release medications, whether 
this has been changed to an alternative to manage administration in patients 
with swallowing difficulties, whether this medication has been manipulated (i.e. 
crushed tablets or opened capsules) or whether there are any other methods 
used to make medicines  easier to swallow such as mixing with foods. 
Duration of study The duration of this study is six months 
Outcome measures • The frequency of prescribing modified release medications for older 
adults with swallowing difficulties 
• The frequency of changing modified release medications to alternative 
medications to aid administration for older adults with swallowing 
difficulties. 
• The frequency of modification of modified release medications to aid 
administration for older adults with swallowing difficulties. 
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STUDY	BACKGROUND	INFORMATION	AND	RATIONALE	
 
1. Introduction 
 
The proportion of older adults (aged 65 and over) in the population is rising; it has been estimated that 
the world population of adults aged 60 and over will be 2 billion by 2050 and by 2035, 23% of the UK 
population will be 65 or over (1,2). Older adults tend to have a greater need for health and social care 
compared to their younger counterparts and account for 50% of prescribed medicines (3,4). Older adults 
are the major users of medication, particularly as they are commonly on multiple medications due to 
comorbidities. One of the challenges faced with administering medication to older adults is swallowing 
difficulties, which is more prevalent in older adults than the younger cohort. It has been reported that 
swallowing difficulties occur in 11% of older adults amongst the general population, 12% in hospitalised 
older adult patients and 68% of institutionalised older adult patients (5–7). This problem is expected to 
become more widespread as the population ages.   
 
2. Healthy swallowing process 
 
The process of swallowing (also known as deglutition) is a rapid and synchronised process and it is 
generally explained in terms of three phases; the oral phase, the pharyngeal phase and the oesophageal 
phase (8). 
 
The oral phase involves chewing food and mixing it with saliva to form a pellet (9). This pellet of food is 
then propelled towards the pharynx. Before the pellet of food enters the pharynx, the larynx is closed so 
that the pellet of food does not enter into the lungs. After the movement of the pellet of food through 
the pharynx (the pharyngeal phase), it enters the oesophagus and is moved towards the stomach through 
contractions (the oesophageal phase) (10). 
 
3. Swallowing difficulties 
 
Swallowing difficulties are defined as the “eating and drinking disorders which may occur in the oral, 
pharyngeal and oesophageal stages of deglutition” (11). It is more likely to occur in older adults compared 
to their younger counterparts because of the natural process of ageing, age-related diseases and certain 
medications (12).  
 
The natural process of ageing can cause swallowing difficulties. This can be caused by poor dentition, and 
decline in neuromuscular function and muscle mass. This can affect the break down of food to form a 
pellet and its propulsion during the oral phase. Delays in all three phases of the swallowing process can 
be observed in older adults  (13). 
 
Diseases such as stroke, Alzheimer’s disease, Parkinson’s disease and other dementia syndromes increase 
in prevalence with age and are known to cause swallowing difficulties (12,14).  It has been reported that 
the prevalence of swallowing difficulties can affect up to 81% of stroke patients, 70% of patients with 
Alzheimer’s disease and 87 % of patients with Parkinson’s disease (15,16). 
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Medicines can also impair the swallowing process, particularly medicines that cause dry mouth, 
oesophageal injuries, central nervous system depressants (also referred to as tranquilisers and sedatives), 
and antipsychotics (13). Although these medications are not specifically used in just the elderly, they are 
frequently prescribed for older adults. Antipsychotics cause symptoms that mimic Parkinson’s disease, 
one of the symptoms of which includes swallowing difficulties. Medicines that cause dry mouth, for 
example, sedatives can affect the formation of the pellet of food, reducing its cohesiveness and this can 
result in residue being left during the swallowing process (17).  
 
Swallowing difficulties can result in severe health implications, including malnourishment, aspiration 
(when food travels through the respiratory tract) and choking. Aspiration may also lead to pneumonia 
which in severe cases can lead to death (9,18). 
 
4. Medicine administration in patients with swallowing difficulties 
 
The oral route for adminstering medications is the most popular as it is more convenient for patients. 
However, it is particularly popular amongst older adults as it can be packaged into dossette boxes to 
ensure older adults, particularly those on multiple medicines, remember to take their medicines (19). 
 
It is challenging to administer medications through the oral route to patients with swallowing difficulties 
and there have been studies on medicine administration for patients with swallowing difficulties. Wright 
(2002) utilised questionnaires for nurses working mainly in nursing homes for older adults in the UK. The 
report revealed that the most common method employed for medicines administration in patients with 
swallowing difficulties were to obtain a liquid alternative (88%), followed by crushing or opening capsules 
(61%) (19). Strachan & Greener (2005) distributed questionnaires to patients in 17 community pharmacies 
(independents and multiples) in England and Northern Ireland, 68% of patients with swallowing difficulties 
revealed the need to open a capsule or crush tablets to help swallow their medicine (20).  Another study 
by Stubbs, Haw, & Dickens (2008) looked at the frequency of authorised and unauthorised drug 
modification, for older patients in a mental health hospital. Medication administration during ward rounds 
were observed, and found that in 26% of administrations, tablets or capsules were crushed or opened to 
aid administration, and only 56% of the tablets crushed or capsules opened were authorised on the drug 
chart (21).  
 
There are concerns regarding the safety and clinical risks associated with medicines administration to 
patients with swallowing difficulties. As mentioned in the studies related to medicines administration for 
patients with swallowing difficulties, the common practice is to crush tablets or open capsules to help 
swallow the medication. There are many factors to consider when modifying medications; the stability of 
the drug can be altered due to light, heat and water sensitivity, which can result in the degradation of the 
drug before its administration. Medications are often formulated with specific properties, crushing tablets 
and opening capsules can change what happens with the drug in the body from what is expected. This can 
compromise therapeutic outcomes and can cause toxicity (19,21).  
 
Feeding tubes are commonly used for medicines administration for patients that cannot ingest substances 
orally. In hospitals, feeding tubes are particularly used in the care of the elderly and surgical wards (22). 
Generally, liquids or dispersible tablets are sought for administration via enteral feeding tubes. Crushed 
tablets are also administered through enteral feeding tubes when suitable alternatives are not available, 
however, this is the most common cause of occlusion within the feeding tube (23). 
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A consensus guideline was developed for medicines management of adults with swallowing difficulties. 
The guideline recommends that suitable alternatives such as liquid formulations should be sought when 
solid oral medications cannot be administered, however, not all patients can swallow liquids and often 
thickeners have to be added to aid swallowing.   Modifying medications, for example, by crushing tablets 
or opening capsules should be the last resort when licensed alternatives are not available (25). 
 
5. Modified release oral medications 
 
Modified release medications are medicines that have a specific structure, such as a special coating or use 
of a matrix that breaks down slowly to allow drugs to be released over an extended period of time. These 
medications often have the letters ‘MR’, ‘SR’, ‘XL’, and ‘LA’ after their name, for example, Dilzem XL (19).  
 
These medications offer three main advantages. They allow less frequent administration of medicines that 
would require multiple dosing due to the release of drug over a longer period of time compared to 
conventional immediate release dosage forms. Sustained release of the drug can also provide optimal 
control over symptoms and improve disease management, particularly in terminal diseases where 
breakthrough symptoms are concerned. Modified release medications also reduce side effects of drugs 
compared to conventional oral medications; the sustained release of drug ensures that drug levels do not 
go beyond the safety limits and thus reduce adverse effects. 
 
Modified release oral medicines often have more drug content than conventional immediate release oral 
tablets and capsules to allow release of the drug for a longer period of time. Manipulating these 
formulations can result in immediate release of the drug content and result in toxicity. The consensus 
guidelines on medicines management for adults with swallowing difficulties, recommends that modified 
release medications should not be modified, i.e. crushed, opened, chewed or sucked (25). 
 
Modified release oral medications are particularly beneficial for older adults. Older adults tend to have 
multiple diseases and on average take more than five medications (14). The use of modified release 
medications reduces the pill burden for these patients and also offers reduced side effects as well as better 
disease management (14,26). However, these medications are usually large and pose difficulties to 
administer in patients with swallowing difficulties.  In practice, they may be switched over to a liquid 
dosage form, or to a conventional immediate release tablet or capsule and modified but then the patient 
would not be able to benefit from the advantages of modified release medications.  
 
It is important to gain information of the extent and nature of problems of administering modified release 
medications to older adults with swallowing difficulties, and the solutions used by health professionals in 
practice to overcome administration difficulties of modified release medications. This information could 
lead to the development of novel modified release medications that are suitable for older adults with 
swallowing difficulties and could guide best practice for management of administration of modified 
release medications in older adults with swallowing difficulties. 
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STUDY	OBJECTIVES	AND	PURPOSE	
 
Aim 
 
The aim of this study is to determine the extent and nature of problems with administration of modified 
release oral medications in older adults with swallowing difficulties and how these problems are solved in 
practice. 
 
Primary objective 
 
To gain a better understanding of the problems surrounding the use of modified release oral medications 
in older adults with swallowing difficulties.  
 
Secondary objective 
 
• To find out the frequency of prescribing modified release medications for older adults with 
swallowing difficulties.  
• To find out if any changes are made in administering or prescribing of modified release medication 
in this patient population. 
• To analyse the problems associated with changes that are made with modified release 
medications to aid administration for older adults with swallowing difficulties. 
• To determine the types of modified release oral medication and the disease categories that causes 
the most concerns for administration of modified release medications in older adults with 
swallowing difficulties. 
	
	
STUDY	DESIGN	
 
Study Configuration 
 
This is a prospective study using medical notes and drug charts to collect information on the use of 
modified release oral medications in older adults with swallowing difficulties.  
 
Study Management 
 
The Chief Investigator (Simmi Patel) will be completing this project as part of a PhD programme of study, 
and will collect the data. The principal investigator (Narinder Bhalla) will lead the project and ensure that 
it is completed successfully and to the highest of standard. The academic supervisors of this project will 
oversee the project and ensure it is of high academic quality.  
 
Duration of the Study and Participant Involvement 
 
The study duration is anticipated to be six months (commencing from August 2014). 
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A member of the direct care team (clinical pharmacists on ward) will identify eligible participants. 
Participants’ medical notes will be checked and their clinicians may be approached to find out whether 
the participant has the capacity to provide informed consent. For participants who can provide informed 
consent (no indication of lack of capacity to consent documented in the medical notes or communicated 
by the participants clinician), a member of the direct care team will approach the eligible participant and 
provide a patient information sheet (Appendix 2). Verbal consent will be sought from eligible participants 
by the member of the direct care team for the participants’ details (patients ward and patients’ name) to 
be passed onto the chief investigator (CI). The CI will then approach the participant, explain the study and 
obtain informed consent. Verbal authorisation for details to be passed onto the CI will be recorded in the 
medical notes by a member of the direct care team that approached the potential participant. Participants 
that are interested in the study will be asked to provide written consent for the chief investigator to collect 
non-identifiable data from the participants’ medical notes and drug charts and they will not be 
approached during the data collection.  
 
For participants that cannot provide consent (lack of capacity recorded in the medical notes or if the 
participants clinician has verbally communicated patients lack of capacity to consent) then the 
information required for the data collection pro forma, which is non-identifiable and anonymous, will be 
provided to the researcher by the pharmacist. 
  
Enrolment will commence after Ethical approval, and after obtaining an honorary contract from 
Addenbrooke’s hospital, Cambridge.  
 
End of the Study 
 
The end of the data collection period of the study will be after data is collected from 209 eligible 
patients. 
 
	
SELECTION	AND	WITHDRAWAL	OF	PARTICIPANTS	
Recruitment of Participants 
 
The study setting is based in secondary care, in Addenbrookes’ hospital, Cambridge. Clinical pharmacists 
will identify patients over 65’s with swallowing difficulties on all wards using the criteria outlined below 
(6): 
 
• Difficulty in oral intake or no oral intake 
• Frequent choking and excessive coughing 
• Need for a diet modified in texture 
• Need for non-oral nutritional support 
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• History of aspiration pneumonia 
• Need for individual mealtime supervision 
 
Clinical pharmacists will identify wards with eligible patients. For all wards involved for data collection, 
participants that can provide informed consent will be approached by clinical pharmacists or speech and 
language therapists and will be provided with a participant information sheet (Appendix 2). Verbal 
consent will be sought from potential participants for their details (patients’ ward and patient name) to 
be passed to the CI who will then approach the participant, explain the study and obtain informed consent. 
Informed consent for the CI to collect non-identifiable data from the patients’ medical notes and drug 
charts will be recorded on a consent form (Appendix 3). 
 
Anonymous, non-identifiable data necessary to complete the data collection pro forma will be provided 
to the researcher for participants that cannot provide informed consent (documentation of lack of 
capacity in medical notes or verbally communicated by participants clinician to the member of the direct 
care team involved in identifying the participant). 
 
Inclusion Criteria 
• Patients must be aged 65 or over 
• Patients with swallowing difficulties  
• Medicines reconciliation must be complete. 
 
Exclusion Criteria 
• No exclusion criteria. 
 
Expected Duration of data collection from patients 
Data will be collected from patients’ drug chart and medical notes until the standard data collection pro 
forma is complete for that patient.  
Withdrawal of data collection from patients  
 
Patients will not be approached during data collection, but there may be circumstances whereby a health 
professional in the patients direct care team may ask to discontinue data collection. These requests will 
be respected and data collection will cease for that patient. 
 
Informed consent 
 
Clinical pharmacists will be involved in identifying eligible participants. Participants that can provide 
informed consent (no documentation of lack of capacity in medical notes or communicated by 
participants clinician) will be approached and provided with a patient information leaflet. Verbal consent 
will be sought for their details (patients’ ward and patient name) to be passed onto the CI. The CI will 
then explain the study to the participants. Participants will be given time to consider whether they 
would like data to be collected from their medical notes and drug charts, and written consent will be 
273 
 
sought later in the day by the CI (Appendix 3). Only after consent is provided, will data be collected from 
the medical notes and charts. 
 
For participants that are unable to provide informed consent (lack of capacity documented in medical 
notes, or communicated by the participants clinician), data required for the data collection pro forma 
(anonymous and non-identifiable) will be provided to the CI. 
  
 
 
 
METHODOLOGY	
 
This is a prospective study using medical notes and drug charts to collect information on the use of 
modified release oral medications in older adults with swallowing difficulties. For patients that can provide 
informed consent (no indication of lack of capacity documented in the medical notes or verbally 
communicated by patients’ clinician), drug charts of patients will be viewed to determine whether the 
patient is prescribed any modified release medications, whether these have been changed to an 
alternative to manage administration in patients with swallowing difficulties, whether this medication has 
been manipulated (i.e. crushed tablets or opened capsules) or any other methods used to make the 
medicine easier to swallow (for example, mixing with food). If this information is not clear on the drug 
chart then questions may be asked to nurses looking after the patient for further clarification. Patients’ 
medical notes will be used to determine the reason for admission, and patients’ current condition(s). For 
patients that lack the capacity to provide informed consent, data necessary for the completion of the data 
collection pro forma, which is anonymous and non-identifiable, will be provided by the member of the 
direct care team (clinical pharmacist) identifying the participant to the CI. All data will be recorded on a 
standardised data collection pro forma (Appendix 1). 
 
The steps that will be taken during the data collection period is summarised in the flow chart (Figure 1) 
below. 
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Figure 1: Flow chart of research methodology 
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Sample Size and Justification 
 
A sample size was calculated to determine how many patients would need to be recruited to provide a 
representative sample of older adults with swallowing difficulties that are prescribed modified release 
medications. An estimation of population proportion was thus made using the margin of error equation: 
 
p±Z√(pq/n) = margin of error 
 
Where Z is the critical value for 95% confidence level is 1.96. 
p is the expected frequency value 
q is 1-p 
Margin of error is a measure of accuracy; it provides a limit by which the sample proportion 
differs from the true population proportion (27). For this calculation, a margin of error of 5% was 
used.  
 
The expected frequency value in this study is the frequency of prescribing modified release 
medications in older adults with swallowing difficulties. This value is not reported and thus, 
primary care prescription data for 2012 were used to calculate how often modified release 
medications were prescribed (Table 1)(28). Primary care data for drugs prescribed for the gastro-
intestinal system, cardiovascular system, central nervous system and endocrine system were 
selected, as diseases relating to these systems are common in the elderly.  
 
Table 1: Frequency of prescribing modified release oral medications 
 
Disease category 
Total items prescribed 
(thousands) 
Modified release oral 
medications 
prescribed 
(thousands) 
Frequency of 
prescribing modified 
release oral 
medications (%) 
Gastro-intestinal 
system 83900.107 1485.816 1.77 
Cardiovascular 
system 300647.907 24350.911 8.10 
Central Nervous 
system 180133.396 9629.898 5.34 
Endocrine system 691332.124 5277.845 0.76 
Total 1256013.534 40744.47 3.24 
 
 
The value of 3.24% is the frequency of items prescribed in primary care to patients of all ages. Older 
adults are prescribed on average 5 or more medications so it is estimated an average of 16.2% (5 x 
3.24%) chance of older adults with swallowing difficulties prescribed with modified release medications 
(14). Based on an estimated frequency of 16.2%, data will be collected from a total of 209 patients. 
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There is no data available on the prescribing frequency of modified release medications in older adults 
with swallowing difficulties. Thus, the sample size was calculated by using primary care data instead of 
secondary care and on the general public instead of older adults with swallowing difficulties. However, 
data collection from 209 patients’ medical notes and drug charts is practical to achieve within the six 
month data collection period and can provide representative information of the problems associated 
with using modified release medications for older adults with swallowing difficulties in a clinical setting. 
 
Data Collection and Analysis 
 
A pilot study will first be conducted; data will be collected from 10 patients and the information gained 
from the pilot study will be used to determine whether there are any deficiencies in the design of the 
data collection pro forma. If there are no changes to be made to the data collection pro forma, then 
results from the pilot study will be included in the data collection. 
 
The standard data collection pro forma (Appendix 1) will be used to collect information of patients’ 
medical background, patients’ medications and more specifically, whether modified release medications 
are prescribed and if there are any changes to this to help the patient swallow their medication. Nurses 
looking after patients may be approached if this information is not clear on patients’ drug chart and 
medical notes. Patient identifiable data will not be collected, and thus information collected will be 
anonymous.  
 
Data collected on the pro forma will be analysed to determine the frequency of prescribing modified 
release medications in patients with swallowing difficulties, any problems associated with changes to 
modified release medications, and which modified release drugs are of most concern for patients with 
swallowing difficulties.  
 
ETHICAL	AND	REGULATORY	ASPECTS	
Ethics Committee and Regulatory Approvals 
 
This study will not commence until approval by the Research Ethics Committee (REC). If any 
amendments need to be made that requires REC approval, the changes will only be implemented once 
the revised version has been approved by the REC. Minor protocol amendments for logistical or 
administrative changes may be implemented immediately; and the REC will be informed. 
 
Person- identifiable data will not be collected in this study, and data will not be collected until consent is 
gained for the patients’ data to be collected and for the CI to use patients’ medical notes and drug 
charts to collect data. Data collection on the pro forma will be anonymous.  
Informed consent and participant information 
 
The process for obtaining participant informed consent will be in accordance with the REC guidance, and 
Good Clinical Practice (GCP) and any other regulatory requirements that might be introduced. The CI 
who will be obtaining consent and the participant shall both sign and date the Consent form before the 
person can participate in the study. 
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	QUALITY	ASSURANCE	&	AUDIT		
Insurance and Indemnity 
Insurance and indemnity for study participants and researcher is covered by the insurance underwriters 
from the University of Hertfordshire.  
Study Data  
 
Data collection pro forma’s will be stored in the Chief Investigators’ locked drawer in a locked office at 
the University of Hertfordshire. Monitoring of study data shall include confirmation of consent; source 
data verification; data storage and data transfer procedures; local quality control checks and 
procedures, back-up and disaster recovery of any local databases and validation of data manipulation. 
The Study Coordinator, or where required, a nominated designee of the Sponsor, shall carry out 
monitoring of study data as an on-going activity.  
 
Study data and evidence of monitoring and systems audits will be made available for inspection by the 
REC as required. 
 
Record Retention and Archiving 
 
The chief investigator will maintain records and documents for 2 years after completion of data 
collection, until the completion of the PhD programme of study.  
Statement of Confidentiality  
 
Personal identifiable data will not be collected during this study.  Data generated as a result of this study 
will be available for inspection on request by the University of Hertfordshire representatives, the REC 
and the regulatory authorities. 
 
PUBLICATION	AND	DISSEMINATION	POLICY	
 
The results from this work will be published in peer reviewed journals as well as presentation to 
appropriate conferences and used within the final PhD thesis. 
 
STUDY	FINANCES	
Funding Source  
This study is funded as part of the Chief Investigator’s PhD research by the University of Hertfordshire. 
Participant Stipends and Payments 
Neither participants nor staff at the pharmacies will be paid to participate in the study. Participants will 
not be identified in any publications. 
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Participant Information Sheet 
 
 
 
 
Participant Information Sheet 
 (Version 4:  31st  October 2014) 
 
Title of Study: “An investigation into the use of modified release medications in older adults 
with swallowing difficulties” 
 
Invitation to take part 
 
You are invited to take part in the above study, however before you decide to take part, it is 
important to understand this research and what it involves.  The information sheet provides 
you with a brief explanation of what will happen during the study and will provide you with 
information on all aspects that the study will cover. Please take the time to read the leaflet 
provided and feel free to ask questions and discuss it with the pharmacist and principal 
investigator. Please take your time and decide whether or not you would like to be a part of this 
study. 
 
Thank you for taking the time to read this leaflet. 
 
What is the purpose of the study? 
 
Swallowing difficulties is common in older adults (patients 65 years and over) and this can make 
swallowing medicines such as tablets and capsules difficult. Difficulties in swallowing tablets 
and capsules can be particularly difficult for a special group of medicines called modified 
release medicines or slow release medicines. These medicines have a special structure that 
releases drug over a long period of time. To accommodate for the slow release over a long 
period of time they have more drug content then normal tablets and capsules and are typically 
larger in size.  These medicines provide many advantages, they allow medicines to be taken less 
frequently, provide better symptom control and reduce the risk of side effects. 
 
The purpose of this study is to determine if there are any difficulties with swallowing slow 
release medicines. The information gained from this study will be used to develop slow release 
medicines that are easier for patients to swallow. 
 
 
Why have I been invited? 
  
You have been invited because the pharmacist has identified you as a patient over the age of 65 
that may have difficulties in swallowing tablets or capsules. 
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Do I have to take part? 
No, it is up to you to decide whether or not to take part. If you decide to take part you are still 
free to withdraw at any time, and without giving a reason. If you decide not to take part, or to 
withdraw from the study at a future date, this will not affect you or the standard of care you 
receive.  
 
What will happen if I decide to take part? 
 
If you decide to take part in the study you will be asked to provide consent for the researcher to 
collect information of the medicines you are prescribed from your drug chart and information 
of any diseases/conditions that you have from your medical notes. All information collected will 
not be identifiable and will be anonymous. 
 
What are the possible disadvantages or risks of taking part? 
 
There are no disadvantages or risks with taking part in this study. The data collected from your 
medical notes and drug charts will be anonymous, and you will not be approached during data 
collection.  
 
The data collected during this study will be stored in a secure and confidential way. Data 
collection sheets will be stored in a locked cabinet in a locked office in the Department of 
Pharmacy, University of Hertfordshire. 
 
What are the possible benefits of taking part? 
 
There is no direct benefit, but the data collected from this study will highlight problems with 
these medicines in practice and the information may help in developing guidelines for 
medicines management for modified release medicines for patients with swallowing difficulties. 
The data collected in this study will also be used to develop novel modified release medicines 
for older adults with swallowing difficulties. 
 
What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study will be addressed. Please 
contact the Patient Advice and Liaison Service (PALS) to make complaints. 
 
Telephone number: 01223 216 756 
Email: pals@addenbrookes.nhs.uk 
Fax: 01223 256 170 
Postal address:  
 
 
 
 
Box 53, Cambridge University 
Hospitals, Cambridge Biomedical 
Campus, Hills Road, Cambridge, 
CB2 0QQ 
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Offices are located in the information centre, just inside the main entrance of the hospital. The centre is 
wheelchair accessible.  
 
 
Will my participation in the study remain confidential? 
 
All information collected during the course of this research is non-identifiable and therefore 
anonymous.  
 
What do I have to do? 
 
To take part in the study you need to let the researcher know that you are happy to do so and 
sign a consent form.  
 
Can I withdraw from the study if I want to? 
 
Yes, your participation is voluntary and you can withdraw from the study at any time. Any 
withdrawal from this study will not affect you, or your care, in any way.  
 
 
What will happen to the results of this study? 
 
The results of the study will be published in the researchers PhD thesis, medical journals and will be 
presented at conferences. There is no possibility that any individual person could be identified in any 
report or article that is published. 
 
Who is organising this research? 
 
I am undertaking this research as part of my PhD study. The research is organised by Department of 
Pharmacy in the University of Hertfordshire.  
 
Who has reviewed the study? 
 
The South Yorkshire REC and the Research and Development team at Addenbrooke’s hospital has 
reviewed this research.  
 
 
Contact for further information 
 
If you wish to ask any questions about this study before providing consent, please contact the chief 
investigator or the principal investigator who would be pleased to help you: 
 
Chief investigator: Miss Simmi Patel, PhD candidate 
        University of Hertfordshire, Department of Pharmacy 
        College Lane, Hatfield, AL10 9AB 
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Tel: 07926938266 
        E-mail: s.4.patel@herts.ac.uk 
 
Principal investigator :  Mr. Narinder Bhalla, Consultant pharmacist in medicines safety. 
            Cambridge University Hospitals NHS Foundation Trust 
                                         Hills Road, Cambridge, CB2 0QQ. 
                                         Tel: 01223217487 
                                         E-mail: narinder.bhalla@addenbrookes.nhs.uk 
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Appendix II 
A STUDY OF PARTICLE SIZE DISTRIBUTION OF 
SAFE-SWALLOW BOLUSES OF COMMERCIAL 
JELLIES  
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Participant information sheet 
 
UNIVERSITY OF HERTFORDSHIRE 
 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS 
(‘ETHICS COMMITTEE’) 
 
 
FORM EC6: PARTICIPANT INFORMATION SHEET 
 
1 Title of study 
 
 A  study of the particle size distribution of safe-swallow boluses of commercial jellies 
 
2 Introduction 
 
 You are being invited to take part in a study.  Before you decide whether to do so, it is 
important that you understand the research that is being done and what your 
involvement will include.  Please take the time to read the following information carefully 
and discuss it with others if you wish.  Do not hesitate to ask us anything that is not clear 
or for any further information you would like to help you make your decision.  Please do 
take your time to decide whether you wish to take part.  The University’s regulations 
governing the conduct of studies involving human participants can be accessed via this 
link: 
 
http://sitem.herts.ac.uk/secreg/upr/RE01.htm 
 
Thank you for reading this. 
 
3 What is the purpose of this study? 
 
Food is normally broken down and mixed with saliva to achieve a consistency that is 
safe to swallow. The purpose of this study is to determine the particle size reduction of 
jelly once it is formed into a bolus in the mouth to enable in vitro studies in a model 
designed to replicate the swallowing process (the Cambridge Throat model). The study 
will generate useful information in the safety of swallowing jellies for patients with 
dysphagia (swallowing difficulties). 
 
4 Do I have to take part? 
 
It is completely up to you whether you decide to take part in this study.  If you do decide 
to take part, you will be given this information sheet to keep and be asked to sign a 
consent form.  Agreeing to join the study does not mean that you must complete it.  You 
are free to withdraw at any stage without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part at all, will not affect any treatment/care that you may 
receive (should this be relevant). 
 
5 Are there any age or other restrictions that may prevent me from participating? 
 
 This study will involve swallowing a spoonful of commercial jellies and water thickened 
with a commercial thickener. Participants with difficulties in swallowing will be excluded 
from the study. Please check the ingredients below for any allergies or any personal 
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reasons that you may not be able to swallow these products. The commercial products contain 
the following ingredients: 
 
 Gelatine, Locust Bean Gum, Xanthan Gum, Gellan Gum, modified maize starch, agar, 
maltodextrin, citric acid, glucose-fructose syrup, hydrogenated maltose syrup, sugar, 
potassium citrates, calcium lactate flavourings and colourings: carmine, anthocyanins, 
beetroot red, stevia, gardenia, erythritol. 
 
 
6 How long will my part in the study take? 
 
If you decide to take part in this study, you will be involved in it for 30 minutes. 
 
7 What will happen to me if I take part? 
 
If you decide to take part in the study you will be asked to provide consent to participate 
in the study. The study will also involve swallowing a spoonful of three different 
commercial jellies and water thickened with a commercial thickener and you will be 
required to fill in a short questionnaire and rate the ease of swallowing of these products. 
 
Following this, you will be asked to chew the commercial food jellies that required 
chewing for swallowing and to spit out once you feel it is ready to be swallowed. 
 
8 What are the possible disadvantages, risks or side effects of taking part? 
 
There are no disadvantages or risks with taking part in this study. Your identity will be 
assigned a code number and you will not be identified in any reports or publications 
generated by the study. 
 
9 What are the possible benefits of taking part? 
 
There is no direct benefit, but the data collected from this study will help in determining 
the particle sizes that are deemed safe to swallow for these products and further 
analysis of the boluses will help us understand mechanical properties of safe-to-swallow 
jelly boluses. 
 
10 How will my taking part in this study be kept confidential? 
 
All information collected about you will be kept strictly confidential. Data generated 
during this study will be retained in accordance with the University of Hertfordshire’s 
policy on academic integrity. Each participant will be assigned a code number to ensure 
anonymity.  
 
12 What will happen to the data collected within this study? 
 
Data collected in this study will be used in a PhD thesis, it may be published in scientific 
journals and presented at scientific conferences at a later date. No participants will be 
identified in any reports or publications.  
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12.2 The data collected will be stored in hard copy by SImmi Patel, University of Hertfordshire 
and stored in a locked cupboard for a year, after which time it will be destroyed under 
secure conditions; 
 
 
 
 
 
13 Will the data be required for use in further studies? 
 
 The data will not be required for further studies. 
 
 
14 Who has reviewed this study? 
 
This study has been reviewed by University of Hertfordshire Health and Human 
Sciences Ethics Committee with Delegated Authority (ECDA) 
 
 
The UH protocol number is LMS/PGR/UH/02759 
 
15 Factors that might put others at risk 
 
 There are no anticipated risks for this study. 
 
16 Who can I contact if I have any questions? 
If you would like further information or would like to discuss any details personally, 
please get in touch with me, in writing, by phone or by email: My name is Simmi Patel 
and I am a PhD researcher in the Department of Pharmacy, University of Hertfordshire. 
My telephone number is 07926938266 and email: s.4.patel@herts.ac.uk.   
 
Although we hope it is not the case, if you have any complaints or concerns about any 
aspect of the way you have been approached or treated during the course of this study, 
please write to the University’s Secretary and Registrar. 
 
Thank you very much for reading this information and giving consideration to taking part 
in this study. 
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Consent form 
 
 
UNIVERSITY OF HERTFORDSHIRE 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS 
(‘ETHICS COMMITTEE’) 
 
 
FORM EC3 
CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS 
 
  
I, the undersigned [please give your name here, in BLOCK CAPITALS] 
 
……………………………………………………………………………………………………………….… 
of  [please give contact details here, sufficient to enable the investigator to get in touch with you, such as 
a postal  or email address] 
 
…..……………………………………………………………………………………………………………… 
hereby freely agree to take part in the study entitled ‘A study of particle size distribution of safe-swallow 
boluses of commercial jellies’ 
 
………………………………………………………………………………………………………………….. 
 
(UH Protocol number LMS/PGR/UH/02759) 
 
1  I confirm that I have been given a Participant Information Sheet (a copy of which is attached to this 
form) giving particulars of the study, including its aim(s), methods and design, the names and contact 
details of key people and, as appropriate, the risks and potential benefits, how the information collected 
will be stored and for how long, and any plans for follow-up studies that might involve further approaches 
to participants.  I have also been informed of how my personal information on this form will be stored and 
for how long.  I have been given details of my involvement in the study.  I have been told that in the event 
of any significant change to the aim(s) or design of the study I will be informed, and asked to renew my 
consent to participate in it.  
 
2  I have been assured that I may withdraw from the study at any time without disadvantage or having to 
give a reason. 
 
3  In giving my consent to participate in this study, I understand that voice, video or photo-recording will 
take place and I have been informed of how/whether this recording will be transmitted/displayed. 
 
4  I have been told how information relating to me (data obtained in the course of  the study, and data 
provided by me about myself) will be handled: how it will be kept secure, who will have access to it, and 
how it will or may be used.   
 
 
 
Signature of participant……………………………………..…Date………………………… 
 
 
 
Signature of (principal) 
investigator………………………………………………………Date………………………… 
 
Name of (principal) investigator [in BLOCK CAPITALS please] 
…………………………………………………………………………………………………… 
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